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Abstract 
The British Association for Psychopharmacology guidelines specify the scope and targets of treatment 
for bipolar disorder. The third version is based explicitly on the available evidence and presented, like 
previous Clinical Practice Guidelines, as recommendations to aid clinical decision making for 
practitioners: it may also serve as a source of information for patients and carers, and assist audit. The 
recommendations are presented together with a more detailed review of the corresponding evidence. 
A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and 
considered the strength of evidence and clinical implications. The guidelines were drawn up after 
extensive feedback from these participants. The best evidence from randomized controlled trials and, 
where available, observational studies employing quasi-experimental designs was used to evaluate 
treatment options. The strength of recommendations has been described using the GRADE approach. 
The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use 
of medicines in short-term treatment of episodes, relapse prevention and stopping treatment. The 
use of medication is integrated with a coherent approach to psychoeducation and behaviour change. 
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Introduction 
Bipolar disorder has been and still is a relatively neglected condition. This feeds a perception, which 
we broadly share, that treatment could and should be improved. Guidelines provide an opportunity 
to enhance quality of care by advocating particular treatment approaches through systematically 
derived statements that can help individual patients and clinicians to make decisions. They have had 
an important impact on patterns of prescribing for bipolar patients (Bjorklund et al., 2015). 
Guideline recommendations are based on evidence. Nevertheless, the principal recommendations 
usually derive from average effects in patient populations. Such recommendations may be expected 
to apply about 70% of the time, so we have used eǆpƌessioŶs like ͞CliŶiĐiaŶs should ĐoŶsideƌ…..͟ iŶ 
the text. However, there will be occasions when adhering to such a recommendation unthinkingly 
could do more harm than good. 
We will also describe treatment options in a way that is not prescriptive. They recognize that 
implementation will depend on individual and local circumstances. Options will reflect up-to-date 
evidence and may highlight current uncertainties. 
Finally, we make consensus statements, the implications of which should shape and inform decision 
making. 
This guideline should be read alongside NICE 2014 Bipolar Disorder: Assessment and Management 
(NICE2014) (https://www.nice.org.uk/guidance/cg185), the recommendations from which are in 
places compared with our own. 
The quality of the evidence base 
Evidence categories (I to IV) traditionally imply a hierarchy from the best evidence, based on high-
quality randomized trials, to the weakest, based on opinion/clinical impression (Shekelle et al., 
1999). This approach explicitly downgrades non-experimental descriptive studies of treatment 
effects in favour of any randomized controlled trial (RCT); in so doing, it confounds design with 
quality. 
In previous editions (Goodwin, 2003, 2009), we ranked individual recommendations on the basis of 
the supporting evidence using this scheme. This can be unduly formulaic. For example, weight may 
be given to positive findings from small, inconclusive studies simply because they were randomized 
trials. Like others (Kessing, 2015), we have been impressed by new observational data linking 
treatment exposures with clinical outcome. In the past such data would have been rated inferior to 
RCTs as a matter of principle (see Table 1). However, the quality and scale of some routinely 
collected data sets can provide relatively unbiased and reliable evidence for the effectiveness and 
safety of a treatment. While non-randomized, such evidence is more convincing than any but the 
highest quality RCTs, and with superior external validity. In addition, the availability of network 
meta-analysis of RCTs has given us the opportunity to re-think how to contextualize the quality of 
the evidence for an individual drug in the overall treatment strategy. 
The need for a more flexible appraisal of the evidence has been recognized by the Cochrane 
CollaďoƌatioŶ͛s G‘ADE sǇs-tem (http://handbook.cochrane.org/chapter_12/12_2.htm). Even though 
we could not adopt the detailed methodology recommended for its full implementation, as a 
bottom-up procedure, we followed the spirit of the GRADE approach, top down, to justify the quality 
standard of recommendations in our different treatment sections. We already have the major data 
synthesis con-ducted for NICE2014, so we did not replicate their efforts. The point of the GRADE 
system is to make the basis for choosing recommendations transparent. 
Finally we have made many recommendations for standards of care. Standards are intended to 
apply rigidly. Many standards are driven by ethical or clinical consensus rather than formal evidence. 
Where standards are evidence based, confidence and cosensus must be very high, requiring that 
standards be adhered to most of the time. We have phrased such recommendations with-out 
ƋualifiĐatioŶ aŶd ŵaƌked ;“Ϳ, so ͚CliŶiĐiaŶs should …… ;“Ϳ͛. 
 Throughout, a particular recommendation will imply an estimation of average benefit/risk. In fact, 
the estimation of potential benefits and harms is not a widely understood science. It is very 
encouraging that the European Medicines Agency (EMA) has allowed pioneering work in recent 
years to apply decision theory to the approval process of new drugs (Phillips et al., 2011). This 
demonstrates the potential to understand benefit–risk using quantitative models (Mt-Isa et al., 
2014). It is an approach that has also informed the estimate of relative harms by drugs that are used 
͚ƌeĐƌeatioŶallǇ͛ ;Nutt et al., ϮϬϭϬͿ. IŶ a ďetteƌ futuƌe, suĐh ŵodels Đould ďe used ďǇ doĐtoƌs oƌ 
patients who want robust estimates of benefits and harms, to inform decisions in an individual case. 
For the time being, we have made do with opinion based on research evidence, the decisions of 
regulators to approve particular medicines and clinical experience. 
Methodology 
This document is the result of an initial meeting held on 9th February 2015. Expert participants were 
asked to review specific areas in which new data have become available from systematic reviews, 
RCTs or observational studies. After brief presentation, a discussion identified consensus and areas 
of uncertainty. A narrative literature review was assembled to illustrate the consensus points. This 
draft was circulated to participants. Their feedback was, as far as possible incorporated into the final 
version of the guidelines. 
Identification of relevant evidence 
All the consensus points and the guideline recommendations can be linked to relevant evidence 
through the literature review. As already explained, our methodology did not allow for a systematic 
review of all possible data from primary sources, and the recent NICE2014 bipolar guideline provided 
a comprehensive collation of relevant data to 3-4 years ago 
(http://www.nice.org.uk/guidance/cg185). Additional publications were identified from MEDLINE 
searches to December 2015. 
Strengths of evidence and recommendations for guidelines 
Strengths of recommendation 
Grading of recommendations is shown in Table 2. This approach allows for judgement to be made 
that downgrades some evidence (e.g. results, even if consistent, from small clinical trials, where bias 
is highly likely), and upgrades other findings (e.g. from observational studies in large samples with 
strong quasi-experimental designs). Where evidence is sparse, it has been necessary to extrapolate 
from relevant evidence where it is available. Weaker levels of recommendation may cover key areas 
of practice. Recommendations will be starred as in Table 2. 
Scope and target of the guidelines 
The content of the guidelines is relevant for all doctors treating patients with bipolar disorder. We 
hope that in most cases these will be doctors who are specialists in psychiatry. However, we have 
also written the guidelines to help inform general practitioners, patients and their families, and 
other health care professionals involved in the management of patients with bipolar disorder. 
Clinical psychologists and other colleagues providing psychotherapy to patients with bipolar disorder 
are a particularly important group who need to understand and acknowledge the complementary 
roles for patients of medication and psychological treatment. 
We have emphasized our interest in evidence. However, we could not review all the relevant 
literature in the detail required to give a fully comprehensive text. Even distilling the evidence and 
summarizing points of consensus, relating mainly to medical management of bipolar disorder, does 
not result in a format that is particularly brief or easy to use. Accordingly, the document consists of 
two parts. Part 1 abstracts the key recommendations (and some of the key points of evidence) and 
can inform every-day practice. Part 2 indicates consensus points that emerged and briefly 
summarizes the evidence. The structure and content are broadly but not precisely aligned between 
Parts 1 and 2. 
 
Finally, in Part 1, we identified a list of quality standards for audit based on our most important 
recommendations. 
Nomenclature 
In this manuscript, we will avoid, where possible, the use of generic terms for drugs based on 
indication and instead prefer to use descriptions of mode of action. The Neuroscience-based 
Nomenclature (NbN) is a new system to promote the description and classification of psychotropic 
drugs in this way. It aims to provide an app-based update of relevant and specific scientific, 
regulatory and clinical information, to support rational prescribing (https://www.ecnp.eu/projects-
initiatives/nomen-clature.aspx). The use of a pharmacologically driven nomenclature, which 
highlights pharmacological targets and modes of action, helps clinicians to make informed choices 
(for example by combining two different targets or adding a complementary mode of action). It is a 
work in progress, and the voluntary suppression of the familiar terms antipsychotic, antidepressant 
and anticonvulsant can only be partial. When we use the term anti-depressant, for example, it 
should be understood that we are referring to drugs used in the treatment of unipolar depression. 
The problem is, of course, that not all the drugs used for unipolar depression are currently described 
as antidepressants, and antidepressants are not active specifically in depression. Thus, 
antipsychotics are effective in psychosis, mania and, in some cases, depression, and anticonvulsants 
are effective in epilepsy but also mania and depression. NbN will give us a larger vocabulary and a 
better grasp of what our medicines actually do if we make the necessary effort. 
Caveats 
We are committed to the principle of basing recommendations on the best possible evidence and, 
for treatment efficacy, this will usually be evidence from RCTs. However, there are important 
limitations to such evidence. We highlight these limitations here, so what follows is informed by this 
perspective. 
Drug treatment trials 
Drug trials are usually conducted by companies seeking to register new compounds. Such trials are 
now usually of good quality: matched placebo medication, randomized and concealed allocation, 
blinded treatment and pre-specified analysis plans. Nevertheless, it is often stated that sponsor 
(allegiance) bias influences the outcome of clinical trials of new medicines (in favour of the 
sponsored product). One important explanation for this global conclusion is that company-
sponsored studies may more often be placebo controlled than independent studies, and will tend to 
have larger effect sizes for that reason. Indeed, for dopamine antagonists and serotonin re-uptake 
inhibitors there were no differences in effect size between industry- supported and non-industry-
supported trials when the designs were similar (Lundh et al., 2012). The unthinking position that 
companies can fix the results of their studies to inflate positive effects is wrong, and is not the main 
reason we should treat such studies with caution. 
In fact, sponsors can only easily influence outcomes by biasing the design of the study: for example, 
choice of dose, comparator or unblinding (if adverse reactions are obvious). Unblinding could lead to 
inflation of effect sizes by biasing assessment. Measures of blinding should be included in all such 
studies for patients and raters, but are often omitted or not reported. This potential problem should 
be kept in mind when examining the coherence of network meta-analyses which include placebo as 
the main comparator. 
The reporting of adverse reactions in clinical trials is also less systematic than it could be, and has 
often relied on ambiguous tick-box categories to capture usually subjective complaints. The 
controversy arising from how self-harm or suicidality should be identified as an adverse reaction has 
been particularly problematic (Gibbons et al., 2015; Posner et al., 2007). This means that the balance 
between benefits and harms can be difficult to assess from trial data. In describing outcomes that 
patients may experience themselves or that may be detectable by observation we will refer to 
͞adǀeƌse ƌeaĐtioŶs͟; ͞adǀeƌse effeĐts͟ aƌe uŶǁaŶted, ŵeasuƌed ĐoŶseƋueŶĐes of dƌug tƌeatŵeŶt 
(Aronson, 2013). 
Sponsor bias is also confused with publication bias. There is no doubt that the way industry-
supported data was published has been a major problem in past decades. This mainly took the form 
of over-stating product advantages and cherry picking for publication the most positive trials or the 
most positive outcome measures. Non-publication of negative results was also very common. This is 
now partially corrected by trial registratioŶ aŶd disĐlosuƌe of ͚Ŷegatiǀe͛ studies ďǇ ĐoŵpaŶies. IŶ 
addition, full disclosure of all ana-lysed data has long been required by the regulatory authorities, 
and this information is usually accessible if not actually published. 
The quality and reproducibility of individual trials is critical. As a rule, companies must convince 
regulators that new drugs are better than placebo. Can they recruit representative patients into the 
necessary trials? While the patients recruited into company trials meet diagnostic criteria for bipolar 
disorder, the list of inclusion/exclusion criteria is often so long as to render the resulting sample 
highly atypical, and not representative of the most ill patients with multiple co-morbidities we 
actually see in practice. The exclusion of patients with co-morbid substance misuse in trials of mania 
and of patients with suicidality in bipolar depression has the highest impact (Hoertel et al., 2013). 
This is compounded by heterogeneous rates of recruitment and associated with heterogeneous 
results across sites in multi-centre trials. In acute studies, high placebo response rates at some sites 
will drown out efficacy signals at others with lower placebo responses (Yatham et al., 2015b). In 
addition, many acute treatment studies in psychiatry are only 6–8 weeks in duration, and the 
artificial nature of clinical trial procedures and the difficulties of recruitment mean drop-out rates 
are high. This severely reduces the power to detect effects, so trial methodology is probably as likely 
to under-estimate drug effect as to magnify it. 
Substantial drop-out rates are common even in quite short-term RCTs. The right to drop out of 
studies is actually emphasized in the information given to participants in trials! However, high 
attrition rates have negative consequences for the power to detect effects and obviously defeat the 
purpose of longer-term studies. The effect is sometimes described as a bias, and NICE2014 heavily 
downgrades many of the RCTs for the medication of bipolar disorder on this basis. We have not 
taken the same view, because it is clearly a limitation of RCTs in general, but when particularly 
severe, it must limit the validity and generalizability of any conclusions (Leon et al., 2006). 
Finally, outcomes in acute treatment studies are often rating scale scores, which are arbitrary counts 
of symptoms and their severity. These are measures rarely used by clinicians because they are 
tedious to obtain by interview. They are intermediate measures suspended between biomarkers, 
which can prove a drug has had the predicted pharmacological effect, and real outcomes relevant to 
patients (for example return to work). Real outcomes are too distal to provide sensitivity in a short 
clinical trial. 
For all these reasons, caution is required in extrapolating the results of such trials to practice, 
whether or not presented as a meta-analysis. 
Independent trials have often been less well resourced and smaller scale, but may lack the stigma 
attaching to industry sponsorship. The results of such trials have the potential to be very misleading 
due to the whole range of potential biases. However, where quality is maintained and sample size is 
reasonable, they can offer important independent support to prove efficacy. They may also recruit 
patients in a less distorted way than commercial clinical research organizations and so generalize 
more convincingly. Positive studies of this kind have been particularly important in shaping some of 
our recommendations (e.g. the use of lithium and lamotrigine). 
One final consideration is that when small trials are negative, caution is required in claiming that the 
trial proves lack of efficacy: under-powered studies by definition run a high risk of type II statistical 
error. 
In conclusion, RCTs provide an important evidence base for all medical practice. Effect sizes in 
psychiatry, in common with the rest of medicine, are moderate (Leucht et al., 2012) but deliver 
worthwhile patient benefit. Nihilism about the results of RCTs should be avoided. However, RCTs are 
essentially experiments; their results are most plausible when confirmed by large-scale, 
independent, pragmatic RCTs conducted in real-world patient samples. There are few examples of 
such trials in psychiatry. More relevant currently are pharmacoepidemiological studies using quasi-
experimental designs. In such studies patients can act as their own controls before, during and after 
treatment, patient numbers can be very large and observation periods can be long. Furthermore, the 
measured outcomes can be objective and highly clinically relevant: admission to hospital, suicide, 
acts of violence, etc. Such studies are crucial in supporting our recommendations for the long-term 
use of drugs in bipolar disorder. Psychotherapy trials 
Psychotherapy trials pose difficulties for evidence-based practice that have not been sufficiently 
recognized. The choice of a fair comparison treatment is much more challenging than for medicines. 
It is ofteŶ siŵplǇ duĐked ďǇ usiŶg a pooƌlǇ speĐified ͚tƌeatŵeŶt as usual͛ ĐoŶditioŶ. While this ŵay 
be defensible in a pragmatic study of effectiveness, it creates problems of interpretation for a proof-
of-concept or efficacy study. If, as is commonly the case, the active treatment is superior to 
treatment as usual, no specificity can be claimed for its ĐoŶteŶt. The alteƌŶatiǀe ͚ǁaitiŶg list͛ ĐoŶtƌol 
group is also problematic because any superiority for an active treatment may be due to (or 
aŵplified ďǇͿ a ǁaitiŶg list͛s eǆpeĐted ŶoĐeďo effeĐt. HeŶĐe, ŵaŶǇ positiǀe tƌials of paƌtiĐulaƌ 
therapies are pseudo-specific, in the sense that we do not know what elements of the 
psychotherapy are actually effective. 
The ĐolleĐtioŶ of ͚adǀeƌse ƌeaĐtioŶs͛ to psǇĐhologiĐal tƌeatŵeŶt also appeaƌs to ďe uŶsǇsteŵatiĐ aŶd 
hence under-appreciated (Nutt and Sharpe, 2008). 
These inherent problems require an approach to refining best practice based on meticulous trial 
design and execution and sequential refinement of the psychotherapy content. Biomarkers or more 
experimental designs could also inform treatment development in psychotherapy trials (Button and 
Munafo, 2015). Unfortunately, development funding is often not available in the way that is taken 
for granted for the development of new drugs by industry. 
As a corollary of limited funding, psychotherapy trials are often small scale and suffer from all the 
disadvantages of similar, independent trials of medicines. Moreover, psychotherapy trials may be 
particularly subject to allegiance bias. This will mean that investigators are heavily invested 
professionally in showing that ͚theiƌ͛ tƌeatŵeŶt ǁoƌks. This ŵaǇ ĐoŶsĐiouslǇ oƌ uŶĐoŶsĐiouslǇ 
influence how trials are designed, treatments delivered and results described. It can also influence 
how results are analysed, if statistical methods are not pre-specified. Publication in a high-profile 
journal or endorsement in a guideline will increase the demand for workshops and training that may 
remunerate a provider personally, and will be used to demonstrate impact by their employing 
institution. Thus, declaration of interest should be taken seriously in the publication of psychosocial 
interventions (Dragioti et al., 2015). Given a strong appetite from patients for psychological 
solutions, there is a prevailing pressure to reach positive but premature judgements. 
Publication bias is objectively as important a problem for psychotherapy trials as for drug trials (Flint 
et al., 2015). However, there is not the safeguard that is provided by the for-mal disclosure of 
negative studies in the regulation of drug treatments. 
Meta-analysis cannot resolve uncertainty where the methodology of the individual RCTs is flawed. In 
the case of bipolar disorder, the paucity of research in psychological and psychosocial treatments is 
as regrettable as for the other domains of treatment. Future studies that can avoid the mistakes of 
the past and present can therefore be enthusiastically anticipated. For now, we have favoured 
caution in interpreting the findings from trials of psychosocial interventions. Just as for drug 
treatments, more large-scale data with harder out-comes (admission to hospital, offending) would 
be very welcome, but are not currently available. Relapse prevention trial designs 
These studies are required by the EMA as proof of continuing efficacy for drugs shown to be 
effective in short-term studies of acute illness. They offer a further proof of acute efficacy since they 
take patients who have recovered while taking a particular active treatment and randomize to 
continue that treatment or be switched to placebo. If patients on placebo relapse to the same pole 
as the index episode, this is taken as further evidence that the drug worked acutely. 
If these studies are extended over 1 or even 2 years, there must be a point at which we can infer 
further that the drug–placebo difference represents prevention of new episodes. Since there is no 
clear discontinuity in the boundary between preventing relapse of the original episode and the 
prevention of new episodes, perhaps they are essentially different sides of the same coin? Relapse 
prevention studies have been interpreted in that way in previous BAP guidelines. However, it is 
recognized that much of the difference between active treatment arms and placebo are due to early 
events, and drop-out rates tend to be very high. Retention of patients in a 1–2-year study may be as 
low as 10%. Hence, interpretation of such studies, except in relation to acute efficacy, may be 
questionable. 
It ŵaǇ also ďe oďjeĐted that suĐh studies aƌe ͚eŶƌiĐhed͛ ǁith patieŶts ǁho haǀe pƌefeƌeŶtiallǇ 
responded to the drug under investigation. Clearly this is true, but in actual practice this may often 
reflect the clinical question a psychiatrist asks: what will happen if I discontinue the drug? Knowing 
that there will be a risk of relapse is useful and informs clinical practice. This is really the only 
experimental evidence that supports the belief that what gets patients well will often keep them 
well. Relapse prevention studies underline that lesson, and offer us more safety data than are 
available in acute studies. 
Finally, the definition of relapse in relapse prevention studies requires care. Acute withdrawal of a 
drug may lead to subjective changes and effects on sleep, which are often the mirror image of 
adverse reactions to taking the drug (for example, vivid dreams after withdrawal of drugs that 
suppress REM sleep). Withdrawal reactions of this kind by definition immediately follow drug dis-
continuation and are relatively transient. However, in theory, withdrawal effects could be mistaken 
for relapse; if so, this must result in an excess of cases of very early relapse which are arte-factual. 
Studies in which such an effect is observed are very difficult to interpret. More subtly, such effects 
could lead to unblinding and bias the assessment of patients later in the course of follow-up. 
On the other hand, drug withdrawal effects may also trigger an excess of true cases of early relapse 
compared with untreated patients. At present such an effect has only been convincingly shown with 
lithium, where it is a clinically important phenome-non (Goodwin, 1994; Suppes et al., 1991). In 
theory, such effects might be more likely with those treatments that most modify the risk of relapse 
and act most proximal to the brain mechanisms involved in, for example, the onset of mania. 
NICE2014 effectively discounted much of the longer-term data generated by relapse prevention 
studies. In contrast, we accept them for what they are while recognizing their limitations. Further, 
where randomized data and high-quality naturalistic data support the same the conclusions, then 
those findings are likely to be of particular validity and should clearly influence treatment 
recommendations. 
Choice of treatment and network  
meta-analysis 
We are impressed by the power of network meta-analysis for understanding treatment efficacy, and 
we will refer to such analyses in supporting the use of medicines to treat different aspects of bipolar 
disorder. The principle is to use all the available data that meet quality standards and include all 
trials where medicines are compared directly or indirectly via a common comparator (often placebo) 
(Cipriani et al., 2013b). This can identify when a data set is internally consistent (A beats B, B beats C, 
so A should also beat C). Where there is consistency between comparisons with placebo on one 
hand, and active comparators on the other, it is less likely that effects have been biased by 
unblinding. In our view, this is probably the most important current test that RCTs are indeed 
reliable and provide a secure evidence base for clinical decision making. In GRADE terminology, a 
coherent network supports strong ranking for treatment recommendations based on RCTs; a sparse 
or unstable network does not. 
Network meta-analysis can also provide a kind of league table to rank different medicines against 
each other (and against placebo). Such findings have strongly influenced the NICE recommendations 
for the treatment of mania and depression. However, confidence intervals around the rankings were 
wide. As we argue in the preceding paragraph, practice can be underpinned by the knowledge that 
the efficacy of the treatment choices has been established in RCTs with a coherent network. It does 
not follow that practice be dominated by evidence that one effective treatment is, on average, 
slightly better than another. In addition, extrapolating from average effects in RCTs and meta-
analyses to what might work amongst a range of effective treatments in a given individual requires 
experience and judgement. Previous history of response, willingness to adhere to a treatment, and 
poteŶtial ďeŶefits aŶd ƌisks giǀeŶ aŶ iŶdiǀidual͛s peƌsoŶal situatioŶ all haǀe a ďeaƌiŶg oŶ theƌapeutiĐ 
outcome. 
The key to success with individual patients is cautious but confident prescribing of adequate doses 
and monitoring of effects, both positive and negative. Moreover, drug choice is an important clinical 
freedom in developing treatment with the individual patient in relation to both efficacy and adverse 
reactions. While NICE2014 is at pains to emphasize the need to respect patient choice, as are we, 
they are less liberal in what choices they actually sanction. 
Part 1. Guidelines 
In making recommendations that will be of practical value to clinicians who treat patients with 
bipolar disorder, we stand on the consensus view of the evidence reviewed in the accompanying 
document. The clinical practice guideline developed by NICE2014 has also been considered. We have 
sometimes reached different conclusions. These differences result from different weights placed on 
the available evidence. Differences of opinion, of course, are most likely to occur when the evidence 
is less than compelling. 
Along with grading of specific recommendations for a strategy or individual treatment, the guideline 
includes statements, the implications of which should also influence practice. The strength of the 
evidence is rated as in Table 1 (and may relate to RCTs or observational findings). 
Currently, medication remains the key to successful practice for most patients in the long term. The 
objective is to achieve a personalized choice of medicine (effective and well tolerated), informed 
adherence and an understanding of illness course shared with the patient and all most involved in 
their care. This needs to be established as early as possible in patients who pre-sent with severe 
illness. 
Fundamentals of patient management 
1. Diagnosis 
Clinicians should make accurate diagnoses of hypomania, mania and depression (Standard of Care, 
(S)). Individual episodes may display mixed features of the opposite pole (Category I evidence, (I)). 
Consider the identification of the core symptoms of mania or depression against a check list as in 
DSM-5 to improve confidence in, and the reliability of diagnosis (S). There is a new requirement in 
DSM-5 for an observable increase in energy and activity in addition to subjective mood elevation for 
hypomania and mania. Practice may also be made more comprehensive with a patient-completed 
screening instrument (Category IV evidence, (IV)). 
Failure to use some form of structured record increases the likelihood that bipolar disorder will be 
missed and/or confused with another diagnosis (Category II evidence, (II)). 
The term hypomania should be used as defined in DSM-5, where it is confined to elated states 
WITHOUT significant functional impairment (S). 
Be careful not to dismiss or minimize mood elevation when it is the cause of disturbed behaviour; 
personality problems or situational disturbance should be invoked only if mania (or hypomania) is 
absent (IV). 
Bipolar patients may present with depression, especially in adolescence (I). Ask about a history of 
distinct periods of elated, excited or irritable mood of any duration and a family history of mania in 
all patients with depression (S). 
Anxiety disorders are highly co-morbid with bipolar disorder (I) from a lifetime perspective. Anxiety 
symptoms are often persistent between episodes and may contribute to mood instability (I). 
Anxiety disorders are associated with increased illness burden and poor outcome (I): they require 
assessment and treatment (S). 
Stimulant drugs may mimic manic symptoms (II). A drug-induced state, including psychosis, should 
wane with the clearance of the offending drug (II): use 5 half-lives as the relevant interval (and the 
longest half-life stated in a range). Levodopa and corticosteroids are the most common prescribed 
medications associated with secondary mania (I). 
More commonly, alcohol and/or drug use is co-morbid with manic or depressive mood change (I). 
The mood state will then significantly outlast the drugged state and a diagnosis of bipolar disorder 
can be made (S). 
Borderline personality disorder is an important diagnosis that may either be confused with or be co-
morbid with bipolar disorder. Reliable diagnosis of either condition can only be achieved by using 
operational criteria properly (S). 
Organic conditions, such as thyroid disease, multiple sclerosis or any lesion(s) involving right-sided 
sub-cortical or cortical areas may be associated with secondary mania (II) and should be considered 
in the differential diagnosis (S). These conditions are most likely to occur in the elderly (I). 
The diagnosis of bipolar disorder in childhood has been controversial. The narrow definition of the 
condition, now endorsed in DSM-5 and described in the latest NICE guideline (NICE2014), recognizes 
unequivocal euphoria and an episodic course as the defining characteristics in pre-pubertal children 
(S). One should not make the diagnosis in children or young people unless there has been a period of 
prospective longitudinal monitoring by appropriately experienced clinicians taking into account the 
Đhild oƌ ǇouŶg peƌsoŶ͛s eduĐatioŶal aŶd soĐial fuŶĐtioŶiŶg ;“Ϳ. 
Within many child and adolescent services, bipolar disorder may well be missed and the challenge is 
to enhance its recognition. The approach to diagnosis in children is poorly operationalized: 
diagnostic instruments are available that could aid clinical practice (II). 
The so-called broad bipolar phenotype of childhood has been replaced by a new diagnosis in DSM-5: 
disruptive mood dysregulation disorder (DMDD). This is not a bipolar diagnosis and is likely to be 
rather common in comparison with bipolar disorder, which is rare in prepubescent children (I). 
Following puberty, the familiar adult criteria can be used with increasing confidence (IV). 
Bipolar symptoms such as irritability or aggression may appear, with the benefit of hindsight, to be 
misdiagnosed by clinicians when a patient is first seen (I). In fact, diagnosis can only be reliable after 
a clear-cut episode of (hypo)mania (S). 
2. Access to services and the safety of the 
patient and others 
Specialized services for bipolar patients of all ages have not been a priority for the NHS, and so 
provision is variable and too often poor (IV). 
Early intervention is a highly desirable objective in the management of young people with bipolar 
disorder (S). There are numerous systemic barriers to its provision and development in UK services 
(IV). This is an urgent problem. 
When mania is diagnosed, always consider admission to hospital or intensive community 
management (S). The particular risks to the patient and others will be the result of poor judgement 
and associated actions in areas of work, personal relationships, alcohol/drug use, spending, driving 
and sexual activity (I). 
Always try to obtain third party information if in any doubt when making a risk assessment (S). 
When any patient is in a mixed state or depressed, ask about suicidal ideation, intention to act on 
these ideas and extent of plans, means or preparation for suicide (S). Social isolation, substance use, 
psychosis (especially with command hallucinations), personality disorder, family history of suicide, 
recent exposure to suicide and any prior suicide attempts may all increase the risk (I). 
The increased incidence of completed suicide soon after an assessment in bipolar patients (I) 
suggests that current practice may under-estimate suicide risk (IV). 
Bipolar patients may be vulnerable to exploitation or violence when in an abnormal mental state, 
which may make admission more desirable (IV). The risk of violence and offending more generally 
(by the patient) is also increased in bipolar disorder (I), and assessment should address this risk (S). 
Carefully document your decisions in formulating a care plan (S). 
The fraĐtioŶatioŶ of ĐliŶiĐal seƌǀiĐes, foƌ eǆaŵple ďetǁeeŶ iŶ aŶd out patieŶts, ͚assessŵeŶt͛ aŶd 
͚tƌeatŵeŶt͛ ƌuŶs ĐouŶteƌ to the Ŷeeds of ďipolaƌ patieŶts iŶ all stages of theiƌ tƌeatŵeŶt ďut paƌ-
ticularly in managing follow-up (IV). Premature discharge to primary care can further dilute the 
treatment package available in the early stages of managing the illness (IV). 
3. Enhanced care 
(a)Establish and maintain a therapeutic alliance. A doctor should take responsibility for diagnosis, 
physical examination, investigations and explanation of the medical plan of management (S). 
Communicate clearly and honestly what you think (S). Take the time to listen to what is bothering 
the patient (S). 
Very disorganized psychotic patients with bipolar disorder will have social needs that merit assertive 
management (IV). 
(b)Educate the patient and his or her family about the disorder. Doctors, patients and carers tend to 
bring different experiences and beliefs to the therapeutic relationship (II) and make different 
estimates of future risks. Make use of evidence to address poor insight, the seriousness of the 
illness, reluctance to give up the experience of hypomania or mania, the risk of relapse and the 
benefit of therapeutic engagement (II). 
(c)Enhance treatment adherence. Treatment adherence is often poor, particularly in younger 
patients early in the illness course (I). 
While respecting patient preferences, education about the ill-ness after an acute episode should 
include information on the potential benefits and risks of medication and emphasize the need to 
continue on it long term (S). 
The known tolerability and safety of available medicines should guide prescribing: inform patients 
about possible adverse reactions and monitor their possible emergence (S). Make the reduction of 
adverse reactions a priority – by using different scheduling (e.g. by prescribing all sedative medicines 
at bed time), alternative formulations or lower dosages (Category III evidence, (III)). Patience may be 
required to establish that lower doses are effective (IV). 
(d) Promote awareness of stressors, sleep disturbance, early signs of relapse, and regular patterns of 
activity. Sleepdisruption is often the final common pathway triggering manic episodes and is also 
associated with depression: stressors that lead to reduced sleep may contribute to relapse  
Regular patterns of daily activities should be promoted (II). Identify and try to modify habitual, very 
irregular patterns of activity, which are common in patients with bipolar disorder: con-sider using 
diaries or apps to self-monitor mood or activities (III). 
Since alcohol and drug use are associated with a poor outcome, they require assessment, 
appropriate advice and treatment (S). 
Help the patient, family members, and significant others recognize emerging symptoms of manic or 
depressive episodes so that they may know when to request early intervention (S). 
While respecting patient preferences, education about the ill-ness after an acute episode should 
include information on the potential benefits and risks of medication and emphasize the need to 
continue on it long term (S). 
The known tolerability and safety of available medicines should guide prescribing: inform patients 
about possible adverse reactions and monitor their possible emergence (S). Make the reduction of 
adverse reactions a priority – by using different scheduling (e.g. by prescribing all sedative medicines 
at bed time), alternative formulations or lower dosages (Category III evidence, (III)). Patience may be 
required to establish that lower doses are effective (IV). 
(d) Promote awareness of stressors, sleep disturbance, early signs of relapse, and regular patterns of 
activity. Sleepdisruption is often the final common pathway triggering manic episodes and is also 
associated with depression: stressors that lead to reduced sleep may contribute to relapse (II). 
Regular patterns of daily activities should be promoted (II). Identify and try to modify habitual, very 
irregular patterns of activity, which are common in patients with bipolar disorder: con-sider using 
diaries or apps to self-monitor mood or activities (III). 
Since alcohol and drug use are associated with a poor outcome, they require assessment, 
appropriate advice and treatment (S). 
Help the patient, family members, and significant others recognize emerging symptoms of manic or 
depressive episodes so that they may know when to request early intervention (S). 
(g) Consider the use of alcohol and drugs (including caffeine). The use of alcohol or drugs may be 
excessive. Quantify their consumption and discuss setting targets for reducing harm (S). Caffeine (in 
coffee and other drinks) may significantly disturb sleep and exacerbate anxiety symptoms in 
sensitive individuals (III). 
(h) Consider risks for various adverse outcomes, including self-harm, suicide, victimization, violence 
and criminality. Bipolar patients are at substantially increased risks of self-harm, suicide, 
victimization, violence and criminality (I). 
Risk factors whose modification could reduce the risks of suicide and criminal outcomes include co-
morbid drug and alcohol use disorders and illness severity (II). 
(i) Increase the focus of care planning in women of child-bearing potential. The post-partum period 
is one of very high risk for relapse in women with bipolar disorder (I). Psychosis or mania is a 
particular risk for bipolar I disorder: it is increased further by a previous post-partum episode. 
Depression is a substantial risk for both bipolar I and II disorder. Women need to decide about using 
medication in pregnancy and during breastfeeding (or whether to breastfeed), bearing in mind the 
very high risk of severe illness at this time (S). See section on special situations below. 
Treatment of different phases of bipolar illness 
Prescribers should be aware of the limitations imposed by licences for different medicines and 
potential safety concerns documented in product descriptions (S). Marketing authorizations are 
pƌiŵaƌilǇ desigŶed to liŵit the aĐtioŶs of ĐoŵpaŶies, NOT ĐliŶiĐiaŶs. AĐĐoƌdiŶglǇ, ͚Off laďel͛ 
prescribing of licensed medicines is implied by some of the recommendations incorporated below. 
However, seek expert advice if unsure about the efficacy or safety of any individual medicine or its 
use in combination (S). 
Residual symptoms predict eventual relapse (II), so the objective of short-term treatment is 
remission of symptoms (S). 
We have not specified doses in this section. See Annex for additional information about individual 
medicines and relevant Product Information Sheets. 
1. Acute manic episodes 
Choice of an initial treatment. Most patients with mania will require short-term treatment with 
medicine(s) in an appropriate clinical setting (I). The evidence from network meta-analysis of many 
RCTs is coherent and supports efficacy of a range of different medicines (I). Thus, comparisons in 
RCTs include many indirect (placebo) and direct comparisons; this reduces the risk that unblinding 
and other bias has significantly distorted the results in individual studies. Choice of medicine should 
respect the balance between the benefit of efficacy and the harm of short-term adverse reactions or 
adverse effects in an individual with mania. 
No psychotherapy currently provides an alternative strategy for management. 
(a) For patients not already taking long-term treatment for bipolar disorder. For severe manic 
episodes, consider oral administration of a dopamine antagonist when seeking rapid anti-manic 
effect (****). Systematic comparison of data from clinical trials suggests that haloperidol, 
olanzapine, risperidone and quetiapine are particularly effective in short-term reduction of symp-
toms. Valproate is an alternative treatment with less risk of adverse motor reactions but should not 
be used for women of child-bearing potential because of its unacceptable risk to the foetus of 
teratogenesis and impaired intellectual development. Aripiprazole, other dopamine antagonists and 
partial agonists, carbamazepine and lithium are also options. 
Where an agitated patient requires parenteral treatment to control behaviour without their full 
consent, the use of dopamine antagonists/partial agonists and GABA modulators (benzodiazepines) 
should follow established protocols (S). The lowest doses necessary should be used (S). Do not 
escalate the dose of dopamine antagonists simply to obtain a sedative effect (S). 
For less ill, non-psychotic manic patients or for hypomania, treatment can be extrapolated from 
practice in mania (IV). 
To promote sleep for agitated overactive patients in the short term, consider adjunctive treatment 
with GABA modulating drugs (***). 
WheŶ possiďle, tƌeatŵeŶt seleĐtioŶ should ďe guided ďǇ a patieŶt͛s pƌeǀious eǆpeƌieŶĐes aŶd 
preferences, especially if expressed in the form of an advance directive under the Mental Capacity 
Act 2005 (S) or an advance statement. 
Antidepressant drugs (i.e. drugs approved for the treatment of unipolar depression) should usually 
be tapered and discontinued in a manic episode (**). 
If successful treatment has been initiated for mania, long-term treatment should be considered (see 
below) (S).  
(b) For patients who suffer a manic episode while taking long-term treatment. If the current 
presentation is due to inadequate symptom control, ensure that the highest well-tolerated dose of 
the current treatment is offered (S). For a dopamine antagonist or partial agonist, or valproate, 
raising the dose may be sufficient to control manic symptoms (IV). 
For lithium, check whether serum concentrations are within the usual target range; consider aiming 
for a higher serum con-centration within the target range (0.6–0.8 mmol/L (or mEq/L)); 
concentrations of 0.8–1.0 mmol/L may be more effective but carry a greater risk of harm if 
continued long term (I). 
If the patient is taking lithium, consider adding a dopamine antagonist or partial agonist, or 
valproate, as in (a) above (****). In general, follow the same principles as for a first episode or an 
episode occurring off long-term treatment. 
If the current episode is due to poor adherence, establish the cause and offer appropriate 
intervention (S). For example, if non-adherence is associated with an adverse reaction, consider dose 
reduction, assuming the adverse effect is dose related, or a switch to a more tolerable alternative 
regimen. If poor adherence is deliberate, and not related to tolerability, use of lithium long term may 
not be indicated due to the risk of mania and depression on its withdrawal (I). 
(c) If symptoms are inadequately controlled with optimized doses of the first-line medicine and/or 
mania is very severe, add another medicine. Consider the combination of lithium or valproate with a 
dopamine antagonist/partial agonist (****). 
Consider clozapine in more refractory illness (**). Electroconvulsive therapy (ECT) may be 
considered for patients whose mania is particularly severe or treatment resistant, those who express 
a preference for ECT and patients with severe mania during pregnancy (***). 
(d) The presence of mixed features in a manic or hypo-manic episode. DSM-5 encourages the 
ideŶtifiĐatioŶ of ŵiǆed featuƌes ƌatheƌ thaŶ a ͚ŵiǆed episode͛ ;as iŶ D“M-IV). The implications for 
treatment are uncertain. Existing data from sec-ondary analysis of trials for mixed episodes suggest 
that treat-ment as for mania is appropriate (I). 
(e) Assess contribution of substance use to a manic or hypomanic episode and consider if medically 
assisted withdrawal is required (S) 
(f) Discontinuation of short-term treatments. Drug discontinuation should be planned in relation to 
the need for long-term maintenance treatment (S). Many medicines shown to be effective for the 
treatment of mania have also been shown to be effective in relapse prevention (I). 
Medicines only used for the acute treatment of mania may be reduced in dose and discontinued 
(tapering over 4 weeks or more) after full remission of symptoms has been achieved (IV). Remission 
will often occur within 3 months (I) but mood stability may require 6 months or more to achieve. 
Any medication used adjunctively for symptomatic effect to promote sleep or sedation should be 
discontinued as soon as symptoms improve (S). 
 
2. Acute depressive episode 
The evidence from network meta-analysis of available RCTs sup-ports the efficacy of a limited range 
of individual medicines with different pharmacology and different weights of evidence. In particular, 
there is uncertainty (and difference of opinion) over the option of choosing antidepressants (i.e. 
drugs shown to be effective in major depressive episodes with a unipolar course) (IV). 
Most of the evidence concerns patients with a bipolar I illness course; however, extrapolation to 
bipolar II disorder appears logical (IV). 
(a) For patients not already taking long-term treatment for bipolar disorder. Consider quetiapine, 
lurasidone or olanzapine (***). Dopamine antagonists have the inherent advantage of being anti-
manic treatments (I). 
Antidepressants (meaning drugs for a major depressive episode in a unipolar illness course) have not 
been adequately studied in bipolar disorder. Only the combination of fluoxetine with olanzapine has 
support as a specific treatment (***). The com-mon use of other antidepressants in patients with 
bipolar disorder is an extrapolation from effects established in a unipolar illness course. When 
considered, they should be co-prescribed with a drug for mania (e.g. dopamine antagonists, lithium, 
valproate) in patients with a history of mania (S). 
Consider initial treatment with lamotrigine, with the necessary incremental dosing schedule, usually 
as an addition to agents preventing recurrence of mania (****). 
Consider ECT for patients with high suicidal risk, treatment resistance, psychosis, severe depression 
during pregnancy or life-threatening inanition (***). Consider simplifying pre-existing polypharmacy, 
which may have raised the seizure threshold. It is very unusual for ECT to be used under mental 
health legislatioŶ ǁithout a patieŶt͛s ĐoŶseŶt; feaƌs that this ŵaǇ oĐĐuƌ should ďe allaǇed. 
When depressive symptoms are less severe, and despite limited evidence, lithium may be 
considered, especially as a prelude to long-term treatment (**). 
Consider family-focused, cognitive behaviour therapy or interpersonal rhythm therapy as an 
additional treatment, when available, since these may shorten the acute episode (**). 
(b) For patients who suffer a depressive episode while taking long-term treatment. Ensure that the 
current choice of long-term treatments is likely to protect the patient from manic relapse (e.g. 
lithium, valproate, dopamine receptor antagonist/partial agonist drugs), by checking adequate doses 
of medicines and/or serum concentrations of lithium within the usual target range (S). Address 
current stressors, if any (S). 
If the patient fails to respond to optimization of long-term treatment, and especially if depressive 
symptoms are significant, initiate treatment as above. See also section on treatment-resist-ant 
depression below. 
(c) Choice of drug for a depressive episode. Treatment preference cannot be securely based on the 
current database of RCTs (IV). The available network meta-analyses may not be stable because 
rankings are strongly influenced by inclusion criteria and indirect comparisons sometimes contradict 
the findings from direct comparisons. 
There is a risk of a switch to mania or mood instability during treatment for depression (I). While this 
will often reflect the natural history of the disorder, it may be increased by monotherapy with 
antidepressants. The dual-action monoamine re-uptake inhibitors (venlafaxine, duloxetine, 
amitriptyline and imipramine) (II)) carry a greater risk of precipitating a switch to mania than single 
action drugs (especially selective serotonin re-uptake inhibitors) (II). 
Antidepressant drugs appear unlikely to induce mania when used in combination with a drug for 
mania (I). 
In bipolar II disorder, if an antidepressant is prescribed as monotherapy, any increase in dose should 
be gradual and there should be vigilance for and early management of any adverse reactions such as 
hypomania, mixed states or agitation (IV). 
In contrast to the common use of antidepressants, audit data suggest that lamotrigine is too little 
used outside specialist centres, given its efficacy in bipolar I, and suitability for bipolar II disorder. 
If successful treatment has been initiated for depression de novo in a bipolar illness course, long-
term treatment should be considered (see below) (S). 
(d) Tapered discontinuation of antidepressant drugs may be considered after full remission of 
symptoms (IV). Depressive episodes that remit in bipolar disorder tend to be shorter than in unipolar 
disorder (I); in the absence of strong data for maintenance efficacy, consider discontinuation of 
antidepressants after as little as 12 weeks in remission (*). 
Longer treatment with antidepressants is justified if patients relapse on their withdrawal (IV). 
(e) Treatment of resistant depression. Relative or even marked treatment resistance may occur in 
depressed bipolar patients (I). This would mean failure to respond not just to an antidepressant but 
also quetiapine, olanzapine, lurasidone and lamotrigine singly and in combination. There is very little 
information from trials on the treatment of such refractory bipolar patients. ECT is an option (***). 
Augmentation strategies may be translated from experience in unipolar patients (see BAP guideline 
on the use of antidepressants: Management when initial treatment fails), but not before evidence-
based bipolar options have been exhausted. Adequate anti-manic cover with lithium, valproate or a 
dopamine antagonist/partial agonist will be necessary (S). 
Choice of initial treatment: psychosocial treatments. There is very little evidence of efficacy of 
psychological treatments alone (without pharmacotherapy) in the treatment of acute bipolar 
depression. 
Recommendations for psychotherapy alone (as in NICE2014, for example) are surprising and based 
on very low-quality data (*). More evidence is needed that this is really an effective approach (IV). 
3. Long-term treatment 
(a) Prevention of new episodes. Consider long-term treatment following a single severe manic 
episode (i.e. diagnosis of bipolar I disorder) (***). 
However, without active acceptance of the need for long-term treatment, adherence may be poor 
(I). Consider a wider package of treatment offering enhanced psychoeducation, motivational and 
family support, especially in the early stages of illness to promote behaviour change and adherence 
to medication (***). 
When a patient has accepted treatment for several years and remains well, they should be advised 
to continue indefinitely, because the risk of relapse remain high (***). 
Consider extrapolating the advice for bipolar I to bipolar II disorder, given increasing evidence for 
common efficacy from clinical trials (**). 
(b) Options for long-term treatment. At present the preferred strategy is for continuous rather than 
intermittent treatment with oral medicines to prevent new mood episodes. The network meta-
analysis of available RCTs with relapse prevention designs supports the efficacy of a limited range of 
individual medicines with different pharmacology and different weights of evidence: lithium, 
olanzapine, quetiapine, risperidone LAI (long-acting injection) and valproate (albeit marginally) 
prevented manic relapse. Only lamotrigine, lithium and quetiapine were convincingly shown to 
prevent depressive relapse. Lurasidone also pre-vents relapse to depression. 
Relatively few patients remain in such trials for as long as 6 months, but lithium is exceptional in 
having strong evidence for relapse prevention from RCTs in which patients were not enriched for an 
acute response to lithium (I). 
Most of the evidence concerns patients with a bipolar I illness course; however, extrapolation to 
bipolar II disorder appears logical (IV). 
Short-term add-ons (e.g. GABA modulators or dopamine antagonists/partial agonists) are necessary 
when an acute stressor is imminent or present, early symptoms of relapse (especially insomnia) are 
present or anxiety becomes prominent (IV). Consider supplying these medicines prospectively to 
patients with instructions how to use at their discretion (*). Higher doses of long-term treatments 
may also be effective, instead of add-ons (*). 
Since the optimum long-term treatment strategy is not established, clinicians and patients are 
encouraged to participate in clinical trials designed to answer key therapeutic questions (S). 
(c) Choice of long-term medicines. In addition to the relapse prevention RCTs, naturalistic data, 
allowing comparison of rates of hospital admission on and off treatment over 4 years, are strongly 
supportive of efficacy for lithium>valproate>olanzapine>lamotrigine>quetiapine>carbamazepine (I). 
Consider lithium as initial monotherapy (****). 
Lithium monotherapy is effective against manic, depressive and mixed relapse (I), has better 
evidence for prevention of new episodes than other agents (I) and a more substantial evidence base 
documenting the risks of prolonged exposure (I). Lithium is associated with a reduced risk of suicide 
in patients with bipolar disorder in RCTs and in both self-harm and suicide in observational studies 
(I). 
Biochemical monitoring of lithium treatment, including plasma lithium concentrations, is a standard 
of care (S); the target range is 0.6–0.8 mmol/L. Lithium concentrations above 0.8 mmol/L are 
associated with an increased risk of renal impairment especially in women (I). Clinicians should know 
that NICE2014 recommended monitoring lithium concentrations at 3-monthly intervals for the first 
year of treatment in otherwise healthy patients, and 6 monthly thereafter (S). 
Consider other options if lithium is ineffective, poorly tolerated or if patients are unlikely to be 
adherent: valproate, dopamine antagonists/partial agonists (****). 
Valpƌoate is ofteŶ aĐĐoƌded aŶ eƋuiǀaleŶt plaĐe to lithiuŵ as a ͚ŵood staďilizeƌ͛. It has a ǁeakeƌ 
evidence base from RCTs, but upgraded naturalistic data supports its position ahead of other options 
(I). Safety concerns in women have already been noted. 
Additional evidence for efficacy of specific treatments comes, as already indicated, from trials in 
which patients have responded favourably to a particular medication in an acute indication. 
Accordingly, in an individual patient, if a medicine leads to prompt remission from the most recent 
manic or depressive episode, this may be considered evidence in favour of its long-term use as 
monotherapy (IV). Because effective in the short term, this may lead to preferential use of dopamine 
antagonists; active consideration of lithium as a better alternative should be promoted (IV). 
Carbamazepine is less effective in maintenance treatment than lithium but may sometimes be used 
as monotherapy if lithium is ineffective and especially in patients who do not show the classical 
pattern of episodic euphoric mania (II). It appears to be almost exclusively effective against manic 
relapse (I). Be aware of the pharmacokinetic interactions that are a particular problem with 
carbamazepine. Oxcarbazepine may be considered by extrapolation because of its lower potential 
for such interactions (I). 
Consider long-aĐtiŶg ;͚depot͛Ϳ foƌŵulatioŶs if pƌophǇlaǆis agaiŶst ƌeĐuƌƌeŶĐe of ŵaŶia is ƌeƋuiƌed 
and adherence to oral medication is erratic or injection preferred (**). Various LAI dopamine 
antagonist/partial agonists are available, including fluphenazine decanoate, haloperidol decanoate, 
olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole 
monohydrate. Only risperidone has RCT support (II). Use of other options will represent 
extrapolation from oral efficacy or class effect of dopamine antagonists/partial agonists and clinical 
experience (IV). 
Lamotrigine and quetiapine may be considered as monotherapy in bipolar II disorder (***). In 
bipolar I disorder, lamotrigine will usually require combination with an anti-manic long-term agent 
(IV). 
(d) If the patient fails to respond to monotherapy and continues to experience subthreshold 
depressive symptoms or relapses, consider long-term combination treatment (GRADE: variable for 
different combinations). When the burden of disease is mania, it may be logical to combine two 
predominantly anti-manic agents (e.g. lithium, valproate, a dopamine antagonist or a dopamine 
partial agonist) (IV). When the burden is depressive, a combination of lithium, lamotrigine, que-
tiapine, lurasidone or olanzapine may be more appropriate (IV). 
The role of antidepressants in long-term treatment is not established by controlled trials; 
nevertheless, they appear to be used effectively in a minority of patients in the long term (**). 
Consider continuation of clozapine if effective in refractory mania (**).Maintenance ECT may be 
considered for patients who respond to ECT during an acute episode but respond poorly to all oral 
agents (*). 
Consider adjunctive psychotherapy to address subthreshold symptoms (**; see (g)). 
(e) If rapid cycling poses particular long-term management problems. Identify and treat conditions 
such as hypothyroidism or substance use that may contribute to cycling (**). 
Consider tapering and discontinuing antidepressants that may contribute to cycling (*). 
There are no specific treatments for rapid cycling. As an often disabling expression of bipolar 
disorder, many patients require combinations of medicines. Evaluate anti-cycling effects over 
periods of 6 months or more by tracking mood states longitudinally. Discontinue ineffective 
treatments to avoid unnecessary polypharmacy (S). 
(f) Discontinuation of long-term treatment. Following dis-continuation of medicines, the risk of 
relapse remains, even after years of sustained remission (II). Accordingly, if discontinuation is 
considered, it should be accompanied by an informed assessment of the potential dangers (S). 
Discontinuation of any medicine should normally be tapered over at least 4 weeks and preferably 
longer (S). Early relapse to mania is an early risk of abrupt lithium discontinuation (I). 
Discontinuation of medicines should not lead to withdrawal of services to patients; short-term care 
and monitoring will still be required if medication is discontinued, together with a management plan 
to recognize and treat early warning signs of future relapse to mania or depression (S). 
(g) Specific psychosocial interventions. Psychosocial interventions may enhance care, reduce 
subthreshold symptoms and reduce risk of relapse (II). Psychoeducation is a component of good 
clinical practice, because clinical communication cannot be effective without it (S); it is formally 
supported by manualized approaches tested formally in clinical trials (****). 
A number of differently named therapies (family-focused therapy, cognitive behaviour therapy, 
interpersonal social rhythm therapy) have also been studied in relapse prevention. It is striking that 
they share many elements with each other and with psychoeducation. Psychological interventions 
appear to be more successful with patients early in their illness course (I). 
The functional impairments of bipolar patients may merit cognitive and functional remediation 
strategies (II). 
User groups can provide useful support and information about bipolar disorder and its treatment 
(IV). All treatment recommendations are summarized in Table 3. 
4. Treatment of alcohol use disorder 
“ee BAP͛s evidence-based guidelines for the pharmacological management of substance abuse, 
harmful use, addiction and co-morbidity. In heavy drinkers, modest reductions in consumption may 
result in substantial health gains (I). 
Offer naltrexone or nalmefene as part of a behavioural programme to help patients reduce their 
alcohol consumption (**). 
Offer acamprosate if naltrexone has not been effective to help patients remain abstinent (*). 
 Consider disulfiram if patient wants abstinence and if acamprosate and naltrexone have failed. The 
patient must be able to understand the risks of taking disulfiram and have their mood monitored (*). 
5. Treatment of co-morbid borderline 
personality disorder 
In co-morbid patients both disorders may require treatment. Hence, avoid a polarizing choice 
between medication (usually required for bipolar disorder) and psychological treatment (the 
preferred approach to borderline problems) (S). 
In the absence of relevant evidence, there is no reason to with-draw or withhold appropriate 
treatment for bipolar disorder or borderline personality disorder. Although the place of 
pharmacotherapy for borderline symptoms is based on limited evidence, the shared symptom of 
mood instability may be appropriately treated by medicines (e.g. lamotrigine, lithium, olanzapine, 
risperidone, aripiprazole and quetiapine) and borderline symptoms improved (*). 
6. Treatment of anxiety and other co-morbid 
disorders 
Consider treatment along the lines suggested by BAP guidelines for the treatment of anxiety 
disorders, attention deficit hyperactivity disorder and substance use disorders (*). Care in the use of 
antidepressants is required (S). 
7. Treatment in special situations 
In children and young people 
For mania. Consider aripiprazole as first line because it is licensed in adolescents (over 13 years) with 
bipolar I disorder (***). Otherwise refer to adult recommendations; there is some primary evidence 
that olanzapine, quetiapine, and risperidone are efficacious in adolescents (**). 
Refer to the British National Formulary (BNF) for Children to modify drug doses (S). Be aware of the 
increased potential for a range of adverse reactions and effects, particularly weight gain (S). 
For bipolar depression. Consider medicines and psychological treatments largely by extrapolation 
from data in adults (*). 
Drugs for depression may induce switch to mania more frequently in children and young people than 
adults (II). 
The need for long-term treatment should be considered in young people because of the potentially 
disruptive effect of relapse and mood instability on cognitive and emotional development (S). 
In elderly people. Consider lower doses of psychotropic medicines of all classes for all phases of 
treatment when adverse reactions or effects are evident with conventional dosing (check the 
Summary of Product Characteristics (SPC) for prescribing recommendations) (*). 
In women and pregnancy 
Women who may become pregnant. There is a risk of teratogenicity from valproate and 
carbamazepine (I). The risk/benefit for valproate contraindicates its use in women of child-bearing 
potential under normal circumstances (I). 
Concerns about lithium and cardiac malformation appear to have been disproportionate (II). 
Since as many as 50% of pregnancies currently occur unplanned, access to family planning advice 
should be ensured whenever feasible (S). 
Women who are pregnant. Low or no risk of teratogenesis appears to be associated with dopamine 
antagonists/partial agonists, antidepressants, lamotrigine and lithium. However, risks from new 
compounds are usually unknown and always justify caution. Any teratogenic risk putatively 
associated with the use of medicines should be considered in the poorly appreciated context of a 
relatively high, age-related, baseline risk for congenital malformations and spontaneous abortion 
and confounding by indication (S). 
Women are not protected from relapse by pregnancy. Discontinuation of medicines risks 
destabilizing mood (IV). Hence, the possible risks of medicines to the foetus needs to be balanced 
with the risk of mental illness in the mother and its effects on the health of the baby (S). 
Many psychotropic drugs used to treat bipolar disorder can cause neonatal symptoms (II & III). 
Neonates should be monitored for possible adverse reactions in the hours and days following birth 
(S). 
Women are at high risk of relapse to mania or depression following childbirth (I). Vigilance is 
essential and effective prophylactic treatment should always be considered and usually 
recommended (S). 
Adverse reactions attributed to maternal psychotropic medicines have been sporadically reported in 
breast-fed infants but the prevalence is unclear (III). 
Women who continue to take psychotropic medication after childbirth should choose between 
breast and bottle feeding after a full explanation of the relevant benefits and harms (S). If a mother 
takes medication and breastfeeds, the infant should be monitored for possible adverse reactions (S). 
There are regular reports of adverse outcomes in the development of the children of women treated 
with antidepressants or other psychotropic drugs. Too often such studies appear inadequately 
controlled for confounding by indication. Accordingly, claims that drugs used in pregnancy cause 
adverse behavioural outcomes should be treated cautiously. 
NICE has published perinatal guidelines relevant to these recommendations 
(http://pathways.nice.org.uk/pathways/antenatal-and-postnatal-mental-health). 
Part 2. Consensus points and review 
Fundamentals of patient management 
1.Diagnosis and psychopathology 
 DSM-5 criteria provide the appropriate schema for diagnosis of Bipolar Disorder. DSM-5 
mania defines bipolar I Disorder (S).  Hypomania is not associated with significant functional impairment. With major depression, 
a history of hypomania defines bipolar II disorder (S).  Hypomania and mania apparently precipitated by antidepressants or stimulants does not 
disallow the diagnosis of bipolar disorder (IV).  Incidence per lifetime is, together, about 1% for bipolar I and conservatively defined DSM-5 
bipolar II disorder (I). Other Specified Bipolar and Related Disorders add a further 2–3% of 
bipolar diagnoses in adults.  Bipolar I disorder is highly heritable (up to 80%) and caused by many common genetic 
variations of small effect.  Bipolar I disorder (mania) occurs rarely in pre-pubertal children, but its improved diagnosis 
in children and young adults is an important priority(S).  Relapse in bipolar I and bipolar II disorder occurs with a higher frequency than in unipolar 
depression (I).  The clinical presentation of major depression is similar for unipolar and bipolar patients. 
Suicide, deliberate self-harm and violence are important risk outcomes across the life span 
for bipolar patients (I).  Anxiety disorders are the commonest co-morbid conditions in bipolar disorder (I) but are 
often missed or ignored (IV).  Alcohol use is common in bipolar disorder (I). Drug use is more relevant to younger patients 
with mania (I). Established addictive problems should be assessed and treated (S).  Delay in diagnosis occurs because the illness may start non-specifically, the diagnosis of 
mood elevation is missed or symptoms are attributed to substance use or personality 
disturbance (II).  There is an unexplained resistance on the part of some clinicians to diagnose bipolar 
disorder even when the syndrome of mania has clearly been present (IV). 
Key uncertainties 
 Severity of mania, presence of psychotic features and mixed features may all influence 
outcome but are poorly characterized in relation to treatment response.  The diagnosis of hypomania in DSM-5 sets an arbitrary minimum time requirement of 4 
daǇs. MaŶǇ ŵoƌe Đases of ͚uŶipolaƌ͛ ŵajoƌ depƌessioŶ appeaƌ to haǀe had shoƌteƌ 
periods of hypomania or simply hypomanic symptoms, so approaching or meeting 
Đƌiteƌia foƌ ͚otheƌ “peĐified Bipolaƌ aŶd ‘elated Disoƌdeƌs͛.  DSM-ϱ eŶĐouƌages the use of ͚ŵiǆed featuƌe͛ speĐifieƌs foƌ iŶdiǀidual episodes to 
capture symptoms of the opposite pole of the illness. The relationship between major 
depressive disorder (MDD) with mixed features and bipolar disorder is uncertain. It may 
be more common in the presence of co-morbid borderline personality disorder (II). 
 The mechanisms linking bipolar states to self-harm or other violent acts (for example, 
impulsivity, disinhibition, inducing or exacerbating low mood via alcohol/drugs) are 
poorly understood.  DSM-5 has introduced a new syndrome (disruptive mood dysregulation disorder or 
DMDD) to capture a childhood syndrome, which may have nothing to do with bipolar 
disorder, but is classified as a mood disorder. 
Reliable diagnosis was arguably the major achievement of the last century in psychiatry. It depends 
upon the use of operational criteria to define cases, and its most important framework is provided 
by DSM-IV (American Psychiatric Association, 1994) and DSM-5 (American Psychiatric Association, 
2013). We will recommend DSM-5 criteria in this text. However, some of the changes in diagnostic 
sub-typing with specifiers will have uncertain implications for current treatments. We also recognize 
that in clinical practice the precise use of research criteria may be too exacting a standard. It is 
however, the standard to which we should aspire. 
Reliability of diagnosis, especially for mania, is high under optimal conditions. The use of checklists 
and standardized inter-views could ensure improved diagnosis under ordinary clinical conditions 
(Hiller et al., 1993). However, we recognize that field trials for DSM-5 showed only average reliability 
for bipolar diagnoses (Freedman et al., 2013). Practice may also be made more comprehensive with 
a patient-completed screening instrument like the Mood Disorders Questionnaire (MDQ) (Hirschfeld 
et al., 2003), the Hypomania/Mania Symptom Checklist (HCL-32) (Meyer et al., 2007) or the 
Computerized Adaptive Technology for Mental Health (CAT-MH) (Achtyes et al., 2015). 
Bipolar disorder is, at present, the most commonly used term to describe serial elevations of mood 
usually along with intercurrent depressions of mood. Descriptions consistent with bipolar disorder 
exist since antiquity, but Kraepelin first used the term manic-depressive psychosis to include all 
cases of affective psychosis. Patients with unipolar, commonly psychotic depression were included in 
the diagnosis whether or not they had experienced mania. The central emphasis on mania and thus 
on bipolar-ity emerged relatively recently. Bipolar I disorder is defined by episodes of mania and 
also, usually, depression. The incidence of bipolar I disorder is estimated between 2 and 21 per 
100,000, per year. Differences in reported rates are probably due to the definition of cases. 
Differences based on first admissions to hospital, which is a proxy estimate of severity, show figures 
that are less variable and, on average, represent a rate of about 3–4 people per 100,000 per year. 
Incidence per lifetime of bipolar disorder is approximately 0.5–1% for bipolar I disorder (I, (Angst and 
Sellaro, 2000; Lloyd and Jones, 2002; Merikangas et al., 2007)). 
Bipolar II disorder is characterized by episodes of hypomania and, invariably, major depression. As 
defined by DSM-IV, its lifetime incidence has also been described as about 1% (I, (Angst, 1998; 
Merikangas et al., 2007)). This estimate depends on where the boundary between bipolar II and 
subthreshold bipolarity is drawn. A figure nearer 0.5% may be more appropriate (Merikangas and 
Lamers, 2012) giving 1% as the figure for life-time diagnosis if bipolar I and II combined. 
Bipolar I disorder is prominent in secondary care because it is a highly prevalent rather than a highly 
incident condition. It follows a relapsing, often chronic course, with an average eight epi-odes over 
the 10 years following diagnosis. The rate of relapse is higher than that seen in unipolar disorder of 
comparable sever-ity (I, (Angst and Preisig, 1995; Winokur et al., 1993)). 
The known aetiology of bipolar disorder is primarily genetic with estimated heritability as high as 
0.93 (I, (Kieseppa et al., 2004; Potash and DePaulo, 2000)). This means it is one of the most heritable 
disorders in medicine. Genome-wide association studies have now been conducted on sufficiently 
large samples to give complete confidence in a growing number of specific genes. These small 
effects when combined can now account for about 20% of the heritability (Cross-Disorder Group of 
the Psychiatric Genomics et al., 2013). Bipolar disorder is highly polygenic so leaving little room for 
causation by rare genes of large effect. Genetic effects are not susceptible to errors of reverse 
causation, otherwise common in observational epidemiological studies. Therefore, these positive 
findings confirm that the DSM diagnosis has some biological validity. However, there is clear 
evidence of overlap with risk genes for both schizophrenia and major depression. This genetic 
architecture was predicted by the elevated rates of bipolar disorder, unipolar depression and 
psychosis in first-degree relatives of bipolar patients (Gershon et al., 1982). Compared with 
schizophrenia, there is weaker evidence for presumed environmental aetiologies such as obstetric 
complications or inner city residence (I, (Bain et al., 2000; Browne et al., 2000; Lloyd and Jones, 
2002)). 
Factors such as early abuse and neglect are elevated in bipolar disorder and increase the risks for 
other co-morbid psychiatric disorders; this probably worsens the course of bipolar illness (I, (Agnew-
Blais and Danese, 2016)). Abuse and neglect are also associated with impairments of memory and 
executive function in bipolar patients (Savitz et al., 2008) and may increase the risk of psychosis 
(Read et al., 2005). 
The overlap of risk genes for bipolar I disorder with those for attention deficit hyperactivity disorder 
(ADHD) is apparently negligible, even though current significant alleles account for about 20% of the 
risk of each disorder separately (Cross-Disorder Group of the Psychiatric Genomics et al., 2013). This 
is perhaps the first example of where genetics may eventually guide psychiatric diagnosis (see 
below). 
The differential diagnosis of elated states in bipolar disorder. Mania defines bipolar I disorder. DSM-
IV criteria for mania, which form the basis for most of the studies cited in these guidelines, are as 
follows (American Psychiatric Association, 1994): 
1. A distinct period of abnormally and persistently elevated, expansive, or irritable mood, lasting at 
least 1 week (or any duration if hospitalization is necessary). 
2. During the period of mood disturbance, three (or more) of the following symptoms have persisted 
(four if the mood is only irritable) and have been present to a significant degree: 
a. inflated self-esteem or grandiosity 
b. decreased need for sleep (e.g. feels rested after only 3 hours of sleep) 
c. more talkative than usual or pressure to keep talking 
d. flight of ideas or subjective experience that thoughts are racing 
e. distractibility (i.e. attention too easily drawn to unimportant or irrelevant external stimuli) 
f. increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor 
agitation 
g. excessive involvement in pleasurable activities that have a high potential for painful consequences 
(e.g. engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments) 
3. The symptoms do not meet criteria for a Mixed Episode. 
4. The mood disturbance is sufficiently severe to cause marked impairment in occupational 
functioning or in usual social activities or relationships with others, or to necessitate hospitalization 
to prevent harm or self or others, or there are psychotic features. 
5. The symptoms are not due to the direct physiological effects of a substance (e.g. a drug of abuse, 
a medication, or other treatment) or a general medical condition (e.g. hyperthyroidism). 
DSM-5 (American Psychiatric Association, 2013) has modified Criterion 1 by adding the requirement 
for increased activity/energy as a core symptom of mood elevation. This represents an effort to 
reduce over-diagnosis of bipolar disorder driven by subjective report, and increase specificity 
(Suppes et al., 2014). 
The symptoms must be present for 1 week and/or require hospital admission. Most critically, the 
criteria include a judgement that function is impaired. Admission to hospital obviously defines loss of 
function and autonomy quasi-objectively. Less obvious impairment will require identification of 
failure in normal work-ing and personal relationships and judgement. Intelligent patients may be 
very difficult to assess from this point of view without corroborating evidence from third parties. The 
contribution this makes to misdiagnosis will be considered below. This definition of mania underpins 
the distinction made between bipolar I disorder and milder elated subtypes. Psychotic mania is 
usually regarded as reflecting severity rather than a subtype. Thus, psychotic symptoms wax and 
wane within individual subjects and are not invariably present from one episode to another. As a 
rule, psychotic symptoms in mania are mood congruent and represent an extension of grandiose 
interpretations, paranoid ideation or heightened awareness. They are relatively common 
(Dunayevich and Keck, 2000; McElroy et al., 1996). However, in a study of over 500 patients with 
mania, only 20% had a presentation dominated by psychosis (Sato et al., 2002). This may mean that 
such symptoms can often be missed in routine clinical practice. 
In a minority of cases, symptoms seem to be mood incongruent and in some cases this is diagnosed 
as schizoaffective disorder. Strictly defined schizoaffective disorder (according to DSM-IV and 5) is 
relatively uncommon in clinical samples because patients must meet diagnostic criteria for both 
bipolar disorder and schizophrenia simultaneously. It may also be unreliable (II, (Maj et al., 2000)). 
The meaning of a schizoaffective diagnosis also remains controversial. It may represent forms of 
illness in some sense inter-mediate between the two Kraepelinian psychosis types, so supporting the 
unity of psychotic states, or it may be the co-occurrence of the two different disorders (II, (Kendell, 
1987; Kendell and Gourlay, 1970)). Genetic findings are increasingly supportive of the former view 
(Craddock and Owen, 2010). 
Although euphoric mania is the classic type of presentation, a significant number of cases of mania 
are far from euphoric and may have a mixture of different symptom dimensions. These dysphoric 
presentations require diagnostic expertise for detection. The most striking example is where 
patients meet the criteria for both mania and depression simultaneously as was required for the 
diagnosis of a mixed state in DSM-IV. However, some significant admixture of dysphoric (depressive) 
symptoms occurs in many manic episodes. Factor analyses of the symptoms of manic patients have 
been relatively consistent in suggesting that the atypical features of depressive mood, irritable 
aggression and psychosis load on separate uncorrelated factors (II, (Cassidy et al., 1998; Sato et al., 
2002)). This agreement suggests the potential to distinguish several relatively separate syndromes 
among manic patients. Subsequent analysis has confirmed that there are at least two mixed mania 
presentations. One has a dominant mood of severe depression with labile periods of pressured 
irritable hostility and paranoia, but a complete absence of euphoria or humour. The second has a 
true mixture of affects with periods of classical euphoria switching frequently to moderately 
depressed mood with anxiety and irritability (II, (Cassidy et al., 2001)). These putative subtypes are 
not identified by existing diagnostic criteria and hence are not distinguished in treatment studies. 
The change in approach to mixed states in DSM-5 is discussed be Severity of mania, presence of 
psychotic features and the admixture of depressive symptoms may all influence outcome but are 
also poorly characterized in relation to treatment response. Future advice on acute treatment may 
take account of differential effects of medicines on the common symptom dimensions. However, at 
present, only severity, especially expressed as over-activity, imposes itself on current treatment 
options. 
With DSM-5, it is now accepted that mania associated with antidepressant treatment should usually 
be regarded as defining bipolar disorder, except when the symptoms are reliably locked in time to 
exposure to a specific antidepressant, like other drug-induced psychoses as discussed below (IV, 
opinion of the consensus group). 
The diagnosis of hypomania. Both the use of the term and the criteria for hypomania have been 
controversial. Its definition has been crucial to the diagnosis of elated states outside bipolar I 
disorder. DSM-IV recognized core symptoms of hypomania as a checklist like that for mania itself; 
DSM-5 has modified Criterion 1 by adding the requirement for increased activity/energy as a core 
symptom of mood elevation in line with its new definition of mania (see above). This is intended to 
make diagnosis more reliable, but will thereby exclude individuals with purely subjective experiences 
of mood elevation from a bipolar II diagnosis. 
The time requirement is for 4 days of symptoms. Patients must display observable but not impaired 
change in function. This will include mood elevations and increases in energy that are often 
positively valued by individuals with bipolar disorder. In contrast ICD-10 chooses a slightly different 
set of sǇŵptoŵs aŶd ƌeƋuiƌes foƌ hǇpoŵaŶia ͞soŵe iŶteƌfeƌeŶĐe ǁith peƌsoŶal fuŶĐtioŶiŶg͟. 
Essentially hypomania under this definition is mild mania and should not include DSM-5 cases of 
hypomania. ICD-10 hypomania contributes little but confusion to current classification because it 
tends to encourage the use of the term for frankly manic states (IV, (Goodwin, 2002)). 
There is continuing interest in the extension of a bipolar diagnosis to a spectrum of cases with less 
severe elated states. Bipolar disorder not otherwise specified (NOS) is a DSM-IV category that 
includes any of the following:(1) recurrent subthreshold hypomania in the presence of intercurrent 
major depression, (2) recurrent (at least two episodes) hypomania in the absence of recurrent major 
depression with or without subthreshold major depression, and (3) recurrent subthreshold 
hypomania in the absence of intercurrent major depression with or without sub-threshold major 
depression. The number of required symptoms for a determination of subthreshold hypomania is 
confined to two criterion B symptoms (from the DSM-IV requirement of three, or four if the mood is 
only irritable) to retain the core features of hypomania in the subthreshold definition. DSM-5 has 
ĐhaŶged the ͚Bipolaƌ NO“͛ gƌoupiŶg to ͚Otheƌ “peĐified Bipolaƌ aŶd ‘elated Disoƌdeƌ͛ ďut Đoǀeƌs the 
same still ill-defined group of disorders; they have a 2.4% community lifetime incidence (Merikangas 
et al., 2007). 
In fact, on the basis of symptom endorsement over a lifetime in clinic samples, Cassano et al. (2004) 
have suggested that mood elevation forms a continuous bridge between unipolar and bipolar 
disorder. The intensity of illness, either depressive or manic, increased in parallel and simply showed 
a higher baseline of elated experience for the bipolar group compared with the unipolar cases. If 
there is indeed no qualitative break between unipolar and bipolar disorder, the question becomes 
one of calibration. At what point on this continuum of experience does mood elevation influence 
treatment choice? 
DSM-5 has introduced the concept of a mixed features specifier (see below), which formalizes the 
identification of manic symptoms in depressive episodes (Angst et al., 2011). These pro-posed 
diagnoses still do not yet have clear implications for treatment. However, to call such cases bipolar 
would increase the temptation for treatment choices to be extrapolated from bipolar I/II data. 
The differential diagnosis of depressed states in bipolar disorder. Major depression in the context of 
bipolar disorder is similar to major depression arising in a unipolar illness course, when severity is 
comparable. Within episodes of depression, grades of intensity – mild, moderate and severe – 
should be distinguished. The use of a scale such as the Inventory of Depressive Symptomatology 
(IDS) or Quick Inventory of Depressive Symptomatology (QIDS), which maps to the diagnostic 
features, gives a severity estimate. The QIDS, in particular, is useful in its self-administered form 
(Rush et al., 2003). 
Bipolar patients may be more likely to demonstrate psycho-motor-retarded melancholic and atypical 
depressive features and to have had previous episodes of psychotic depression (II, (Mitchell et al., 
2001)). Retarded or psychotic depression, particularly in young people, should raise the suspicion of 
a bipolar illness course. Indeed, there are a number of other clinical features suggesting a bipolar 
illŶess, suĐh as ͚atǇpiĐal͛ depƌessiǀe featuƌes ;hǇpeƌsoŵŶia, hǇpeƌphagia aŶd leadeŶ paƌalǇsisͿ, 
pathological guilt and lability of mood, but none can convey a categorical certainty. There may be 
scope for the development of such features as a measure of probability that an episode of 
depression is the manifestation of bipolar disorder in the absence of evidence of mood elevation 
(Mitchell et al., 2008). 
Poor outcomes in bipolar disorder. Deliberate self-harm and completed suicide are important risks in 
bipolar disorder and are associated with depression and mixed states (I, (Black et al., 1987a; ten 
Have et al., 2002)). For patients identified by admission to hospital, absolute rates of suicide are 
about 0.4% per year (Tondo et al., 2003). This is 20-fold greater than population rates and translates 
into risks at long-term follow-up between 3–6% (I, (Chesney et al., 2014; Crump et al., 2013)), which 
are amongst the highest for any psychiatric disorder. The increased odds of self-harm and suicide 
compared with sibling controls, arguably a more relevant comparison, is still 6–8-fold (Webb et al., 
2014). 
The risk of violent and non-violent crime is also elevated in bipolar patients, especially males. The 
increase compared with sibling controls is 2–4-fold. This risk may not be as widely appreciated as the 
risk for suicide, but offending is actually a more common outcome and thus associated with a higher 
absolute risk. Rates of violent crime in male patients were 8% and, for non-violent crime, 18% in one 
population cohort study, with most of these patients committing their crimes within 5 years of 
diagnosis (Webb et al., 2014). 
Suicide has always received more attention than other adverse outcomes. The risk of suicide is 
highest early in the course of the illness (Hoyer et al., 2000). Suicide is independently associated with 
male gender, previous self-harm, alcohol and drug use dis-orders, and previous criminality (Webb, 
2014). An early review identified hopelessness at index admission as another risk factor (Hawton et 
al., 2005). A longer list of possible contributory factors emerges from a broad review of the literature 
(Pompili et al., 2013); the contribution of individual risks is poorly quantified and many are likely to 
be confounded. 
The lifetime prevalence of non-fatal suicidal behaviour (self-harm or attempted suicide) in those 
with bipolar disorder is approximately 30% (Chen and Dilsaver, 1996; Tondo et al., 2003) and may be 
as high as 50% in secondary care samples (Valtonen et al., 2005). A recent Swedish population study 
estimated rates of hospital-presenting self-harm at 10% in male patients and 14% in female patients 
(Webb et al., 2014). Studies have shown that a wider range of factors are associated with self-harm 
than suicide itself, presumably because the former is a more common outcome. These factors 
include mixed states, rapid cycling, alcohol and drug use, co-morbid anxiety, a positive family history 
of suicide and, possibly, early abuse or a bipolar II diagnosis (Hawton et al., 2005; Schaffer et al., 
2015). Bipolar patients have the highest rate of suicide of all psychiatric disorders. In addition, 
independent associations have been found for female gender, previous criminality, parental 
psychiatric disorders and low family income (Webb et al., 2014). Aggression and impulsivity may also 
be associated with suicide attempts (Oquendo et al., 2000, 2004). 
Specifiers in DSM-5 
DSM-5 has introduced a device to recognize the heterogeneity of episodes in bipolar disorder in the 
form of specifiers. These can be used with any primary diagnosis (mania, hypomania, depression) to 
enrich the clinical description. 
The mixed features specifier. In DSM-IV, a mixed episode was defined as requiring the full syndrome 
of mania and major depression to be present simultaneously for at least 1 week. In practice this 
proved to be a rare diagnosis, although it was widely recognized that symptoms from the opposite 
pole might be present in a bipolar episode: this has already been discussed above for mania. DSM-5 
has dƌopped the ĐategoƌǇ ͚ŵiǆed episode͛ aŶd iŶtƌoduĐed a Ŷeǁ featuƌe to the diagŶosis of a 
primary manic, hypomanic or depressive episode: the mixed feature specifier. A specifier requires 
the presence of three symptoms from a list restricted to those symptoms unique to the pole in 
question. Thus a manic episode can be said to have mixed features (of depression) if there are three 
or more of subjective depression, worry, self-reproach/guilt, negative evaluation of self, 
hopelessness, suicidal ideation or behaviour, anhedonia, fatigue or psychomotor retardation. 
The BRIDGE study of over 5000 adults with a major depressive episode identified 47.0% (95% 
confidence interval (CI), 45.7–48.3%) as meeting the bipolarity specifier criteria. Associations (odds 
ratio >2; p<0.001) with bipolarity were observed for family history of mania/hypomania, multiple 
past mood episodes and co-morbid substance use disorder (Angst et al., 2011). 
This change may have important implications for clinical care, education and research in the future 
(Vieta and Valenti, 2013). For the moment, we do not know whether a more precise categorization 
of episodes in this way will influence indications for treatment. A particular potential confusion is the 
possibility to add a mixed feature specifier to a depressive episode in a unipolar illness course. This 
appears to be most likely when there is a co-morbid borderline diagnosis (Perugi et al., 2015). 
Rapid cycling specifier. Patients with four or more episodes of depression, mania, mixed state or 
hypomania in the preceding 12 months are conventionally described as showing rapid cycling. Rapid 
cycling is another specifier. It conflates patients with frequent illnesses allowing remission between 
episodes with those who cycle continuously (or switch continually) from one polarity to the other 
without euthymia (II, (Maj et al., 1999)). The lifetime risk of rapid cycling is around 16% and it is 
weakly associated with female gender, bipolar II disorder, current hypothyroidism and a poor 
response to lithium (especially the depressive component) (II–III, (Calabrese et al., 2001)). Rapid 
cycling obviously implies temporal severity and it may often be difficult to treat. In 30–40% of cases 
it may be preceded by exposure to antidepressants, and worsened by treatment with 
antidepressants (see below: treatment of depression), but there is no proof of a causal relationship. 
NICE2014 has chosen not to make specific recommendations for treatment of rapid cycling bipolar 
disorder, coŵŵeŶtiŶg ͞Offeƌ people ǁith ƌapid ĐǇĐliŶg ďipolaƌ disoƌdeƌ the saŵe iŶteƌǀeŶtioŶs as 
people with other types of bipolar disorder because there is currently no strong evidence to suggest 
that people with rapid cycling bipolar disorder should be treated diffeƌeŶtlǇ.͟ This is uŶdeƌstaŶdaďle 
given the paucity of evidence, and we agree with their conclusion. 
Other specifiers in DSM-5. Other specifiers that may be included in the description of a relevant 
episode are anxious dis-tress, mood-congruent psychotic features, mood-incongruent psychotic 
features, catatonia, peripartum onset, seasonal pattern and for a depressive episode, melancholic 
feature or atypical features. Their value either for research or clinical practice remains to be 
established. 
Predominant polarity. Although not included in DSM-5 as a course specifier, the majority of patients 
with bipolar disorder have a tendency to develop more episodes of one pole over the other. This has 
relevant clinical and therapeutic implications and can be clinically useful in planning drug and 
psychological treatment (Carvalho et al., 2015; Colom et al., 2006). 
Gender. Women with bipolar disorder have a slightly different profile of illness on average from 
men. The differences include more rapid cycling, a more seasonal pattern, more and longer 
depressive episodes, more mixed and dysphoric mania, more bipolar II cases, more co-morbidity 
with medical disorders (e.g. thyroid disease, migraine, obesity) and anxiety disorders, less substance 
abuse, fewer completed suicides and later onset (Diflorio and Jones, 2010). Except for the 
implications of pregnancy and childbirth, such differences do not carry implications for treatment. 
Co-morbidity. Co-morbidity of bipolar disorder with a range of other psychiatric conditions poses 
problems of two diametrically different kinds. First, non-specific psychological symptoms and 
disturbed behaviour may be the harbinger of bipolar disorder in young people. Diagnostic 
uncertainty or the wrong diagnosis at the very early stages of the illness can delay its accurate 
recognition (I, (Lish et al., 1994)). Secondly, in the presence of recognized bipolar disorder, co-
morbid conditions may contribute to poor treatment response and outcome. 
Anxiety disorders and persistent anxiety symptoms. Com-munity samples show replicated, high 
lifetime co-morbidities of bipolar I disorder with a range of anxiety-related disorders and substance 
use (I, (Kessler et al., 1997; Merikangas et al., 2007)). Lifetime rates are extremely high in some 
estimates: as many as 90% of bipolar I patients reported at some time to have had an anxiety 
disorder in the influential US National co-morbidity survey (I–II, (Freeman et al., 2002; Merikangas et 
al., 2007)). The most recent meta-analysis of 40 studies, including 14,914 individuals from North 
America, Europe, Australia, South America and Asia, suggested a more conservative lifetime 
prevalence of anxiety disorders of about 45% (95% CI 40–51%) (Pavlova et al., 2015). 
This raises the question of how to view anxiety symptoms within the behavioural phenotype in 
bipolar disorder. The earliest symptoms that a patient experiences may be those of anxiety but the 
dominant picture subsequently may be mania and depression. On the other hand, anxiety is not 
uncommon between acute episodes and in bipolar depression. Mixed affective states can be 
misdiagnosed as anxiety and vice versa. 
Where the anxiety disorder dominates the outcome, this must clearly influence evaluations of 
successful treatments. Anxiety disorder co-morbidity is associated with a range of worse out-comes 
in bipolar disorder such as worse functioning, poorer quality of life, increased suicide rates, rapid 
cycling and the transition from unipolar to bipolar depression (Fagiolini et al., 2007; Simon et al., 
2004), and yet has received little specific attention in developing treatments. For adequate 
assessment, anxiety should be regularly monitored (in addition to the usual focus on depression and 
mania). 
In fact, anxiety in bipolar disorder may have particular features that should influence approaches to 
treatment development. There is scope to improve assessment to consider bipolar-specific features 
like anxiety-provoking mental imagery (Hales et al., 2011; Ivins et al., 2014) because this may amplify 
the expectation of futuƌe thƌeat. MeŶtal iŵageƌǇ iŶǀolǀes ͚seeiŶg iŶ the ŵiŶd͛s eǇe͛. While this ŵaǇ 
ƌelate to iŶtƌusiǀe past eǀeŶts ;͚flash ďaĐks͛ as iŶ post-traumatic stress disorder (PTSD)) it is also 
ƌeleǀaŶt as a ͚flash foƌǁaƌd͛ eǆpeƌieŶĐe. PƌeǀiouslǇ suiĐidal patieŶts ŵaǇ, for example, report vividly 
simulating a future out-come such as jumping off a cliff (Hales et al., 2011). Such experience can be 
asked about in assessment (in addition to the content of verbal thoughts) (Di Simplicio et al., 2012). 
Alcohol and drug use. As with anxiety, excessive use of alcohol or drugs is so common in bipolar 
patients that there seems to be a shared vulnerability to either or both outcomes. Experimental 
studies even suggest how this may arise for alcohol dependence (Yip et al., 2012). The risk of alcohol 
dependence is, therefore, another common (and clinically significant) co-morbidity of bipolar I and 
perhaps to a lesser extent bipolar II disorder. Drug, especially stimulant, use is more relevant to 
younger patients with bipolar II disorder and is associated with poorer outcome. It can confound the 
diagnosis and makes engagement with treatment more difficult (I, (Strakowski et al., the very early 
stages of the illness can delay its accurate recognition (I, (Lish et al., 1994)). Secondly, in the 
presence of recognized bipolar disorder, co-morbid conditions may contribute to poor treatment 
response and outcome. 
Anxiety disorders and persistent anxiety symptoms. Com-munity samples show replicated, high 
lifetime co-morbidities of bipolar I disorder with a range of anxiety-related disorders and substance 
use (I, (Kessler et al., 1997; Merikangas et al., 2007)). Lifetime rates are extremely high in some 
estimates: as many as 90% of bipolar I patients reported at some time to have had an anxiety 
disorder in the influential US National co-morbidity survey (I–II, (Freeman et al., 2002; Merikangas et 
al., 2007)). The most recent meta-analysis of 40 studies, including 14,914 individuals from North 
America, Europe, Australia, South America and Asia, suggested a more conservative lifetime 
prevalence of anxiety disorders of about 45% (95% CI 40–51%) (Pavlova et al., 2015). 
This raises the question of how to view anxiety symptoms within the behavioural phenotype in 
bipolar disorder. The earliest symptoms that a patient experiences may be those of anxiety but the 
dominant picture subsequently may be mania and depression. On the other hand, anxiety is not 
uncommon between acute episodes and in bipolar depression. Mixed affective states can be 
misdiagnosed as anxiety and vice versa. 
Where the anxiety disorder dominates the outcome, this must clearly influence evaluations of 
successful treatments. Anxiety disorder co-morbidity is associated with a range of worse out-comes 
in bipolar disorder such as worse functioning, poorer quality of life, increased suicide rates, rapid 
cycling and the transition from unipolar to bipolar depression (Fagiolini et al., 2007; Simon et al., 
2004), and yet has received little specific attention in developing treatments. For adequate 
assessment, anxiety should be regularly monitored (in addition to the usual focus on depression and 
mania). 
In fact, anxiety in bipolar disorder may have particular features that should influence approaches to 
treatment development. There is scope to improve assessment to consider bipolar-specific features 
like anxiety-provoking mental imagery (Hales et al., 2011; Ivins et al., 2014) because this may amplify 
the eǆpeĐtatioŶ of futuƌe thƌeat. MeŶtal iŵageƌǇ iŶǀolǀes ͚seeiŶg iŶ the ŵiŶd͛s eǇe͛. While this ŵay 
ƌelate to iŶtƌusiǀe past eǀeŶts ;͚flash ďaĐks͛ as iŶ post-traumatic stress disorder (PTSD)) it is also 
ƌeleǀaŶt as a ͚flash foƌǁaƌd͛ eǆpeƌieŶĐe. PƌeǀiouslǇ suiĐidal patieŶts ŵaǇ, foƌ eǆaŵple, ƌepoƌt ǀiǀidlǇ 
simulating a future out-come such as jumping off a cliff (Hales et al., 2011). Such experience can be 
asked about in assessment (in addition to the content of verbal thoughts) (Di Simplicio et al., 2012). 
Alcohol and drug use. As with anxiety, excessive use of alcohol or drugs is so common in bipolar 
patients that there seems to be a shared vulnerability to either or both outcomes. Experimental 
studies even suggest how this may arise for alcohol dependence (Yip et al., 2012). The risk of alcohol 
dependence is, therefore, another common (and clinically significant) co-morbidity of bipolar I and 
perhaps to a lesser extent bipolar II disorder. Drug, especially stimulant, use is more relevant to 
younger patients with bipolar II disorder and is associated with poorer outcome. It can confound the 
diagnosis and makes engagement with treatment more difficult (I, (Strakowski et al., the very early 
stages of the illness can delay its accurate recognition (I, (Lish et al., 1994)). Secondly, in the 
presence of recognized bipolar disorder, co-morbid conditions may contribute to poor treatment 
response and outcome. 
Anxiety disorders and persistent anxiety symptoms. Com-munity samples show replicated, high 
lifetime co-morbidities of bipolar I disorder with a range of anxiety-related disorders and substance 
use (I, (Kessler et al., 1997; Merikangas et al., 2007)). Lifetime rates are extremely high in some 
estimates: as many as 90% of bipolar I patients reported at some time to have had an anxiety 
disorder in the influential US National co-morbidity survey (I–II, (Freeman et al., 2002; Merikangas et 
al., 2007)). The most recent meta-analysis of 40 studies, including 14,914 individuals from North 
America, Europe, Australia, South America and Asia, suggested a more conservative lifetime 
prevalence of anxiety disorders of about 45% (95% CI 40–51%) (Pavlova et al., 2015). 
This raises the question of how to view anxiety symptoms within the behavioural phenotype in 
bipolar disorder. The earliest symptoms that a patient experiences may be those of anxiety but the 
dominant picture subsequently may be mania and depression. On the other hand, anxiety is not 
uncommon between acute episodes and in bipolar depression. Mixed affective states can be 
misdiagnosed as anxiety and vice versa. 
Where the anxiety disorder dominates the outcome, this must clearly influence evaluations of 
successful treatments. Anxiety disorder co-morbidity is associated with a range of worse out-comes 
in bipolar disorder such as worse functioning, poorer quality of life, increased suicide rates, rapid 
cycling and the transition from unipolar to bipolar depression (Fagiolini et al., 2007; Simon et al., 
2004), and yet has received little specific attention in developing treatments. For adequate 
assessment, anxiety should be regularly monitored (in addition to the usual focus on depression and 
mania). 
In fact, anxiety in bipolar disorder may have particular features that should influence approaches to 
treatment development. There is scope to improve assessment to consider bipolar-specific features 
like anxiety-provoking mental imagery (Hales et al., 2011; Ivins et al., 2014) because this may amplify 
the eǆpeĐtatioŶ of futuƌe thƌeat. MeŶtal iŵageƌǇ iŶǀolǀes ͚seeiŶg iŶ the ŵiŶd͛s eǇe͛. While this ŵaǇ 
ƌelate to iŶtƌusiǀe past eǀeŶts ;͚flash ďaĐks͛ as iŶ post-traumatic stress disorder (PTSD)) it is also 
ƌeleǀaŶt as a ͚flash foƌǁaƌd͛ eǆpeƌieŶĐe. PƌeǀiouslǇ suiĐidal patieŶts ŵaǇ, foƌ eǆaŵple, ƌepoƌt ǀiǀidlǇ 
simulating a future out-come such as jumping off a cliff (Hales et al., 2011). Such experience can be 
asked about in assessment (in addition to the content of verbal thoughts) (Di Simplicio et al., 2012). 
Alcohol and drug use. As with anxiety, excessive use of alcohol or drugs is so common in bipolar 
patients that there seems to be a shared vulnerability to either or both outcomes. Experimental 
studies even suggest how this may arise for alcohol dependence (Yip et al., 2012). The risk of alcohol 
dependence is, therefore, another common (and clinically significant) co-morbidity of bipolar I and 
perhaps to a lesser extent bipolar II disorder. Drug, especially stimulant, use is more relevant to 
younger patients with bipolar II disorder and is associated with poorer outcome. It can confound the 
diagnosis and makes engagement with treatment more difficult (I, (Strakowski et al., diagnose 
bipolar disorder appears to incur significant additional costs (McCombs et al., 2007). Any patient 
who is being treated for depression should be asked if they have a personal history of abnormal 
mood elevation of any duration or a family history of affective disorder (IV, opinion of consensus 
group). 
Diagnosis of bipolar disorder in children. It is fully accepted that bipolar I disorder can present before 
puberty and should be diagnosed as such. It is a relatively rare condition and its recognition should 
rest on the detection of the symptoms of mania – specifically euphoria and grandiosity and never 
simply irritability. Most studies of childhood bipolar disorder have been conducted in the absence of 
empirically supported guidelines for determining the presence of the manic syndrome, which poses 
real operational problems for definition in children. For example, what constitutes grandiosity at age 
8 versus age 15, and at what point does silliness and laughing, usually associated with normal child-
hood behaviour, become indicative of mania? NICE2014 recommends that the diagnosis of mania in 
a person under 18 years of age requires a distinct period of abnormally and persistently elevated or 
eǆpaŶsiǀe ŵood. Plus, theƌe has to ďe a ĐhaŶge iŶ the peƌsoŶ͛s Ŷoƌŵal pattern of behaviour that is 
not developmentally appropriate and which is associated with impairment. Therefore, the condition 
is episodic, not chronic. It is quite likely that mania is more often misdiagnosed than over-diagnosed 
in the UK con-text. It is very important clinically to recognize that the first presentation is often 
depression; so those with recurrent depression, or with treatment-resistant depression, may have 
bipolar disor-der. Because it is proportionally more common in young people (unipolar depression 
tending to a later incidence) it may often be a diagnosis that is overlooked. 
NICEϮϬϭϰ ƌeĐoŵŵeŶds that ͞DiagŶosis of ďipolaƌ disoƌdeƌ iŶ ĐhildƌeŶ oƌ ǇouŶg people should ďe 
made only after a period of intensive, prospective longitudinal monitoring by a health-care 
professional or multidisciplinary team trained and experienced in the assessment, diagnosis and 
management of bipolar disorder in children and young people, and in collaboration with the child or 
ǇouŶg peƌsoŶ͛s paƌeŶts oƌ Đaƌeƌs͟. It should take iŶto aĐĐouŶt the Đhild oƌ ǇouŶg peƌsoŶ͛s 
educational and social functioning. The group endorse this as a standard of care. However, it should 
not be an injunction that simply delays diagnosis (and appropriate treatment) when diagnostic 
criteria are already, clearly met. 
There is some consistency in reports of the prevalence of bipolar diagnoses in young people in 
different countries. The average rate for age 7–21 years was 1.8% (95% CI, 1.1–3.0%). This is 
probably higher than appreciated (Van Meter et al., 2011). The developmental trajectory is still to be 
established definitively by prospective studies. People of above average ability are over-represented 
in bipolar cohorts (MacCabe et al., 2010). 
DiagŶosis ďeĐaŵe ĐoŶtƌoǀeƌsial ďeĐause ͚Đhildhood ďipolaƌ͛ diagŶoses ďeĐaŵe iŶĐƌeasiŶglǇ ĐoŵŵoŶ 
in some services in North America (II, (Geller et al., 1995)), but generally not in the rest of the world 
(II, (Wals et al., 2001)). In North America rates of diagnosis increased 40-fold in children and young 
people in a decade (Blader and Carlson, 2007; Moreno et al., 2007). The desire to move diagnosis 
earlier in the life history is entirely understandable. Unfortunately, to do so inevitably risks sacrificing 
specificity to sensitivity. At the risk of over-simplification, softening the diagnosis of bipolar disorder 
to allow irritability and chronicity risks confounding with more common problems such as ADHD and 
oppositional disorder. Indeed, these disorders were usually described as very commonly co-morbid 
with child-hood bipolar diagnoses in US case series. Affective instability is undoubtedly a component 
of ǁhat tƌouďles ŵaŶǇ ĐhildƌeŶ, ďut it does Ŷot alloǁ ͚eaƌlǇ diagŶosis͛ of tƌue ďipolaƌ disoƌdeƌ. 
DSM-5 moved to diffuse the problem of diagnosing overactive children with emotional instability as 
͚ďipolaƌ͛ ďǇ iŶǀeŶtiŶg the diagŶosis of DMDD. This is aĐĐoƌdiŶglǇ defiŶed ďǇ seǀeƌe ƌeĐuƌ-rent temper 
outbursts manifested as verbal rages and/or behaviour-ally (physical aggression towards people or 
property) that are grossly out of proportion in intensity or duration to the situation or provocation. It 
is required to be inconsistent with development and to occur frequently (on average, three or more 
times per week). It appears to have links in later life with depression, a common out-come at follow-
up. However, it remains questionable whether this is really a diagnosis that merits classification as a 
mood disorder, rather than as a particularly severe form or variant of oppositional defiant disorder 
or ADHD. The separation from the latter is a potential source of confusion in the coming years. 
It is now clear that clinical assessment should be supported by structured assessment tools to 
increase reliability and validity of diagnosis (Youngstrom and Van Meter, 2015). Instruments exist for 
the children themselves, parents and teachers. The detection of mania is more reliable on the basis 
of ŵotheƌs͛ ƌepoƌts thaŶ eitheƌ the ĐhildƌeŶ theŵselǀes oƌ teaĐheƌs ;YouŶgstƌoŵ et al., ϮϬϭϱͿ. This 
has implications for the assessment of young people who have left home and for whom parental 
evidence may be lacking. 
2. Access to services and the safety of the patient and others 
•The DepaƌtŵeŶt of Health͛s ͚NatioŶal “eƌǀiĐe Fƌaŵeǁoƌk͛ iŶ the UK set a teŵplate foƌ speĐialist 
mental health ĐliŶiĐal seƌǀiĐes to foĐus oŶ ͚psǇĐhosis͛; this ƌeŵaiŶs ďƌoadlǇ uŶĐhaŶged ǁith a 
consequent lack of understanding among policymakers of the need for high-quality specialized 
services for bipolar patients (IV), either in relation to early intervention or to provision of adult 
services. 
•This contrasts with the approach to schizophrenia even though the burden of disease for bipolar I 
disorder is comparable with schizophrenia (I). 
•Mania is usually a medical emergency. 
•Assessment should be offered by a trained psychiatrist with an understanding of both the 
medicines and psycho-logical treatments available for the management of bipolar disorder (S). 
•Patients should have access to early intervention, which must include the option of hospital 
admission (S). 
•Appropriate use of legal powers of detention is essential for the successful management of risk in 
some patients with acute mania and severe depression (S). 
•Consistent outpatient follow-up is necessary and many individual patients may require complex 
interventions in community settings (S). 
•Risk assessment has poor positive predictive value for adverse outcomes and should not be over-
emphasized in management (I). 
•There is an increased incidence of completed suicide soon after an assessment in bipolar patients 
(I), which suggests that current practice under-estimates suicide risk (IV). 
 Figure 1. The problem for early detection of bipolar disorder. 
Adapted from Berk et al. (2007). 
Early intervention. Early detection and intervention is an increasing aspiration for mental health 
services. In the UK, the development of all mental health services has been distorted by an emphasis 
on psychosis and, in early intervention, psychosis has also been the paradigm focus. This could imply 
that a significant proportion of manic patients will be seen and treated, but actual practice appears 
to be inconsistent. A psychosis criterion will usually exclude patients with bipolar I disorder who 
present with depression until they become manic, and will completely exclude bipolar II cases. 
The illness model proposed for schizophrenia was based on two related ideas: first to reduce 
duration of untreated psycho-sis and provide a service that was geared to treating younger people; 
avoiding stigma was a key element. The secondary purpose was inspired by the idea of a prodromal 
presentation and early intervention to prevent onset of syndromal illness. There is an inherent 
contradiction for these two approaches being pursued by the same service. Earlier detection of 
established illness implies diagnostic confidence and an earlier choice of evidence-based treatments. 
In contrast, a prodrome is likely to be a relatively non-specific predictor of subsequent illness, in the 
absence of a diagnostic biomarker. Hence, there would be tolerance of diagnostic uncertainty, and 
no established approach to treatment. 
Early presentations with affective disorder pose the same dilemma. The necessary diagnostic tools 
to identify bipolarity in the prodrome are under active investigation (Howes et al., 2011; Youngstrom 
et al., 2015). However, we lack the necessary service structure to deliver any clinical programme. 
One version of a staging model for bipolar disorder is shown in Figure 1. An important caveat is that 
staging implies predictable progression (most classically in the context of a cancer diagnosis) and 
bipolar illness course is much less predictable. Indeed the high rates of symptomatic diagnoses in 
young people suggest the outcome can be benign in a significant number of individuals assessed as 
teenagers (Tijssen et al., 2010). 
There is a reluctance to make a diagnosis in young people with bipolar disorder, which is to some 
extent reinforced by NICE2014. Thus, NICE recommendations place an emphasis on specialist and 
detailed assessment. Much as this may always be desirable, it may be unnecessary if symptoms and 
history are obvious. If detailed assessment is not available, one result is likely to be failure to 
intervene in a way that might engage younger people with bipolar disorder at a time when 
treatment has most potential to be both effective and efficient (Kessing et al., 2013; Jones et al., 
2015b). The first symptoms of bipolar disorder commonly occur in the teenage years, with a mean 
age of onset by age 20 but many diagnoses are not made before the age of 30 (Figure 1). 
First and early episodes. Early-onset bipolar patients are about twice as likely to present with 
depression as mania (see Figure 1 and Biffin et al., 2009). Depression with psychosis in young people 
may predict subsequent bipolar disorder (Tohen et al., 2012). Highly recurrent illness and a family 
history may also raise the index of suspicion that a young person with a depressive episode has 
bipolar disorder. The use of antidepressants (i.e. drugs for unipolar depression) in these patients 
appears to be quite common. There is very little controlled data, but the findings from large 
naturalistic studies suggest that a patient whose diagnosis subsequently changes to bipolar is more 
likely to receive multiple treatments for their first depressive episode and so may be relatively 
treatment resistant (Good-win, 2012). This may be a further clue to diagnosis. In addition, the drugs 
themselves may increase the risk of manic switch or mood instability. In either case, they do not lend 
strong support to the use of antidepressants for unipolar depression in bipolar cases (see later). 
Even where the diagnosis can be made with confidence there is a dearth of evidence concerning the 
optimal management of a first syndromal episode. The key objective must be to prevent recurrence 
and the accrual of disability in young people, because they tend to have poor clinical outcomes 
(Coryell et al., 2013). The optimal treatment choices or combi-nations are not established; the 
available data to be reviewed below concern mature patients. 
Any acute episode, regardless of polarity, should receive active treatment. Mania, in particular, is a 
relative emergency because of the important personal and social consequences that result from the 
errors of judgement that are intrinsic to a highly elevated mood state. The complexity of bipolar 
disorder makes it desirable that assessment should be offered by a trained psychiatrist with an 
understanding of both the medicines and psychological treatments available for the management of 
bipolar disorder. Patients should have access to early intervention within an episode, which must 
include the option of hospital admission. 
Appropriate use of legal powers of detention is essential for the successful management of some 
patients with acute mania and psychotic depression. Patients who are unlikely to co-operate with 
treatment because of difficulties in accepting their diagnosis, who use drugs, or in whom violence, 
risk taking or self-harm complicate their mood change may require complex, community-based 
interventions, although the optimal approach remains controversial (Burns et al., 2002). 
Risk assessment in bipolar disorder. There has been consider-able emphasis in mental health policy 
and corresponding research interest in risk assessment in the UK and other high-income countries. 
This approach is problematic if it is based on the notion of accurate prediction – the predictive value 
of assessment scales for suicide and violent risk are currently poor to moderate, and the ability of 
these tools to identify high-risk groups is uncertain. For outcomes with very low base rates such as 
suicide, risk factors will only be weakly predictive of the event, and most suicides will occur in 
patients who, in statistical terms, are at low risk (Powell et al., 2000); this is also called the 
prevention para-dox. Therefore, the idea that high-risk groups can be appropriately targeted in 
providing services is a fallacy. 
All bipolar patients are at risk of suicide, especially if admit-ted to hospital, when their first episode 
is depressive, if prone to recurrent depression and mixed states, have co-morbid anxiety (Harris and 
Barraclough, 1997; Schaffer et al., 2015) or co-morbid drug and alcohol use disorders (Webb et al., 
2014). The logical approach is to provide good long-term clinical care to as many of them as possible. 
One area where suicide risk assessment needs to be examined more carefully is in self-harm patients 
with bipolar disorder presenting to hospital. Here the subsequent risk of suicide is high in the 
following year particularly (Tidemalm et al., 2008), and therefore risk assessment really may enable 
more effective targeting of those that need enhanced follow-up. This is important because risk may 
be underestimated in bipolar patients. 
Thus, in a large survey of suicides in the UK, more than 60% of the bipolar group were in contact 
with services the week prior to suicide but were assessed as low risk (Clements et al., 2013). A 
diagnosis of bipolar disorder should modify an optimistic risk assessment of a symptomatic patient. 
Concerns about the risk of violence by psychiatric patients (not necessarily bipolar patients), has led 
to a proliferation of often very lengthy assessment schedules. A systematic review of the better 
known instruments suggest that they perform quite well at predicting individuals at low risk of 
offending, but the positive predictive value for those who will offend is not strong (Fazel et al., 
2012). Thus, there is little evidence to support the routine use of the current set of commonly used 
instruments in bipolar disorder. New instruments will have to be assessed on their own merits, using 
multiple measures of performance. They need to be scalable, evidence based, and not lead to 
patient harms (as positive predictive values will be low). 
In conclusion, the central purpose of risk assessment should be clinical diagnosis and estimation of 
severity of depression. For suicide and violence risk, beyond identifying co-morbid sub-stance abuse 
and past history of self-harm and criminality, further quantification of risk is unlikely to help plan 
treatment and ser-vices. Many suicides occur in the first year after a serious episode of self-harm, so 
reinforcing the need for attention to this clinical context and to early treatment engagement. 
Prisoners represent another high-risk group who merit the same consideration (Fazel and Seewald, 
2012; Fazel et al., 2013). 
The potential for the prevention of suicide and violent offending. The most important perspective 
for risk assessment is the potential for successful long-term treatment to reduce suicide risks by 
preventing new episodes or reducing chronic symptoms. Suicide has never been the primary 
outcome measure for a clinical trial in bipolar disorder, because in practice observable rates are too 
low. However, naturalistic studies have long suggested that suicide rates are lower in patients who 
receive long-term treatment (Angst et al., 2002). Furthermore, lithium may have particular efficacy. 
This conclusion is again based largely on naturalistic comparison of patient cohorts on and off 
lithium, but the findings from different centres are consistent and the treatment effect is very large 
(I, (Toffol et al., 2015; Tondo et al., 2001)). One short-term RCT also found suicides and attempted 
suicides to be associated with carbamazepine and not lithium treatment (Ib, (ThiesFlechtner et al., 
1996)). Indeed, meta-analysis of all the randomized controlled data for lithium suggests an 
important effect on suicide in studies which are individually inconclusive because of inadequate 
power (I, (Cipriani et al., 2013a)). An emerging study of a large Swedish database which allows 
within-subject comparisons on and off treatment in a so-called quasi-experimental design, has 
ĐoŶfiƌŵed lithiuŵ͛s effeĐt iŶ reducing suicide attempts by 30%; the same effect was not seen with 
valproate (Song et al., 2015). Both lithium and valproate treatment were associated with 90% 
reduction in completed suicide. 
There is also recent evidence that treatment may be effective in reducing the rate of violent crime in 
patients with bipolar dis-order. The data again come from record linkage of medications and 
outcome. Dopamine antagonists halved the rates of offending in bipolar disorder and schizophrenia. 
Drugs for relapse preventioŶ ;͚ŵood staďilizeƌs͛, so lithiuŵ aŶd ǀalpƌoate ŵaiŶlǇͿ had aŶ eƋuallǇ 
potent effect in bipolar disorder (but not in schizophrenia) (Fazel et al., 2014). These results are 
impressive because the events are relatively common, effect sizes are so large and the outcomes so 
important. As already emphasized in relation to data quality, they move the argument for benefit to 
a completely different level, compared with effects on symptoms or even symptomatic relapse. 
Consequently we have upgraded them in assessing the evidence supporting the use of medications 
in the long term. 
The National Confidential Inquiry data for England and Wales (1997–2006) included 1243 bipolar 
patients (10% of the sample) who had died from suicide, and been in contact with mental health 
services in the previous 12 months (Clements et al., 2013). They make sobering reading. Only 390 
(31%) were adherent with medication at time of death. This is an important measure of how 
ineffective management strategies currently are for our patients. Only 13 (about 3%) died by poi-
soning with prescribed drugs, so the benefit/risk potential appears favourable. The challenge 
appears to be the delivery of effective treatment. 
The need for a service model. The neglect of the specific needs of bipolar patients in UK government 
policy (Morriss et al., 2002) justifies our restating the obvious in the previous paragraphs. The term 
bipolar disorder or manic depression was given no special consideration (and entirely omitted from 
the glossary of key terms) in the National Service Framework for mental disorders in the United 
Kingdom (Department of Health, 1999). It remains a monolithic social model of mental illness, which 
is inappropriate to bipolar disorder (Goodwin and Geddes, 2007). 
The complexity of the disorder, the resulting need for specialist and expert care and the potential for 
preventing bad out-comes by early treatment all argue for a concerted effort to improve treatment. 
The recent NICE guideline implied that this objective could be achieved by the appropriate 
deployment of existing services. We are very sceptical. In our view, a separate, serious effort to 
extend early intervention to young people with affective disorder, with appropriate identified 
funding, is long overdue. The absence of early stage specificity has led to pioneering approaches to 
youth mental health services in Australia, where distress rather than a diagnostic criterion applies, 
and bipolar patients can, in principle, make appropriate access (McGorry et al., 2007). 
In addition to the lack of focus on bipolar disorder, and certainly contributing to making it worse, is 
the traditional fault line between child and adolescent services and adult services. This falls at 
exactly the point where continuity is most obviously needed for young people developing severe 
psychiatric disorder (IV). 
Nevertheless, there remains a need for better quality evidence on which to argue for an improved 
approach to care. According to an analysis for the charity MQ, funding for research on bipolar 
disorder has been about one-third that for schizophrenia in the decade to 2013 
(http://www.joinmq.org/pages/mental-health-research-funding-landscape-report). It is hardly 
surprising that our knowledge base is less than it might be: this must change. 
The best service model? The single most relevant study concerned bipolar patients discharged from 
inpatient care for their first, second or third episode of bipolar disorder in Denmark (Kessing et al., 
2013); they were randomized to either specialized or standard care. The specialized care reduced re-
admission over the subsequent 6 years by about 20%. This approach would not necessarily be cost 
effective for less severely ill patients, but it translates into very appreciable cost savings in a group of 
patients at high risk of relapse and re-admission. 
The key ingredients of expert care appear to have been psychoeducation (based on the Barcelona 
model (Colom and Vieta, 2006)), an algorithmic psychopharmacology (based on the previous BAP 
guidelines) and continuity/consistency of care. A critical ingredient of psychoeducation is likely to be 
active monitoring for signs of relapse to mania, and this approach should be a standard of care 
(Morriss et al., 2007). The system in Denmark is broadly comparable to the UK, so these results may 
well generalize. They deserve very serious consideration in arguing for a better future in the care of 
bipolar patients. 
In the USA, a collaborative care model has been proposed involving a key worker to keep close 
contact with the patient, encourage adherence to treatment algorithms and guidelines and follow-
up in the case of non-attendance. Two similar studies 
 
 
 
 
showed small positive effects on a number of outcomes (Bauer et al., 2006a, 2006b; Simon et al., 
2006). This may have been mediated in part by improved adherence in the collaborative care arms 
of the studies (Bauer et al., 2009). Finally, collaborative care focused on physical health improved 
blood pressure in a small RCT (Kilbourne et al., 2013). The lessons of these findings are less easy to 
translate to the UK because primary care and community provision is usually so limited in the USA 
and so there is the potential for a much bigger impact of service out-reach. This was the lesson 
previously drawn from systematic comparisons of community care models for schizophrenia, which 
outside the USA had less if any impact on outcomes (Fiander et al., 2003). 
Finally, one negative or failed trial (Crowe et al., 2012) has the possible lesson that collaborative care 
needs to be an integral part of a service, rather than an add-on that risks disrupting the continuity of 
the core service provision. 
NICE2014 published evidence from patients that supported employment initiatives as highly relevant 
to improving social outcomes. There are a few specific issues like risks of overspending, recklessness 
that may require some safeguards, undesirability of shift work for some bipolar disorder patients 
and the ability to take time off relatively quickly if early signs of mania or depression emerge. 
Psychiatrists and other professionals should be aware of these issues when counselling return to 
usual employment as well. 
In conclusion, very little work has pragmatically addressed the best model of service delivery for 
bipolar patients. Our conclusions are summarized alongside those reached by NICE2014 in Table 4. 
The NICE approach essentially proposes that generic NHS care can be readily extrapolated to the 
needs of bipolar patients who require admission and access to secondary care services. 
Our primary conclusion is that we really do require more evidence of what works at the systems 
level. In Table 4 most of the recommendations by NICE2014 are not based on formal evidence, 
certainly for applicability to bipolar disorder. Instead they appear largely driven by what is currently 
provided in theory by psychosis-orientated NHS services. However, it appears a priori self-evident 
that services should be led by specialists with expertise in guideline-based psychopharmacology, 
there should be continuity of care and psychosocial management should be informed by and apply 
lessons from psychoeducation. 
Recent further fractionation of clinical services, for example between in and out patients, 
͚assessŵeŶt͛ aŶd ͚tƌeatŵeŶt͛, is a ƌeĐeŶt ĐoŶĐeƌŶ. It ƌuŶs ĐouŶteƌ to the Ŷeeds of ďipolaƌ patients in 
all stages of their treatment but particularly in managing follow-up. Premature discharge to primary 
care can further dilute the treatment package available in the early stages of managing the illness 
(IV). 
3. Enhanced clinical care 
•EŶhaŶĐeŵeŶt of patient care can be achieved by structured interventions based on 
psychoeducation (II). This has the potential to complement and inform treatment with medicines, 
not replace it (IV). 
•While the evidence for efficacy in preventing relapse comes from mature patient samples, the 
same approach can inform early assessment and intervention with young people (IV). 
•We suppoƌt NICE͛s asseƌtioŶ that assessŵeŶt aŶd ŵaŶageŵeŶt of ďipolaƌ disoƌdeƌ should ideallǇ 
involve partners, families and carers. 
•Bipolar patients are at high risk of cardiovascular, metabolic and respiratory disease: there should 
be an annual auditable check for hypertension, central obesity, raised blood glucose, and 
dyslipidaemia (S). 
•Assess consumption of alcohol and drugs. Drinking up to 14 units of alcohol per week represents 
lower risk drinking levels for men and women (<1% increase in excess mortality). High-risk drinking 
(10% excess mortality) is 35 units or over per week. 
•Bipolar patients may have a particular problem with the use of tobacco (I). Treatment with 
effective nicotine substitutes will often be indicated (IV). 
Key uncertainty 
The optimal approaches to enhanced care are evolving rapidly with the rapid development of self-
monitoring and instruction from mobile apps. 
As noticed in the previous section, the services in which care is delivered clearly constrain what is 
possible. However, good individual clinical practice is a commonplace but essential objective. 
Psychiatrists must take responsibility for diagnosis, physical examination, investigations and 
explanation of the medical plan of management. They must communicate clearly and effectively. A 
therapeutic alliance between doctor and patient is essential for the management of any complex 
chronic condition, which bipolar disorder certainly is. 
The role of structured psychological treatment in the management of bipolar disorder remains at an 
experimental and exploratory level. However, the findings are already important because they 
suggest that enhanced care can improve outcomes in bipolar I and, probably, bipolar II patients. 
Broadly speaking, the interventions that have been offered in bipolar disorder are pragmatically 
directed to identified clinical problems. They do not depend on specific models of psychopathology. 
There is also appreciable overlap in content of the different approaches, although it is conventional 
to consider them under separate headings. The following general principles are important. 
1) Bipolar disorder is a long-term problem, so psychological treatments should produce enduring 
behavioural change. Acute effects of any psychological approach need also to be considered in the 
longer term. 
2) We endorse the NICE statement on caregiver involvement. In essence, partners, families and 
carers can con-tribute significantly to the assessment process, the management of acute episodes, 
the promotion of long-term recovery and the prevention of relapse. This has the further implication 
that carers may benefit from information and support to improve how they achieve these 
objectives. 
KŶoǁledge ;oƌ ͚psǇĐhoeduĐatioŶ͛Ϳ. Theƌe is a ĐoŶseŶsus that good ĐliŶiĐal ŵaŶageŵeŶt of patieŶts 
with bipolar disorder involves an appreciable educational component for both patients and their 
relatives. The objective of acquiring knowledge about the illness is prevention of relapse. Successful 
long-term management involves a high degree of patient involvement and autonomous judgement 
about return of symptoms, etc. It is essential to address the seriousness of the illness, any reluctance 
to give up the experience of hypomania or mania, the risk of relapse and the benefit of therapeutic 
engagement (IV). For patients to know what to do, and why, appears usually to be an essential 
prelude to actually doing it. 
One option is to provide a formal group course, the efficacy of which was shown in a RCT (II, (Colom 
et al., 2003)). This com-pared psychoeducation with an equivalent group experience in which the 
content was simply unstructured supportive discussion. The use of an appropriate control 
intervention gives this trial particular credibility, and the benefits of psychoeducation appear to be 
sustained because mood episodes of all types were reduced over a 5-year follow-up of the original 
trial participants (Colom et al., 2009). The effect size compared with other psychoeducation RCTs 
makes it an optimistic outlier (Bond and Anderson, 2015). Nevertheless, the findings described previ-
ously from Denmark over 6 years may also underline the potential for long clinically relevant effects 
in patients with recent illness onset (Kessing et al., 2013). Comparison with other alter-natives, 
notably cognitive behaviour therapy (CBT) (see also below), has also illustrated the economy of a 
more educational approach (Parikh et al., 2012). 
Despite our endorsement, virtually as a standard of care, negative or just marginally positive findings 
have been common in trials of psychoeducation. de Barros Pellegrinelli et al. (2013) failed to show 
any difference in clinical outcomes for 16 psychoeducation versus non-psychoeducation sessions 
using the Barcelona manual; a slightly different psychoeducational approach run in UK mental health 
teams failed to separate convincingly from treatment as usual (Lobban et al., 2010). A related, more 
sustained intervention (the Life Goals program) showed minor effects on manic symptoms over 2 
years (Simon et al., 2006) but more substantial gains in function (not reduced symptoms) over 3 
years (Bauer et al., 2006b). These failed or marginally positive trials indicate the methodological 
challenge to future treatment development. 
Failure to find a difference between groups is associated with higher proportions of patients with 
more previous episodes (Scott et al., 2007). Age appears not to vary between studies of adult 
patients, so intensity rather than length of illness appears to be the limiting factor. Clearly, lack of 
efficacy in large numbers of patients with more recurrent illness represents a challenge to 
understand the failure of existing approaches and an unmet need to develop better treatment 
approaches in the future. 
The key ingredients of all psychotherapies so far found useful for bipolar disorder (including 
psychoeducation) are as follows (Miklowitz et al., 2008): 
1. Monitor moods and early warning signs 
2. Recognize and manage stress triggers and interpersonal conflicts 
3. Develop relapse prevention plans 
4. Stabilize sleep/wake rhythms and daily routines 
5. Encourage medication adherence 
6. Reduce self-stigmatization 
7. Reduce alcohol or drug use (including caffeine in sensitive individuals) 
 
The involvement of carers/family is highlighted in family-focused treatment for younger patients, 
which has similar ingredients (Geddes and Miklowitz, 2013). In fact, these elements are also 
commonly present in treatments formally described in clinical trials as something other than 
psychoeducation (e.g. CBT and interpersonal social rhythm therapy (IPSRT)), which is a source of 
confusion. The role of CBT will be considered in a little more detail in relation to the treatment of 
bipolar depression and relapse prevention. 
Optimal delivery of psychoeducation. The group format may not be culturally generalizable, so 
individual or family, rather than group approaches to psychoeducation, are also likely to be helpful 
and can inform ordinary practice. Facilitated use of a five-session psychoeducational package 
increased comprehension of the principles and practice of self-management compared with self-
instruction (Miklowitz et al., 2012). 
Current practice also favours didactic teaching, live or by video, written materials or guided internet 
searching for high-quality material (e.g. the National Electronic library for mental health: 
http://www.nelh.nhs.uk/). There is also an explosion of self-help apps, most still of rather low 
quality (Nicholas et al., 2015), that may incorporate personal mood and activity monitoring on 
mobile devices. The approach has enormous intuitive appeal, but systematic examination of the 
effects of self-monitoring has not led to immediate proof of concept (Faurholt-Jepsen et al., 2015). 
Such individual, rather than group, approaches includes the use of auto-didactic on line 
psychoeducation (Barnes et al., 2011): to see this in action visit http://www.beatingbipolar.org. The 
possiďilitǇ of ƌeĐoƌdiŶg theƌapǇ sessioŶs oŶ patieŶts͛ phones for subsequent review also has the 
potential to enhance patient care. This is an area likely to see major advances in the coming years 
and, hope-fully, clarification of what really helps. 
A time very early in the illness course may not be the most propitious for patient acceptability; 
however, it may be a critical period for the greatest impact of behavioural change on clinical 
outcome. Thus, the goals of education need to be sustained and incremental. There also needs to be 
a shared and consistent approach across mental health disciplines. Psychoeducation also appears to 
offer an approach to intervention in the early stages of the disorder before diagnosis is necessarily 
established and medicines are indicated. 
Adherence to medicines. As we will review, there is good evidence that long-term treatment is 
effective in preventing relapse in bipolar disorder. However, adherence to prescribed medicines is 
poor in most chronic illness (I, (Horne et al., 2013)). Bipolar disorder is no exception (II, (Johnson and 
McFarland, 1996; Lin-gam and Scott, 2002; Scott and Pope, 2002)). The simplest framework for 
understanding adherence weighs the perceived need for treatment against concerns about its 
possible effects (Clatworthy et al., 2009). Understanding need will necessarily be a matter for 
education and personal experience. Adverse reactions are a major consideration given the 
limitations of existing medicines, and should be minimized by all possible means. These include 
once-daily administration (e.g. at bed time), switching between formulations and dose adjustments. 
Other efforts to improve adherence such as user-friendly packaging, monitoring of pill taking, 
delivery of supplies of medicine may contribute to successful treatment in certain individuals. 
The motivation to take tablets is heavily dependent upon the attitudes, beliefs and perceptions of 
risk shown by patients and their carers. These cultural factors may often divide clinical staff from 
patients. Pragmatic motivational interviewing to improve adherence to prescribed medicines has 
already been shown to be moderately effective in patients with psychosis. The best-known early 
study included a sub-group with bipolar disorder (II, (Kemp et al., 1998)). Since non-adherence with 
treatment occurs in up to 50% of most clinical samples (Scott and Pope, 2002), the development of a 
focused and generally applicable approach to this problem would be welcome. The published 
methodology emphasizes the involvement of a third party and there is clearly a potential role here 
for pharmacists, who occupy an advisory role for patients in other contexts. Where barriers to 
adherence are identified and targeted interventions delivered, adherence is more likely to improve 
(Staring et al., 2010). Patient-related factors include younger age, male gender, low educational 
level, alcohol and drug use. Disorder-related factors include severity, insight and lack of awareness 
of illness. And treatment-related factors are obviously adverse reactions to medications and 
perceived lack of efficacy. To improve adherence, clinical practice should address the underlying 
causes of non-adherence within the over-all frame work of psychoeducation (Leclerc et al., 2013). If 
the bottom line for adherence is the balance between the perceived necessity of drug treatment and 
concerns about it, this should inform clinical efforts to improve it. 
Clinical trials, in bipolar disorder as in other conditions, are likely directly to enhance patient care (I, 
(Ashcroft, 2000)). We believe that participation per se in well-designed clinical trials is a benefit for 
both doctors and patients. To put it bluntly, a con-trolled experiment is likely to be better than 
participation in the uncontrolled experiment that is ordinary practice. Furthermore, the results from 
trials will eventually enhance the evidence base for improving patient care. Participation in trials is 
potentially related to adherence and hence we make the point here. 
Awareness of stressors, sleep disturbance and early signs of relapse, and regular patterns of activity. 
Manic relapse in particular may follow a relatively stereotyped course in individual patients. Sleep 
disturbance is perhaps the most commonly described final common pathway to mania (II, (Wehr et 
al., 1987)). The sleep of bipolar patients between episodes is often disturbed in a very similar way to 
that of patients with primary insomnia (Harvey et al., 2005). Despite this, formal trials to improve 
sleep in bipolar disorder are only just beginning. Pilot data suggest effects of CBT for insomnia 
generalize to bipolar symptoms (Harvey et al., 2015). 
The more usual emphasis is on tell-tale signs and symptoms of relapse; this may take the form of 
particular impulses and preoccupations which accompany or even precede it. Efforts to train 
patients on individual scripts which access their own experience and enable them to take evasive 
action appear to be effective in avoiding new episodes of mania (II, (Perry et al., 1999)). This 
approach was less successful with episodes of depression. The original intensive trial involved up to 
12 sessions of training, and there is a need to know whether a more dilute approach or one focused 
uniquely on personal scripts for relapse into mania would be more widely applicable. The 
involvement of family members with experience of previous episodes may be helpful (Reinares et 
al., 2008). 
IPSRT developed out of particular ideas about what behavioural features contribute to relapse in 
bipolar disorder (II, (Swartz and Frank, 2001)). The reestablishment of routine and regular activity for 
those behaviours that recur at least once per week is a primary goal in treatment. IPSRT provides a 
simple framework for practical advice and feedback. It has also informed the development of a 
phone-based app for sensing activity and providing feedback to shape social activity (Matthews et 
al., 2014). 
The further role of structured psychotherapy will be considered in relation to relapse prevention. All 
such therapy recognizes as axiomatic the value of a highly collaborative therapeutic relationship with 
the patient. The commitment by a clinician to see a patient long term can contribute to an optimal 
management plan. 
The general point emerges that outcomes for patients can be improved simply by enhancing 
ordinary clinical care, most obviously by adopting a consistent approach to psychoeducation or 
knowledge sharing. Translating this observation into enhanced care for more patients should be an 
important objective for treatment. 
Functional impairments. Clinicians must anticipate the need to give advice about expectations and 
capacity to work. Major life decisions may not be auspicious when made in a depressive or manic 
state. Furthermore, patients may experience considerable difficulty performing at the level for which 
their education may have prepared them (II, (MacQueen et al., 2001)). This may be a result of 
common subsyndromal symptoms of depression or anxiety (I, (Denicoff et al., 2000)) or other 
barriers to psychological well-being (II, (Scott, 1996)). Factors specific to bipolar disorder such as 
experience when high, or personality style, may also con-spire to widen the gap between aspiration 
and achievement. Finally, there is evidence that objective impairments of neuropsychological 
function are both significant and enduring (I, (Bourne et al., 2013)). These objective problems in 
sustaining attention, memory and executive function appear to be made worse by repeated 
episodes (Clark et al., 2002; Martinez-Aran et al., 2004) and are more severe in bipolar I patients 
(Bourne et al., 2015). In other words, they may be a quasi-toxic consequence of the intensity of the 
illness course. Polypharmacy may also compound the problem (Clark et al., 2002; Frangou et al., 
2005). 
The National Service Framework for Mental Health recognized the vital role of informal carers in the 
delivery of mental health care (Department of Health, 1999). However, it treated the needs of adults 
of working age as generic and was probably influenced by evidence from research in schizophrenia 
(I, (Fadden et al., 1987)) and the dementias (I, (Clyburn et al., 2000)). The literature concerning 
bipolar disorder is sparse, but the perceptions and beliefs of carers about it, as for other diseases, 
may have important effects on levels of burden that are experienced (II, (Perlick et al., 1999)). There 
is scope to develop improved psychosocial interventions tailored to bipolar patients and their 
families. A particular uncertainty, neglected hitherto, is the impact of manic states upon carers, and 
indeed their children. A preliminary investigation of the families of 86 stable patients showed that 
caregivers still showed a moderate level of subjective burden. The highest levels of distress related 
to the patieŶt͛s hǇpeƌaĐtiǀitǇ, iƌƌitaďilitǇ, sadŶess aŶd ǁithdƌaǁal. The illŶess had also affeĐted the 
Đaƌeƌs͛ eŵotioŶal health aŶd life iŶ geŶeƌal. Pooƌeƌ soĐial aŶd oĐĐupatioŶal fuŶĐtioŶiŶg, aŶ episode 
in the last 2 years, history of rapid cycling and the caregiver being responsible for medication intake 
explained a quarter of the variance of the subjective burden (Reinares et al., 2006). 
It seems reasonable to note the emphasis on recovery with return of function as the modern 
aspiration for bipolar patients. Cognitive impairment is a barrier to good outcomes and there is 
preliminary evidence that cognitive remediation can play a part in improving function (Torrent et al., 
2013). 
Physical health, alcohol and drug use. In this country, a retrospective cohort study compared 46,136 
patieŶts ǁith ͚seǀeƌe ŵeŶtal illŶess͛ ;“MIͿ ǁith ϯϬϬ,ϰϮϲ ǁithout “MI ;using the GP Research 
Database). Hazard ratios (HRs) for coronary heart dis-ease (CHD) mortality in people with SMI 
compared with controls were 3.22 (95% CI, 1.99–5.21) for people 18–49 years old and 1.86 (95% CI, 
1.63–2.12) for those 50–75 years old. For stroke deaths, the respective HRs were 2.53 (95% CI, 0.99–
6.47) and 1.89 (95% CI, 1.50–2.38). Event rates in these age groups are quite low, but increased HRs 
for CHD mortality occurred irrespective of sex, SMI diagnosis or prescription of medication during 
follow-up (Osborn et al., 2007). 
The risk across the life span has been documented in a series of studies for bipolar disorder 
specifically. In most countries the estimate of years lost in bipolar patients is between 10 and 20 
years (Chesney et al., 2014). Put another way, just under 25% of the male population in Sweden die 
before the age of 70 years. The corresponding age for bipolar patients is just over 50 (Laursen and 
Nordentoft, 2011). Cardiovascular causes account for almost 40% of the deaths, which is nearly 
twice the number of suicides and accidental deaths; the risk is elevated across the life span. 
Moreover, the survival in the 5 years from diagnosis of a cardio-vascular event is substantially 
reduced in bipolar patients (Westman et al., 2015), which may mean either that patients present 
later in their illness course or receive inferior treatment (or both). 
The metabolic syndrome/obesity and type II diabetes are important in the mediating pathologies to 
cardiovascular disease. In a meta-analysis of the data from bipolar patients, rates of the metabolic 
syndrome were elevated about two-fold compared with controls (Vancampfort et al., 2013). 
Treatment with dopamine antagonist drugs was associated with a rate of 43%, com-pared with 32% 
in those not so treated. However, the variation from country to country suggested a major 
contribution from dietary habits as well. In impressive population data from Taiwan, the times to 
initiation of treatment for both hyperlipidaemia and diabetes were significantly delayed for patients 
with bipolar dis-order compared with the general population (Bai et al., 2013). 
Thus, effective medical management of physical illness in patients with severe bipolar disorder is a 
major challenge. The higher risk of cardiovascular disease in bipolar patients is not solely due to 
medication, and lifestyle factors like smoking, diet and lack of exercise are also important. 
Consequently, a bipolar diagnosis should imply annual screening for metabolic risk factors even if a 
dopamine antagonist is not prescribed. 
The metabolic syndrome is a composite of biochemical, blood pressure and weight indices. It is 
associated with older age, higher body mass index and higher values for each individual criterion of 
the metabolic syndrome. The absolute waist circumference (>102 cm (40 in) in men and >88 cm (35 
in) in women) and the waist–hip ratio (>0.9 for men and >0.85 for women) are both used as 
measures of central obesity. In a small study, the presence of central obesity was the most sensitive 
indicator (92.0%) and fasting glucose 7.0 mmol/L or over was most specific (95.2%) in correctly 
identifying the presence of metabolic syndrome (Straker et al., 2005). The treatment of blood 
pressure over 120/80 mmHg, and the use of statins in bipolar patients should follow existing medical 
practice. 
Weight gain, in part driven by medication, is a particular problem. A comprehensive guideline, much 
of ǁhiĐh ǁill ďe ƌeleǀaŶt to ďipolaƌ patieŶts as ǁell as patieŶts ǁith psǇĐhosis, is pƌoǀided ďǇ ͚The 
BAP guideline on the management of weight gain and metabolic disturbances associated with 
psǇĐhosis aŶd aŶtipsǇĐhotiĐ dƌug tƌeatŵeŶt͛ ĐuƌƌeŶtlǇ iŶ pƌepaƌatioŶ foƌ this jouƌŶal. 
The consumption of alcohol and drugs will contribute to both physical and psychiatric morbidity and 
mortality. The assessment of these contributory factors and lifestyle advice are key to a more 
synergistic approach to treatment in bipolar disorder. Public Health England suggest that up to 14 
units of alcohol per week for men and women represents lower risk drinking levels (excess mortality 
<1%). There is a monotonic increase in the risk of alcohol-related death with higher levels of 
consumption. Excess mortality exceeds 10% at a consumption around 35 units per week. It is 
recommended that drinking is spread over the week but with two or more alcohol-free days. This 
represents a tightening of advice for men particularly, based on new data showing an increased 
excess of cancers in drinkers (https://www.gov.uk/gov-
ernment/uploads/system/uploads/attachment_data/file/489797/CMO_Alcohol_Report.pdf). 
Advice on the use of tobacco is also essential because in data from the US, bipolar disorder has the 
highest rate of current and lifetime use and the lowest quit rate of any other psychiatric dis-order (I, 
(Lasser et al., 2000)). Treatment with effective nicotine substitutes will often be indicated (I, 
https://www.nice.org.uk/guidance/ph45). 
Audit of current practice: Prescribing Observatory for Mental Health. The Prescribing Observatory 
for Mental Health (POMH-UKͿ is ďased at the ‘oǇal College of PsǇĐhiatƌists͛ CeŶtƌe foƌ QualitǇ 
Improvement and runs audit-based quality improvement programmes (QIPs). The vast majority of 
UK mental health trusts participate in these traditional audit, intervention, re-audit cycles. For some 
QIPs it is possible to abstract current prescribing practice for people with bipolar disorder specifically 
and for other QIPs data relating to those with a diagnosis of an affective disorder. 
Treatment with dopamine antagonist agents should always trigger screening for four cardio-
metabolic risk factors (hypertension, central obesity, raised blood glucose and dyslipidaemia). In a 
national POMH audit conducted in 2012 (Prescribing Observatory for Mental Health, 2013), 22% of 
patients with an affective disorder who were prescribed antipsychotic medication had been 
screened for all four of these measures in the previous year, 54% for up to three measures, and 24% 
had received no screening. The respective figures for those with a diagnosis of a schizophrenia or 
related disorder were 36%, 49% and 15%. Thus, despite the major cardio-vascular health risks for 
bipolar patients, these audit findings suggest that, when receiving antipsychotic medication, they are 
less likely to have physical health screening and monitoring than patients on such treatment with a 
diagnosis of schizophrenia. 
When prescribing lithium, the practice standards (derived from NICE guidance) require that a patient 
be informed at the start of treatment about the potential adverse reactions, how they could 
recognize toxicity and how they should avoid toxicity. Audit data at baseline revealed that the 
proportion of patients provided with this information at the start of lithium treatment ranged 
between 42 and 62% (Prescribing Observatory for Mental Health, 2013). At a subsequent audit, 
conducted after provision of a bespoke, patient-held lithium information pack, the respective figures 
rose to between 54 and 68% (Paton et al., 2013). 
A further finding was that approximately one in five patients who started lithium had no 
documented baseline test of renal function or thyroid function, and this proportion remained 
relatively consistent over 5 years (2008–2013). However, there is some evidence that monitoring of 
serum lithium, renal and thyroid function improved over the same period; at baseline, there had 
been no documented monitoring of these parameters in the previous year for 10%, 19% and 18% 
respectively, but by the fourth audit, these proportions had fallen to 5%, 7% and 10%. Serum lithium 
concentrations within the usual target range (0.4–1 mmol/L) are found in almost 100% of patients in 
some NHS Trusts, but the proportion is as low as 50% in others. 
Psychotropic drug prescribing for bipolar patients in the UK was fairly consistent over time. For 
patients taking lithium, around 20% took lithium alone, 45–50% took a second drug, about 30% a 
third, and 5% a fourth. This underlines current levels of polypharmacy. The added medicines are 
dopamine antagonists/partial agonists (55–60%), antidepressants (35–40%), valproate (13%), 
lamotrigine (5%), and depot or long-acting drug (5%). For valproate, age/child-bearing potential did 
not seem to influence prescribing. 
Given these data, antidepressants appear to be relatively over-prescribed and lamotrigine relatively 
under-prescribed given the evidence of benefit (q.v.). However, when prescribed, lamotrigine use 
seems to follow the indications presented in guidelines (Grande et al., 2012). 
A template for audit of bipolar disorder is suggested in Table 5. 
Treatment of different phases of bipolar disorder 
Terminology and treatment strategy 
 Bipolar disorder usually presents for treatment in an acute illness episode (mania, 
depression or mixed state) 
Table 5. Recommendations for audit in bipolar patients. 
Diagnosis 
Is there a structured patient-completed (or structured interview) record? 
Is there a record of the manic symptoms in mania? 
Is there a record of the depressive symptoms in depression? 
Have symptoms of borderline personality disorder been recorded as present or absent? 
Is there a record of anxiety symptoms? 
Has the history of alcohol and drug use (including caffeine) been documented? 
Has impairment of memory and executive function (or functional impairment) been considered? 
Risk assessment 
Is suicide risk recorded? 
Is neglect of self and dependents, exploitation by others considered? 
Is risk of violence or offending considered? 
Physical health 
Is a physical health screen conducted annually? 
weight, blood pressure, lipids, fasting glucose 
renal and thyroid function, calcium concentration if taking lithium 
Has appropriate treatment been offered for physical health problems? 
Treatment 
Lithium 
Has lithium been offered for maintenance treatment? 
Is the use of lithium safe? 
(baseline eGFR, lithium concentrations, thyroid function, calcium) 
Are serum concentrations of lithium measured regularly? 
Are serum concentrations of lithium maintained above 0.6 and below 0.8 mEq/L? 
Dopamine antagonists/partial agonists. 
Are doses within accepted limits? 
Are multiple dopamine antagonists/partial agonists being prescribed together? 
Is long-term use justified? 
Drugs for bipolar depression 
Is prescription of antidepressants for depression or anxiety? 
Is there evidence of treatment response to the antidepressant? 
Is use justified? 
Have options with a better evidence base for treating depression been considered (e.g. 
lamotrigine, quetiapine) 
Valproate 
Is valproate being used in women of child-bearing age? 
If so, is a written justification recorded in the case notes? 
Has the patient clearly understood the risks? 
Has effective contraception been offered? 
Psychological interventions 
Has psychoeducation been offered? 
Is there a mechanism in place for regular mood monitoring? 
Is there a plan which anticipates the actions required when the patient relapses with mania, 
develops a worsening of depressive symptoms or expresses suicidal ideas? 
Is the person delivering the psychological intervention linked to other members of the care 
team? 
(I). The objective of short-term treatment is to reduce the severity and shorten the duration of 
the acute episode and achieve remission of symptoms (S). 
• Long-term treatment is inable 5. Recommendations for audit in bipolar patients.definite for 
the prevention of new episodes and to achieve adequate inter-episode control of residual or 
chronic mood symptom (S). 
• Because of the high risk of relapse and the apparent progression to more frequent episodes, 
long-term treatment with appropriate medicines is advocated from as early in the illness course 
as is acceptable to a patient and their family (S). 
• Between episodes, mood instability or chronic depressive symptoms are common (I) and 
generally underestimated. 
Key uncertainty 
 Switch to depression after mania may occur in any illness course: it is not established which 
treatments, if any, make this more likely. 
Dopamine antagonists/partial agonists (antipsychotic drugs). Mania can develop extremely 
quickly and incur risks both for the patient and for others. In its more severe form, mania is 
almost invariably treated with dopamine receptor antagonists/partial agonists, and patients with 
psychotic mania were among the first patients treated successfully with chlorpromazine. Dopa-
mine receptor antagonists/partial agonists are anti-manic, not simply sedative. However, despite 
their widespread use by an earlier generation of psychiatrists, placebo-controlled data to show 
that the oldeƌ dopaŵiŶe aŶtagoŶists ;͚fiƌst geŶeƌatioŶ͛ aŶti-psychotics) were effective in mania 
were very limited before the turn of the century (e.g. II, (Johnstone et al., 1988)). This changed 
when placebo-controlled studies of new drugs included haloperidol as a comparator. 
While the neurobiology of mania is still poorly understood, mania may be a hyperdopaminergic 
state appropriately treated by blockade of dopamine D2/3 receptors with antagonists or partial 
agonists. This is a common effect of the anti-manic drugs described below. The detailed 
additional pharmacology is described for some of the drugs in the section on treating 
depression, because it may be more relevant for that indication. 
A series of RCTs have been completed showing the efficacy for mania of aripiprazole, asenapine, 
cariprazine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone in 
comparison with placebo (Yildiz et al., 2011, 2015). Olanzapine, aripiprazole and ziprasidone are 
also available in parenteral formulations for acute use. Ziprasidone and caripra-zine are not 
available in the UK. 
The newer antipsychotic drugs were developed with a primary objective to reduce the incidence 
of extrapyramidal symptoms. Therefore their efficacy showed that an anti-manic action could be 
achieved in the absence of extrapyramidal symptoms (II, (Keck et al., 2000)). This is an important 
clinical message, which should influence prescribing practice, for all dopamine antagonists. 
The ŵaƌketiŶg of the Ŷeǁeƌ dƌugs as ͚atǇpiĐal͛ iŵplied a Ƌualitatiǀe ďƌeak fƌoŵ the past ;the 
͚tǇpiĐal͛ aŶtipsǇĐhotiĐsͿ iŶ ƌegaƌd to eǆtƌapǇƌaŵidal sǇŵptoŵs. This ǁas ŵisleadiŶg. The ƌeduced 
tendency to produce extrapyramidal symptoms depends on dose and pharmacology. The use of 
muscarinic antagonists (antiparkinsonian medication) provides a proxy for clinically significant 
extrapyramidal symptoms. In head-to-head studies (Rummel-Kluge et al., 2012), risperidone was 
associated with more use of such medication than clozapine, olanzapine, quetiapine, and 
ziprasidone. Quetiapine showed significantly less such use than olanzapine and risperidone. In 
addition, patients with bipolar dis-order may be more at risk for extrapyramidal symptoms than 
patients with schizophrenia, for example when treated with high-potency dopamine antagonists 
like haloperidol (Cavazzoni et al., 2006). Accordingly, successful treatment of mania without 
extrapyramidal symptoms is an important practical clinical objective that can be facilitated by 
differentiation between drugs that are anti-manic. 
The relative efficacy and acceptability of the treatments for mania has been analysed using 
network meta-analysis (Cipriani et al., 2011; Yildiz et al., 2015). All the dopamine antagonists 
(and the partial agonist, aripiprazole) showed superiority to placebo. Network meta-analysis 
demonstrated an order of relative superiority that ranked risperidone, olanzapine, quetiapine 
and haloperidol at the top; haloperidol was less well ranked for acceptability (drop-outs from 
trials). The network was highly coherent, and so strongly supports the validity of the overall rec-
ommendation to use dopamine antagonist/partial agonists in mania. The individual rankings of 
drugs are of interest but show considerable overlap in confidence intervals. 
Clozapine may also be considered by extrapolation from its likely superiority in treating 
psychosis (Leucht et al., 2013) and limited observational data in treatment-resistant mania 
(Green et al., 2000; Li et al., 2015). 
Other factors that influence the choice of drug include proper-ties such as sedation, which may 
be desirable in the short term but not in the long term, and the choice of formulation. Finally, in 
the UK oŶlǇ aƌipipƌazole is liĐeŶsed foƌ up to ϭϮ ǁeeks͛ tƌeatŵeŶt of ŵodeƌate to seǀeƌe ŵaŶiĐ 
episodes in bipolar I disorder in young people (13 years and older). 
The availability of parenteral formulations is valuable in emergencies and should form part of 
any local protocol for treating highly agitated patients (I, (Wilson et al., 2012)). In the past, often 
in an effort to achieve sedation, patients were habitually treated with high doses of, for 
example, haloperidol or droperidol (the latter now withdrawn in the UK), which could produce 
marked extrapyramidal symptoms unless combined with a muscarinic antagonist. When 
possible, such extrapyramidal adverse reactions should be avoided, even when managing an 
emergency. 
If sedation is the aim, benzodiazepines such as diazepam, lorazepam and clonazepam are more 
appropriate and can usually produce adequate sedation. When prescribed regularly at night they 
may also facilitate the return of a normal sleep–wake cycle (II, (Post et al., 1996)). 
Other medicines for acute mania: lithium, carbamazepine and valproate. Acute treatment trials 
support the use of lithium, carbamazepine and valproate in mania (Yildiz et al., 2011, 2015). 
Network meta-analysis ranks them below the more efficacious dopamine antagonists (Cipriani et 
al., 2011), but their use may often be considered if planning their long-term continuation. Expert 
guideliŶes iŶ the U“A haǀe iŶ the past ŵade lithiuŵ aŶd ǀalpƌoate ;͚ŵood staďilizeƌs͛Ϳ theiƌ fiƌst-
line preference for mania for this reason (American Psychiatric Association, 2002). 
The low therapeutic index of lithium means that lithium is usually commenced at a low dose and 
increased incrementally approximately every 5–7 days depending on results of serum lithium 
levels. Thus, one cannot usually start a patient on a therapeutic dose of lithium on the first day 
of treatment, whereas this can often be achieved with a dopamine antagonist or partial agonist. 
The much improved evidence base for the use of the dopamine antagonists and partial agonists 
has resulted in a convergence of practice and experiment in their acceptance as first line for 
mania. 
Valproate is the term that is often used to describe different formulations of valproic acid, the 
active chemical entity. Sodium valproate has been widely used in epilepsy and is also availablein 
a sustained-release formulation. Valproate semisodium (also known as divalproex) is a non-
covalent dimer molecule (com-prising sodium valproate and valproic acid) which has been stud-
ied in bipolar disorder and is licensed in the UK as ®Depakote (see Annex for information on 
dosing of different formulations). 
Valproate semisodium is effective in severe mania (II, (Macritchie et al., 2003)), when the dose 
should be titrated upwards quickly to get control: 750 mg on day 1 and 20 mg/kg+ on day 2. 
Previous US Guidelines gave unusual weight to the efficacy data for valproate and the conviction 
that lithiuŵ aŶd ǀalpƌoate aƌe ͚ŵood staďilizeƌs͛ ;see ďeloǁͿ. 
Exposure to valproate in utero is associated with developmental disorders and foetal 
malformations in women. Warnings against its use in women of child-bearing potential, and the 
need for their informed consent if proposing to do so, have been strengthened recently 
(https://www.gov.uk/drug-safety-update/medicines-related-to-valproate-risk-of-abnormal-
pregnancy-out-comes). 
The combination of a dopamine antagonist drug with lithium or valproate in acute mania. In 
practice, patients may already be taking lithium or valproate when mania occurs as a 
breakthrough during long-term treatment. Under these conditions it would be common to 
optimize the maintenance treatment and/or add a dopamine antagonist/partial agonist drug. 
Optimization is favoured if symptoms are not severe, the history suggests that lithium or 
valproate has been effeĐtiǀe uŶtil the ĐuƌƌeŶt ͚ďƌeak-thƌough͛, the ĐuƌƌeŶt tƌeatŵeŶt is ǁell 
tolerated and, in the case of lithium, the most recent plasma level suggests that a dose increase 
will not push the level above the upper limit of the normal therapeutic range. Otherwise, 
combination treatment with a dopamine antagonist/partial agonist will be favoured. Most 
patients included in trials which have compared combination/augmentation therapy versus 
monotherapy with lithium or valproate had prior treatment with lithium or valproate, whereas 
most participants in trials com-paring combination/augmentation therapy versus dopamine 
antagonist as monotherapy had not been on medications or were washed out from their 
previous medication before randomization (Ogawa et al., 2014). The clearest effect was 
demonstrated when the dopamine antagonist/partial agonist is added to lithium or valproate 
not the reverse. Also, in Swedish database studies, the impact of long-term combination 
treatment on violence was only seen when dopamine antagonists were added to mood 
stabilizers and not vice versa (Fazel et al., 2014). Thus, the asymmetry may be a consistent 
finding and reflect the greater acute efficacy of dopaminergic drugs. 
The issue of long-term treatment with lithium and valproate will be addressed below. While it 
may seem logical to initiate one or other option in acute mania as a prelude to long-term 
continuation (in combination with a dopamine antagonist), there are no reasons to make this 
mandatory. Lithium in particular is sometimes difficult to use in exhausted, dehydrated patients. 
Moreover, efforts to prescribe lithium for patients with poor adherence may be misplaced. 
Patients very often stop taking lithium; the median time to discontinue was only 6 months in 
Denmark (Kessing et al., 2007). Discontinuation is associated with admission to hospital (I, 
(Johnson and McFarland, 1996)). This association will be due, in large part, to relapse of mania, 
which can be provoked by abrupt lithium discontinuation. Unless patients are adherent to 
lithium therapy for a minimum of 2 years, these withdrawal effects will nullify any potential 
prophylactic effect (Goodwin, 1994). 
Carbamazepine is not the optimal partner for combination therapy. Carbamazepine induces the 
metabolism of many other drugs and combinations are better avoided (Monaco and Cicolin, 
1999). Alternatives, licensed for use in epilepsy and less likely to interact with other drugs, 
include oxcarbamazepine and eslicarbazepine acetate (rapidly converted to eslicarbazepine after 
oral administration). Eslicarbazepine acetate failed in trials on mania on primary but not all 
secondary outcomes in trials limited by high placebo response rates (Grunze et al., 2015). Thus, 
the use of alternatives to carbamazepine represents a plausible extrapolation, not well 
supported by direct evidence. 
GABA modulators (benzodiazepines). Diazepam, lorazepam, clonazepam and related agents are 
useful in the management of acutely agitated manic states (Allen et al., 2001). They are 
adjunctive, so are indicated when sedation or tranquilization is a priority and when there is a 
pressing need to induce sleep. Their safety in relatively high sedative doses and the absence of 
important pharmacokinetic interactions with other agents are advantages. 
The use of adjunctive GABA modulators can help to avoid excessive doses of dopamine 
antagonists drugs with the attendant risk of cardiovascular and other adverse reactions, 
including the neuroleptic malignant syndrome. 
The switch into depression following mania. It is often stated that treatment with relatively 
selective and potent dopamine antagonists, like haloperidol, is more likely than treatment with 
lithium or valproate to result in a switch from mania to depression. This is also a reason that is 
sometimes given for preferring a drug with dopaminergic/serotonergic effects, such as 
olanzapine or risperidone. Evidence is very limited but one large, naturalistic study suggested 
switch rates of about 5% in the 12 weeks following initiation of treatment for mania (Vieta et al., 
2009). Patients with previous depressive episodes, substance abuse and illness severity were 
more at risk. The study was deliberately enriched for olanzapine (together with an assortment of 
otheƌ ͚atǇpiĐal͛ aŶd ͚tǇpiĐal͛ aŶtipsǇĐhotiĐ dƌugs, Ŷot speĐified). The choice of atypical drugs 
(usually implying a mixed dopaminergic/serotonergic pharmacology) was associated with 10% 
fewer depressive relapses, in confirmation of clinical impression. Controlled data for perphen-
azine (an older drug) supports the potential negative impact of some dopamine antagonists 
;)aƌate aŶd ToheŶ, ϮϬϬϰͿ; hoǁeǀeƌ, this ǁas a sŵall studǇ aŶd peƌpheŶaziŶe͛s phaƌŵaĐologǇ is 
not very different from the newer dopaminergic/serotonergic antagonists 
(http://www.guidetopharmacology.org/). The data from the lamotrigine/lithium/placebo 
relapse prevention trials are a reminder that the risk of relapse of the index episode will usually 
be higher than the risk of switching (Goodwin et al., 2004). 
At present, it would be unwise to base an acute treatment strategy on the assumed risk of 
switch to depression. However, high doses of dopamine antagonists, especially those with high 
affinity for dopamine receptors, may cause akathisia and dysphoria and should be avoided 
(Mizrahi et al., 2007). 
Discontinuation of short-term treatments. Doses of drugs used in short-term treatment of 
mania, particularly dopamine antagonists/partial agonists, should be reduced only after 
complete remission of symptoms, and preferably after 8 or more weeks of euthymia. Benefits of 
continuation of olanzapine and risperidone were still seen 6 months (but not 12 months) after 
ill-ness onset (Yatham et al., 2015a). As a precaution, doses should not be reduced abruptly but 
tapered over several weeks (IV). 
Lithium or valproate, if used in treatment of an acute manic episode, are potentially a rational 
choice for long-term continuation. However, if either is to be discontinued after full remission of 
an acute manic episode, the same consideration applies. Lithium discontinuation should occur 
over a minimum of 4, and preferably 8 weeks, given the risk of premature relapse (Suppes et al., 
1991). Tapering is also preferable to sudden discontinuation for valproate (IV) (Franks et al., 
2008). 
Adjunctive drugs used during short-term treatment of mania, particularly GABA modulators, 
should be reduced gradually once the symptoms for which they were prescribed (e.g. agitation, 
insomnia) have responded and in addition the underlying manic illness has responded to the 
primary anti-manic treatment. 
All patients who have recovered from a manic episode, including their first manic episode, 
should consider subsequent maintenance treatment. The patient and clinician may decide to 
continue the drug that proved effective in the treatment of acute mania; this will often be a 
dopamine antagonist/partial agonist. However, consideration should also be given to switching 
to lithium (see below) (IV). 
Short-term treatments of mixed states. Most treatment recommendations for mixed states 
(DSM-IV-TR) have resulted from sub-group or secondary analysis of data from trials in mania. 
Pooled data from acute efficacy trials of dopamine antagonists/partial agonists have not 
suggested important differences in sub-group effects (Baldessarini et al., 2003). With the 
accumulation of new data from acute (3–6 week) studies of dopamine antagonists (asenapine, 
olanzapine, paliperidone-ER, risperidone, and ziprasidone) and aripiprazole, either as mono-
therapy or as adjunctive therapy, versus placebo, meta-analysis has confirmed efficacy in 
treating acute mixed episodes with predominant manic symptoms (Muralidharan et al., 2013). 
Their efficacy in treating depressed episodes with mixed features remains unclear. 
The demise of the mixed state diagnosis in favour of the extended specifier description will have 
implications for future trials, but as yet little has emerged that is of relevance to choice of 
treatment. 
There is no indication to either start or continue treatment with an antidepressant in a mixed 
state (IV). 
Electroconvulsive therapy. ECT may be considered for manic patients who are severely ill, whose 
mania is treatment resistant (including mixed states (Valenti et al., 2008)), who express a 
preference for ECT and patients with severe mania during pregnancy. Formal evidence for 
efficacy in mania is limited; patients with severe mania are difficult to enter into trials. However, 
audit findings of clinical practice support high rates of response and remission (Mukherjee et al., 
1994). Indeed an earlier study suggested a 60% remission rate in manic patients who had previ-
ously responded poorly to lithium or dopamine antagonists/partial agonists (Black et al., 1987b). 
These observational data are strong and consistent enough to merit moderate ranking in the 
GRADE system. 
It can be argued that ECT should be considered especially in cases of delirious mania, since this 
may be a medical emergency when accompanied by fever, dehydration, and autonomic 
dysfunction and in treatment of resistant mixed states (Medda et al., 2015). 
In view of the polypharmacy common in bipolar disorder, vigilance is required because fit 
thresholds may be altered and the potential for either too brief or prolonged seizures during ECT 
increased. 
It is more usual for ECT to be considered in depression (see below). 
Comparison with NICE guidelines. There are no substantial differences between the conclusions 
of the NICE committee and ourselves regarding the treatment of an acute manic episode. 
2. Short-term treatment of depressive episodes 
•QuetiapiŶe has the ŵost convincing short-term efficacy and relapse prevention profile for 
bipolar depression (I). Olanzapine (in combination with fluoxetine and to a lesser extent as 
monotherapy) and lurasidone also have data supporting acute efficacy. 
•Antidepressant drugs approved for unipolar depression may be effective for treating 
depression in bipolar disorder but the evidence base is very poor. The case is based primarily on 
extrapolation. They require co-prescription of another agent that will reduce the risk of mania 
(lithium, valproate or dopamine antagonist/partial agonist drug) in bipolar I disorder (I). 
•Lamotrigine has evidence for acute efficacy and relapse prevention (I). 
•The risk of a switch to mania is greater for tricyclic anti-depressants or other dual-action 
medications, such as venlafaxine, than with SSRIs (II). 
•While they are unlikely to provoke a manic switch, lithium, valproate, and carbamazepine have 
poor evidence for acute efficacy in bipolar depression. 
•ECT has efficacy in treatment-resistant bipolar depression (II): other options have not been 
adequately studied. 
•Discontinuation of an antidepressant should follow BAP recommendations for unipolar 
depression, but with a more rapid taper in rapid cycling patients (IV). 
Key uncertainties 
•Theƌe is a pauĐity of evidence to decide between different agents in the treatment of bipolar 
depression. 
•Refractory depression is not uncommonly associated with a bipolar illness course. 
•Folate may impair the response to lamotrigine. 
•Most data are for a bipolar I illness course: it is often uncertain whether the treatment of 
bipolar II and particularly the other specified bipolar disorder cases with depression should be 
different from the treatment of unipolar cases. 
•There may be a risk in bipolar II disorder, that antidepressants induce hypomania, mixed states 
or rapid cycling. It is uncertain whether this is mitigated by concurrent anti-manic medication. 
 The role of psychological treatments in bipolar depression remains uncertain, in the absence 
of replicated good-quality evidence. Negative trials of CBT in bipolar disorder suggest 
caution in extrapolation of the approach from experience in unipolar depression. 
Dopamine antagonist drugs (antipsychotic drugs) in bipolar depression. The use of dopamine 
antagonist drugs in bipolar depression has assumed increasing importance as doubt has grown 
over the role of conventional antidepressants. Efficacy can only be supported for specific agents, 
not for the class. This is because the relevant pharmacology is probably not antagonism at 
dopamine receptors per se. The affinities at other receptors are both multiple and varied (Michl 
et al., 2014). What among these properties confers antidepressant efficacy is not known. This is 
partly because not all drugs have been studied equally for depression, so the data on which to 
map efficacy to drug action are very incomplete. 
Most of the controlled data come from studies of major depressive episodes in a bipolar I illness 
course. Where there is sufficient evidence from secondary analysis of bipolar II sub-groups it will 
be noted in the following. Relapse prevention studies offer supporting evidence for acute 
efficacy. Such studies compare the effect of double-blind continuation of an active drug with its 
discontinuation to placebo. The active drug is used to treat the index episode. Where the index 
episode is depression, the data will support efficacy in depression. Such designs will be relatively 
uninformative about preventing relapse to mania (and vice versa when the index episode is 
mania). All such studies are associated with high drop-out rates, so that interpretation of 
drug/placebo differences over the longer term (the prevention of new episodes) will be 
problematic. 
Quetiapine. In common with a number of other drugs for psychosis, quetiapine has moderate 
affinity for dopamine D2 and serotonin 5-HT2A receptors. At doses of 300 and 600 mg/day it 
produced large and early attenuation of depressive symptoms in bipolar patients compared with 
placebo (Calabrese et al., 2005; Thase et al., 2006). Pooled analysis of these two similar trials, 
together randomizing nearly 1000 patients, showed effects in bipolar I and bipolar II participants 
(with slightly lower response rates to active treatment in the latter sub-group) (Weisler et al., 
2008). The only concern about the relatively large effect sizes in these trials is the problem of 
unblinding, which must occur for quetiapine, owing to its sedating subjective effects. This 
justifies downgrading the trials in the GRADE system. 
In relapse prevention studies of patients responding to quetiapine and randomized to continued 
quetiapine or switch to placebo, continuing quetiapine is associated with fewer episodes of 
mania, mixed mania and depression after recovery from either mania or depression (Suppes et 
al., 2013). This further supports the evidence for acute efficacy and, arguably, for relapse 
prevention (see below). 
Current uncertainties relate to the dose: even 300 mg produces substantial rates of somnolence 
and sedation, with associated drop-out from treatment and the longer-term risks of metabolic 
disturbance. After only 8 weeks there is evidence of weight gain and significant increases in 
triglycerides blood glucose. While not of great importance in short-term treatment, these 
changes are an important signal to monitor and treat such problems in the medium to long 
term. There are important differences in metabolic impact between different dopamine 
antagonist drugs, and quetiapine appears to lie towards the more problematic end of the 
spectrum (Leucht et al., 2013). 
Quetiapine may have unusual properties relative to other dopamine antagonists; one suggestion 
is that an active metabolite, norquetiapine, binds with moderate affinity to the noradrenaline 
transporter (Goldstein et al., 2007). This may contribute to its antidepressant action (Cross et al., 
2016). 
If norquetiapine is the active antidepressant agent, implications follow from the polypharmacy 
common in bipolar disorder. The nor-alkylation (N-desalkylation) is catalysed primarily by 
CYP3A4. This enzyme may not only be inhibited, but also induced by other drugs 
(http://medicine.iupui.edu/flockhart/table.htm). Relevant agents that block N-desalkylation 
include fluvoxamine and norfluoxetine, and inducers include carbamazepine, modafinil, and St 
JohŶ͛s ǁoƌt. Thus, fluǀoǆaŵiŶe iŶĐƌeases ƋuetiapiŶe ĐoŶĐeŶtƌatioŶs ďǇ ϭϱϵ%, ǁhile 
carbamazepine can reduce them by 86% (Castberg et al., 2007); effects on norquetiapine 
concentrations have not been reported but might be the reverse depending on its route of 
metabolism. 
Quetiapine has also been investigated and found effective in unipolar depression and 
generalized anxiety (Zhornitsky et al., 2011). Hence it would be misleading to think of it as a 
selective drug for bipolar depression: by the same token its efficacy in bipolar depression is not 
evidence for a biological difference between bipolar and unipolar depression, although the 
effect size was larger in the bipolar trials. 
Olanzapine. Olanzapine has affinity for dopamine D2, serotonin 5-HT2A, muscarinic and 
histamine receptors. Interest in the use of dopamine antagonists or partial agonists as mono-
therapy began when a large RCT showed that olanzapine had a weak antidepressant effect in 
bipolar I depression compared with placebo (Tohen et al., 2003). A second study has been 
pooled with the original data and also supports modest efficacy for olanzapine (I, (Tohen et al., 
2013)). Its combination with fluoxetine in the original study showed even better separation from 
placebo. A relapse prevention study against placebo also supported efficacy against depressive 
relapse (Tohen et al., 2006). 
Olanzapine is accordingly an option for the treatment of bipolar depression: its combination 
with fluoxetine will be discussed below. Similar considerations to those for quetiapine (sedation, 
unblinding) mean RCT evidence may have been subject to bias, so downgrading its quality rating. 
Lurasidone. Lurasidone is an antagonist at D2, 5-HT2A, and 5-HT7 receptors, and a partial 
agonist at 5-HT1A receptors. It has lower binding affiŶitǇ foƌ αϮC aŶd ϱ-HT2C receptors. It has 
been demonstrated to show efficacy in two short-term studies in bipolar depression: one as 
monotherapy and the other as add-on to lithium or valproate (Loebel et al., 2014a, 2014b). 
Lurasidone has a low subjective adverse reactions burden and produced minimal changes in 
weight, blood lipids, or glycaemic control. The commonest reported adverse reactions are 
akathisia and somnolence. At the time of publication it did not have a licence for use in bipolar 
depression in Europe, but has an indication for schizophrenia. In the US it has a licence for the 
acute treatment of bipolar depression as well as schizophrenia. 
Aripiprazole. Aripiprazole is a partial agonist at D2 and 5-HT1A receptors. Data on aripiprazole 
are of interest. In two 8-week monotherapy studies in bipolar depression, it failed to separate 
from placebo at the pre-specified 8-week endpoint, although separation at earlier times was 
evident (Thase et al., 2008a). It has been conventional to accept this negative find-ing as 
definitive, along with the failure to demonstrate efficacy on the depressive pole in the existing 
relapse prevention study (Keck et al., 2007). However, the monotherapy studies in bipolar 
depression may have failed because of shortcomings in the trial design, and the relapse 
prevention study was clearly under-powered to detect effects on depressive relapse. 
By contrast, in treatment-resistant unipolar patients, two trials of adjunctive aripiprazole 
suggested antidepressant efficacy (Thase et al., 2008b). There is no comparable controlled 
evidence for refractory bipolar depression, but a small, uncontrolled case series claimed benefit 
from adding aripiprazole to a variety of other treatments (Ketter et al., 2006). 
Any use of aripiprazole for bipolar depression is clearly an extrapolation from the unipolar data, 
but its dopamine partial agonist activity gives it modest plausibility as a treatment option with a 
different mode of action. 
Cariprazine. Cariprazine is a highly selective dopamine D3 and D2 receptor partial agonist with 
preferential binding to D3 receptors. Its mechanism of action is therefore novel and of potential 
interest for the treatment of bipolar depression. Evidence for efficacy in bipolar depression has 
been published (Durgam et al., 2016, 2015). 
Antidepressants. Antidepressants are commonly prescribed for people with bipolar depression 
(35–40% prevalence in the POMH-UK audit). Their use is nevertheless controversial (Pac-
chiarotti et al., 2013). The usual criticisms are either that antidepressants lack efficacy in bipolar 
depression or they destabilize mood and cause switch to mania. This is undeniably contradic-
tory, since it seems to imply either too little or too much effect. Unfortunately, there is a real 
dearth of placebo-controlled trials on which to make an evidence-based recommendation. 
Meta-analysis a decade ago compared the few drugs tested, as a group, versus placebo 
(imipramine, fluoxetine and tranylcypromine). Most randomized data were obtained in patients 
also receiving lithium or valproate and, in aggregate, comparison with placebo supported 
efficacy for antidepressants in general (Gijsman et al., 2004). The STEP-BD trial weakened that 
conclusion (Sidor and Macqueen, 2011), but did not contradict it. The exception was fluoxetine 
in combination with olanzapine, which has shown individual efficacy versus placebo and, 
modestly, lamotrigine (Brown et al., 2006; Tohen et al., 2003). 
Recently there has been a double-blind comparison of venlafaxine with lithium in bipolar II 
depression suggesting an important advantage to venlafaxine in continuation treatment 
(Amsterdam et al., 2015). This adds to other small studies in bipolar II patients suggesting an 
advantage for fluoxetine com-pared with lithium and provides the very limited evidence favour-
ing the use of antidepressants in bipolar II disorder (McInerney and Kennedy, 2014). Expert 
opinion has also proposed SSRIs to stabilize mood in significant numbers of bipolar II patients 
(Parker et al., 2006). It is recommended that if an antidepressant is prescribed as monotherapy 
in bipolar II disorder, any increase in dose is gradual and that there be vigilance for, and early 
management of, any adverse reactions such as hypomania, mixed states or agitation (IV). 
In contrast to the dearth of evidence in bipolar patients, there has been a very large number of 
trials examining the efficacy of antidepressants in unipolar major depression (I, (Anderson, 2001; 
Undurraga and Baldessarini, 2012)); these studies systematically excluded patients with a bipolar 
illness course. The drugs tested enhanced noradrenaline and/or serotonin function by inhibiting 
monoamine re-uptake or metabolism. Hence their actions are likely to be rather homogeneous. 
The unipolar data support this: network meta-analysis shows major overlap of efficacy for SSRIs 
with venlafaxine, duloxetine and mirtazapine. Reboxetine, a selective noradrenergic re-uptake 
inhibitor, was the only clear outlier (Cipriani et al., 2009). Accordingly, the general finding of 
antidepressant efficacy in bipolar depression may be supported by the experience of treating 
unipolar depression. It means that the use of these drugs as a class in bipolar patients is 
essentially an extrapolation. 
The anergic pattern of illness often seen in bipolar patients may favour the use of activating 
antidepressants such as mono-amine oxidase inhibitors (MAOIs) (IV). It is usual to caution that 
while efficacy may be extrapolated for classes of drugs, adverse reactions may be less 
predictable. However, the extensive experience of using antidepressants in unipolar disorder 
means that this is not an important limitation, except potentially with the risk for switch to 
mania. If antidepressants can cause a switch to mania or the emergence of a mixed state, it 
seems further to imply efficacy, even if it is an argument against using antidepressants except 
with considerable vigilance. 
Another approach to comparing unipolar and bipolar depression has been to audit the response 
to the same treatments in hospitalized patients (II, (Bottlender et al., 2001; Moller et al., 2001)): 
the severity of illness and times to response with tricyclic antidepressants appeared to be 
identical for bipolar and unipolar groups. Less positively, audit data from a very large Taiwanese 
database suggested that a poor response (usually to SSRIs) in first episodes of depression was 
predictive of a subsequent bipolar diagnosis (Li et al., 2012). This may imply that compared with 
unipolar patients, bipolar patients are simply more difficult to treat, but an equally plausible 
interpretation would be that antidepressants are less effective in the bipolar group (Goodwin, 
2012). The issue is inevitably confounded in an observational study. 
The view that we cannot safely extrapolate efficacy from unipolar to bipolar depression is widely 
held. There are several negative studies cited to support it. The STEP-BD study compared 
paroxetine and bupropion with placebo and the results were certainly negative (Sachs et al., 
2007). However, whether this result represents a failure of the trial or of the active treatments is 
a moot point. The EMBOLDEN-II study compared two doses of quetiapine with placebo and 
included paroxetine as a comparator (McElroy et al., 2010). Paroxetine did not separate from 
placebo. However, half the patients in the study were treated with quetiapine, which arguably 
carries an appreciably higher risk of unbinding than paroxetine, and this may have reduced the 
chances of finding a positive effect. Finally, agomelatine failed in a placebo-controlled trial in 
which very high placebo response rates will have reduced assay sensitivity (Yatham et al., 
2015b). Such negative studies provide a poor basis for the conclusion that antidepressants do 
not work at all in bipolar patients. Comparable studies can also fail in unipolar populations for a 
variety of technical reasons (Schalkwijk et al., 2014), and the studies them-selves were powered 
to detect conventional positive effects, not to determine equivalence with placebo (non-
inferiority). 
The argument that antidepressants work in unipolar but not in bipolar depression also implies 
that there must be an important neurobiological difference between the two conditions. This is 
not expressed phenomenologically except in the sense that sever-ity appears to increase across 
the bipolar spectrum (Moreno et al., 2012); one exception could be where depression emerges 
immediately out of a manic episode and the episode itself is effectively bipolar or mixed, but this 
is atypical. Neurobiological differences appear likely to be quantitative rather than qualitative 
(Redlich et al., 2015), although potentially of great interest. Indeed, if there are differences in 
the responsiveness to antidepressants between bipolar and unipolar groups, it provides a 
starting point for further dissection of how antidepressants work. For example, one hypothesis is 
that antidepressant action involves correction of negative emotional bias (Harmer et al., 2009); if 
bipolar subjects have less negative emotional bias, it might correlate with the reduced 
effectiveness of conventional antidepressants. 
Anticonvulsants in depression. There is no basis for supposing antidepressant effects to be a 
class effect of anticonvulsant action. However, lamotrigine is of particular interest since it may 
offer important clues to common or unique mechanisms of action relevant to the development 
of new treatments. 
Lamotrigine. Lamotrigine inhibits voltage-sensitive sodium channels in the brain, which may limit 
cell firing. It also blocks L-, N-, and P-type calcium channels and is a weak 5-HT3 receptor 
antagonist. It is a weak inhibitor of dihydrofolate reductase (DHFR). 
The efficacy of lamotrigine has been uncertain for acute bipolar depression. The original 
published study of lamotrigine suggested benefits in bipolar depression compared with placebo 
(Calabrese et al., 1999) and a second study was also supportive (III, (Frye et al., 2000)). However, 
four previously unpublished trials conducted by GSK individually failed to show a separation 
from placebo. These negative findings appeared paradoxical when relapse prevention studies 
were positive (see below) (Goodwin et al., 2004). How can a drug prevent relapse to depression 
if it does not have efficacy in the acute episode? 
A pooled analysis of the original patient data from all five trials was, in fact, able to show a 
modest benefit for lamotrigine in bipolar I and II patients with acute depression (I, (Geddes et 
al., 2009)). Further analysis of the patients with HAM-D scores of 24 and above at baseline 
showed, as predicted, a more substantial effect. By contrast, patients with scores below 24 at 
entry simply showed too high a placebo response to allow detection of an effect of the active 
treatment in any of the individual studies. These findings give limited support for the use of 
lamotrigine as a monotherapy treatment for bipolar depression. 
The addition of lamotrigine to lithium proved effective in bipolar depression in an independent 
European study (van der Loos et al., 2009, 2011). This combination would have the additional 
theoretical benefit of combining two drugs with positive long-term data and complementary 
polarity indices (Popovic et al., 2012, 2014). Similarly, in the CEQUEL trial of depressed bipolar 
patients already taking quetiapine, addition of lamotrigine showed both an early effect on 
depressive symptoms compared with placebo and important benefits for remission, sustained to 
1 year of follow-up (Geddes et al., 2016). Finally, an under-powered, open-label comparison in 
treatment-resistant bipolar depression also suggested benefits as an add-on com-pared with 
risperidone and inositol (Nierenberg et al., 2006). 
The CEQUEL trial included a folate 500 µg/placebo comparison as a factorial addition. It was 
expected that folate might augment treatment effects, but in fact the converse was the case. 
Folate impaired the response to lamotrigine. This effect is noted here because folate is believed 
to be neutral or beneficial for mood, and is widely used in pregnancy, of course. Negative effects 
on mood might be an important adverse reaction to patients taking lamotrigine. The known 
interaction of lamotrigine with the enzyme DHFR makes it more likely that the effect is real (and 
would implicate this pathway in its mechanism of action). 
In summary, lamotrigine has established acute efficacy both as a monotherapy and in 
combination with lithium and quetiapine. The acute findings are supported by relapse 
prevention studies (see below). While the need to titrate the dose might seem likely to delay its 
onset of action, this was not evident in the acute trial data. Nevertheless, the slow titration may 
be a consideration in monotherapy when speed of action is a priority. Its low burden of adverse 
reactions mean unbinding in RCTs was unlikely and risk of bias low. 
The presence of a recent rapidly unstable mood or a mixed state may be a particular reason to 
consider lamotrigine (IV). 
Lamotrigine is uncommonly a single first-line agent in bipolar I but it can be considered in bipolar 
II on the basis of limited positive evidence, including benefit in rapid cycling patients (Bowden et 
al., 1999). 
Valproate. In a recent review and meta-analysis, four small studies support an effect of valproate 
in bipolar depression (Smith et al., 2010). This accords with relapse prevention data for 
depression (see below). A larger, more convincing study is required to establish acute efficacy. 
Lithium in depression. Treatment guidelines (Sachs et al., 2000) have repeatedly suggested an 
overwhelming expert preference for the use of lithium as first-line treatment rather than anti-
depressants. However, the actual evidence for acute efficacy of lithium in bipolar depression, 
either as a sole agent or in combi-nation with others, is disappointing (II, (Bhagwagar and Good-
win, 2002; Young et al., 2010)). Relapse prevention and anti-suicide effects are tangible benefits, 
however (see below). 
Dopamine agonists. The reported efficacy of cariprazine in controlled studies and the evidence 
foƌ aƌipipƌazole͛s effiĐaĐy in resistant depression suggests that dopamine agonism or partial 
agonism might be a potential mechanism of antidepressant action. The full agonist pramipexole 
has also been reported to show efficacy in small studies in treatment-resistant unipolar and 
bipolaƌ depƌessioŶ ;Dell͛Osso aŶd Ketteƌ, ϮϬϭϯ; )aƌate et al., ϮϬϬϰͿ. Adǀeƌse ŶeuƌologiĐal 
ƌeaĐtioŶs to dopaŵiŶe agoŶists, ǁell estaďlished iŶ the tƌeatŵeŶt of PaƌkiŶsoŶ͛s disease, iŶĐlude 
oro-facial and other dyskinesias and compulsive behaviours. 
Modafinil. Modafinil has some antagonist affinity for the dopamine re-uptake site and perhaps 
as a partial agonist at the dopamine D2 receptor. It elevates histamine concentrations in the 
brain. Its indication is as a wakefulness-promoting agent in narcolepsy, with additional clinical 
use in shift work sleep disorder and excessive daytime sleepiness associated with obstructive 
sleep apnea. It has also been studied as the R-enantiomer (armodafinil). In bipolar depression 
(and unipolar disorder) there is very limited evidence for efficacy (Goss et al., 2013). 
Ketamine. There is considerable interest in the potential for ketamine, a NMDA (N-methyl-D-
aspartate) receptor antagonist, to be an important addition to treatment options in major 
depression (Abdallah et al., 2015). This is particularly the case in relatively treatment-resistant 
cases. However, there is only limited evidence in bipolar depression for efficacy of a single 
intravenous dose of ketamine (as add-on therapy to mood stabilizers), not for remission. 
KetaŵiŶe͛s psǇĐhotoŵiŵetiĐ effeĐts teŶd to Đoŵpƌoŵise studǇ ďliŶdiŶg aŶd Ŷo studies so faƌ 
have tried to control for this. The use of ketamine and other glutamate receptor modulators has 
been the subject of a Cochrane review (McCloud et al, 2015). There are considerable 
uncertainties about how any acute benefit from ketamine, which is often clinically evident, can 
best be sustained. The obvious approach is to give repeat doses and to titrate response on an 
individual basis. The main concerns relate to the safety of repeat administration, which has not 
been systematically established. Ketamine treatment is not widely available outside research 
centres in the UK. 
Electroconvulsive therapy and vagal nerve stimulation. ECT is effective in severe depression: the 
relevant trials will have included bipolar cases, although trials exclusively in bipolar dis-order did 
not exist before one important review (I, (The UK ECT Review Group, 2003)) and remain rare. 
However, in a recent study, ECT proved superior to an evidence-based drug treatment algorithm 
in a RCT in treatment-resistant bipolar patients (Scho-eyen et al., 2015), although full remission 
was not much improved by ECT. 
ECT͛s effiĐaĐǇ agaiŶst ďoth poles of ďipolaƌ disoƌdeƌ pƌediĐts it ǁould ďe a ƌeasoŶaďle ĐhoiĐe foƌ 
patients with mixed features (bipolar or unipolar). As noted above, an observational cohort 
study that described high rates of response and remission to ECT in bipolar patients with a DSM-
IV-TR defined mixed state (Medda et al., 2015) has supported this conjecture. 
Beliefs about ECT in the general population appear to remain influenced by unfavourable media 
portrayal (Lebensohn, 1999) and this has not diminished (IV). While clinicians have a respon-
sibility not to pander to ignorance and prejudice, it may be help-ful to allay fears that ECT is 
often used against the will of individual patients (S). In fact, it is unusual for ECT to be used 
ǁithout a patieŶt͛s ĐoŶseŶt, aŶd uŶdeƌ ŵeŶtal health legislatioŶ, eǀeŶ iŶ seƌǀiĐes ǁith a high 
utilization rate; even then, outcomes appear reassuring (Wheeldon et al., 1999). 
Vagal nerve stimulation has limited support for use in treatment-resistant depression: there is 
no specific role identified in bipolar disorder (Shah et al., 2014). 
 
The risk of a switch to mania during treatment of a depressive episode. One short-term outcome 
of treatment for depression is a switch to mania. This may occur as a consequence of illness 
course or because some treatments have a greater potential to cause switching than others. Of 
course, clinically there is an obvious gradient between patients with highly variable mood and 
those with a much more episodic pattern. There have been few efforts to differentiate the 
tƌeatŵeŶt ƌespoŶses aloŶg this gƌadieŶt, eǆĐept ďǇ ƌefeƌeŶĐe to ͚ƌapid ĐǇĐliŶg͛, ǁhiĐh is aŶ 
imprecise course specifier. 
In a meta-analysis of patients without a previous history of mania, treatment with tricyclic 
antidepressants was twice as likely to result in a manic event as treatment with SSRIs or placebo 
(Peet, 1994). In short-term bipolar treatment trials with anti-depressants, switch rates were low 
but there was again a higher rate of switch for tricyclic antidepressants compared with other 
antidepressants (SSRIs in particular) (Gijsman et al., 2004). Fluoxetine plus olanzapine was 
effective in reducing depressive symptoms without provoking manic relapse (Tohen et al., 2003). 
However, a broader meta-analysis of the available data reached the pessimistic conclusion that 
drugs for unipolar depression may produce switching even in the presence of mood stabilizers, 
although the study could not exclude confounding effects as an alternative explanation (Tondo 
et al., 2010). 
Venlafaxine may also increase the risk of switching patients, perhaps because of its action on 
serotonin and noradrenaline re-uptake. In the Stanley network study, patients treated with 
venlafaxine switched to mood elevation (defined as a YMRS rating over 13) in 31% of cases, 
compared with sertraline (15%) and bupropion (14%): response rates were similar at around 
50%, but there was no placebo control (Post et al., 2006). These rates are high, which seems 
likely to have been due to the inclusion of rapid cycling patients. 
High-quality naturalistic data have much to offer this question. Recent linkage of clinical data 
with prescribing data in Sweden suggested that monotherapy with drugs for unipolar depression 
is indeed associated with manic relapse in bipolar I patients, compared with combination with a 
mood stabilizer (Viktorin et al., 2014). There was no increase in the rate of manic relapse in 
patients taking lithium, valproate or carbamazepine. This employed a powerful within-individual, 
longitudinal design to determine relative risk, although patient numbers in the mono-therapy 
group were small. 
The naturalistic data, and clinical common sense, suggest that a drug for mania in combination 
with the drug for depression may reduce the risk of a manic switch in depressed patients with a 
high risk of mania. The drug for mania could be lithium, valproate or a dopamine 
antagonist/partial agonist. The International Society for Bipolar Disorders (ISBD) consensus on 
the use of antidepressants in bipolar patients highlighted the clinical consensus discouraging 
their use in patients with rapid cycling, depressive episodes with mixed features and as 
monotherapy (Pacchiarotti et al., 2013). 
Discontinuation of long-term treatment for depression. There  
is uncertainty about the value of long-term treatment with antidepressants, so it is frequently 
implied that early discontinuation is desirable (Montgomery et al., 2000). This has been echoed 
more dogmatically in recent NICE guidance. Absence of evidence is not evidence of absence, in 
this case, of short-teƌŵ ďeŶefit ;see also ďeloǁͿ. IŶdeed, the I“BD͛s task foƌĐe ƌepoƌt 
recommended continuation of antidepressants over the long term in those who had had a 
relapse in depression after stopping antidepressants (Pacchiarotti et al., 2013). 
Both the anti-manic and the antidepressant medicines should be terminated together if the 
intention is that treatment should be simply for an acute episode. Discontinuation of an 
antidepressant should follow recommendations in related BAP guidelines and taper over 4 
weeks if possible (Cleare et al., 2015). In particular, the possibility of adverse withdrawal effects 
should be discussed and reassurance offered. 
Paradoxical manic episodes have been described during withdrawal of antidepressant drugs in 
patients with bipolar and unipolar depression (Narayan and Haddad, 2011). 
In patients who do switch to mania during treatment, the anti-depressant should be tapered and 
discontinued (IV, consensus opinion). 
Conclusions: the comparative efficacy and acceptability of different drugs for bipolar depression 
(Table 6). NICE2014 used network meta-analysis to shape its recommendations. The analysis 
plan required a minimum sample size and handled each treatment separately. Most of the 
comparisons between treatments were indirect (via placebo). The conclusion was that six 
interventions were statistically superior to placebo (valproate>the combination of fluoxetine and 
olanzapine>lurasidone>quetiapine> olanzapine alone=lamotrigine). Other interventions that 
were included in the network but were not statistically superior to placebo were imipramine, 
lithium, moclobemide, paroxetine, and ziprasidone. 
An independent approach to the same data combined the SSRIs and the tricyclic antidepressants 
for comparison with the better-studied treatments (Taylor et al., 2014). The exact order of the 
resulting ranks was different but not radically so. The question posed by this analysis is whether 
it can/should usefully inform clinical practice, since it depends so heavily on small studies and 
indirect comparisons. In discussion, our consensus group noted a number of contradictions. For 
example, SSRIs (which included paroxetine) ranked higher than quetiapine even though 
paroxetine was inferior to quetiapine in the only head-to-head trial (McElroy et al., 2010). In 
addition, venlafaxine was excluded from the analysis, because studies were not double blind, 
but appeared to have a relatively large effect (Vazquez et al., 2013). It was agreed that the 
limitations of the data pre-vented uncritical acceptance of final rankings, and new data might 
well change the outcome in the coming years. Nevertheless, they provided a useful summary of 
where the field currently is, in all its weakness. 
The ŵost ĐoŶtƌoǀeƌsial issue ǁas NICEϮϬϭϰ͛s eŶdoƌseŵeŶt of the use of fluoǆetiŶe, aŶ 
antidepressant, with olanzapine. While this was a specific recommendation, there seems little 
reason not to regard fluoxetine as a representative SSRI. Therefore, to rank it first line is to rank 
SSRIs in general first line by extrapolation. In bipolar I patients antidepressants should then be 
prescribed only as an adjunct to anti-manic medications (not necessarily olanzapine, of course). 
Opinion was divided between those inclined to accept this extrapolation and those who feel 
strongly that the limited bipolar depression data are inconclusive at present. Currently it is not 
possible to resolve these opposing views. However, given that there are limited options to treat 
bipolar depression, the group concluded that it was reasonable to consider a trial of an 
antidepressant in a patient with bipolar depression if other treatments with a stronger evidence 
base were ineffective or not tolerated. The group noted that the ISBD international task force, in 
trying to balance the same opposite opinions, did not broadly endorse antidepressant use, but 
acknowledged the experience that individual bipolar patients may benefit nevertheless. The 
frequent current use of antidepressants appears not to be proportionate to the established 
benefit in bipolar I patients. Their role in bipolar II patients is equally controversial. 
The group noted that quetiapine has an unusual weight of evidence to support its use in adults 
with bipolar depression and may have a unique combination of pharmacological actions which 
account for this. It therefore merits first-line status. Olanzapine, and lurasidone, may also be 
considered as options, though neither is currently licensed in Europe to treat bipolar depression. 
Lurasidone appears to have a more favourable metabolic profile than either quetiapine or 
olanzapine (Leucht et al., 2013). 
There is little evidence to guide next-step treatment if the first choice fails. Before resorting to 
strategies derived from unipolar patients with treatment-resistant depression, the options 
shown to be effective in bipolar depression should be exhausted first, per-haps in combination. 
The use of aripiprazole can only be by extrapolation, given the failed trials in bipolar depression, 
but cariprazine, also a dopamine partial agonist, has now shown efficacy in two studies (Durgam 
et al., 2016, 2015). This seems to support the pharmacological argument that dopamine agonism 
(or partial agonism) contributes to antidepressant action. 
Dopamine antagonists should not be regarded as potential options for the treatment of bipolar 
depression in the absence of appropriate trials. 
Finally, lamotrigine has supportive data for an acute effect, notably from two independent 
adjunctive studies, which together with longer-term data should make it a more widely used 
option. It appears currently to be under-used outside expert centres. 
Unlike NICE2014, the group did not see evidence to support psychotherapy alone for the 
treatment of depression. NICE2014 made a distinction between primary and secondary care 
implying that there are mild cases of bipolar disorder that can be managed with psychological 
treatment alone. It may apply to young people with possible diagnoses of bipolarity, mild 
symptoms (and a good prognosis). However, the prominent endorsement of psychological 
tƌeatŵeŶts foƌ ďipolaƌ disoƌdeƌ, ǁithout ƋualifiĐatioŶ, as ͚KeǇ pƌioƌities foƌ iŵpleŵeŶtatioŶ͛, 
goes well beyond the evidence. The partial way in which the data appears to have been 
reviewed by NICE2014 to justify their conclusions has also been highlighted (Jauhar et al., 2016). 
3. Long-term treatment 
•Lithiuŵ ƌeŵaiŶs the ŵost effeĐtiǀe tƌeatŵent preventing relapse and admission to hospital in 
bipolar I disorder (I). Lithium should be considered for all patients with bipolar I disorder willing 
to take it reliably (S). 
•Lithium prevents relapse to mania and, less effectively, depression (I). The highest dose that 
produces minimal adverse reactions and effects should be employed. Concentrations below 0.6 
mmol/L are potentially too low to be fully effective and adverse reactions and effects become 
important above 0.8 mmol/L. Lithium may be effective in a minority of patients as monotherapy 
(I). 
•Lithium reduces the risk of suicide (I). 
•Valproate as monotherapy has limited trial data, is some-what less effective than lithium in the 
prevention of relapse and should not usually be considered for women of child-bearing potential 
(I). 
•Carbamazepine as monotherapy is less effective than lithium, has little if any effect on relapse 
to depression and is liable to interfere with the metabolism of other drugs (I). 
•Lamotrigine is effective against depression in long-term treatment (I) and should be considered 
where depression is the major burden of the illness (IV). 
•Dopamine receptor antagonists and partial agonists reduce the risk or relapse and admission in 
long-term treatment (I). Relative effects on the manic and depressive poles of the illness appear 
to depend on the complex pharmacology of the drugs but may be predicted by acute treatment 
effects. 
•Antidepressants to which patients have shown an acute treatment response may, 
appropriately, be continued long term when the risk of a severe depressive relapse is high (III). In 
bipolar I disorder, they should be used in combi-nation with a medicine that has long-term anti-
manic efficacy (II). 
Discontinuation of long-term treatment is not indicated when there is good clinical control of 
the illness. When it is necessary, it should be tapered (IV). In the case of lithium there is a 
specific risk of manic relapse if it is discontinued within a 2-week interval (I). Poor adherence is a 
contra-indication to lithium because of the risk of new illness episodes on discontinuation (I). 
Key uncertainties 
•Theƌe is uŶĐeƌtaiŶtǇ iŶ ƌelatioŶ to the effeĐts of shoƌt-term treatment on day-to-day or week-
to-week mood stability. 
•Successful long-term management often appears to require combination treatment (III). 
Combination of lithium with valproate, or quetiapine with lithium or vaproate is superior to 
monotherapy. At present there is little to guide practice other than safety concerns and 
pragmatic outcomes in individual cases. 
•The long-term value of antidepressants is not sufficiently established. 
•Extrapolation of long-term strategies for bipolar I disorder to bipolar II or the bipolar spectrum 
remains speculative. 
Bipolar disorder tends to be a long-term, indeed, life-long challenge. At present the preferred 
strategy to prevent relapse is for continuous rather than intermittent treatment with oral 
medicines, to prevent new mood episodes. That means a negotiated decision to take one or 
more medicines for the long term – in effect, indefinitely. Such a decision is best made when 
patients are in remission, and ideally, the evidence for the efficacy and safety of any treatment 
should have been established over long periods of time. In practice, controlled data may cover 
much shorter periods of time, and for that reason NICE have been resistant to considering the 
data from such trials. As already explained, we take a more nuanced view, especially where 
practice can be supported by naturalistic data and clinical experience. 
There is now good naturalistic data from Denmark that, for patients treated with lithium, 
starting early in the illness course is more often associated with a very good outcome compared 
with those starting later (Kessing et al., 2014). There is no RCT data to support the validity of this 
finding, but its plausibility supports the intention to initiate treatment early in the bipolar illness 
course. However, the study illustrates the population challenge because under 20% of patients 
started on lithium early remained without relapse at 10 years of follow-up. Early relapse (within 
2 years) was the rule. 
The central problem is that, whatever the intention, adherence to long-term treatment appears 
to be poor (Kessing et al., 2007). To underline this point, about 40% of bipolar patients who com-
mit suicide are not receiving long-term lithium or valproate (Clements et al., 2013). For this 
reason, early psychoeducation should receive high priority in clinical management. With rational 
psychopharmacology, it appears to work in practice to improve outcome (Kessing et al., 2013). 
Medicines with putative efficacy against depressive and (hypo)manic relapse are sometimes 
described as mood stabilizers. We do not favour this terminology because it implies equal 
efficacy in the prevention of depression and mania (which is not seen with most drugs) and does 
not refer to a mechanism of action. In fact, the long-term use of a variety of agents alone or in 
combination may contribute to mood stability. 
The management plan must incorporate additional flexible treatment when an acute stressor is 
imminent or present, early symptoms of relapse (especially insomnia) occur, or anxiety becomes 
prominent. Higher doses of long-term treatments or, perhaps more simply, short-term add-ons 
(e.g. GABA modulators) will be necessary. The focus will often be sleep disturbance, so the 
patient may keep a benzodiazepine or other hypnotic in small supply. 
DopaŵiŶe aŶtagoŶists/paƌtial agoŶists ŵaǇ also ďe kept oŶ haŶd ǁith the doĐtoƌ͛s agƌeeŵeŶt, 
and, if taken at the onset of a manic episode, may reduce its severity. It may also be agreed that 
the patient can increase the doses of their other medicines under specific circumstances. This 
approach serves two purposes: the individual is more likely to comply with the treatment 
regimen if they feel they have greater control, and they can also take immediate action, when it 
may otherwise take too long to get an appointment with their psychiatrist. 
Finally, if a patient has accepted treatment for several years and remains well, they should still 
be strongly advised to continue indefinitely, because the risks of relapse remain high. This can be 
concluded from the findings in several small studies of lithium responders. Even when lithium 
withdrawal was super-vised and intended to be slow, relapse was much more common in the 
withdrawn group (Biel et al., 2007; Yazici et al., 2004). That said, patients may, of course, decide 
to discontinue long-term treatment. This may be most propitious when they have made a full 
recovery from their last episode, have had no bipolar episodes in the preceding 4 years, have no 
history of severe con-sequences from mania or bipolar depression and no previous his-tory of 
cycling with many bipolar episodes. Naturalistic data certainly suggest that patients with residual 
symptoms have significantly worse outcomes, so drug discontinuation in a poor prognosis group 
would not be rational (Angst et al., 2003; Judd et al., 2008). Whatever the circumstances, short-
term support and a management plan to recognize and treat early warning signs of mania or 
depression will be necessary. 
Long-term treatment with lithium. Lithium occupies a particularly important place in the 
management of bipolar I disorder. Thus, the strongest evidence among medicines that are often 
referred to as mood stabilizers for bipolar I disorder is still for lithium. Lithium certainly prevents 
relapse to mania and depression. 
Adequate numbers of patients have been randomized into placebo-controlled short-term or 
͚ŵaiŶteŶaŶĐe͛ tƌials of lithium treatment dating from soon after its introduction (I, (Burgess et 
al., 2001)), and more recently when lithium has been a reference compound for other 
treatments (Severus et al., 2014). The relative risk of relapse on lithium over a year or more was 
0.6 compared with placebo. So of 753 patients on lithium 258 (34%) relapsed; of 827 on placebo, 
467 (56%) relapsed. That means in general that one would need to treat about five patients for 
about a year with lithium to avoid one relapse. 
Considering relapse to either pole of the illness individually, there was a greater relative 
reduction in the risk of manic relapses (0.5) compared with depressive relapses for lithium (0.7–
0.8). In fact, on current evidence, lithium is only modestly effective in protecting against 
depressive relapse (Severus et al., 2014). 
The largest study of lithium to date was a double-blind comparison of switching to lithium or 
placebo in patients who responded acutely to quetiapine (Weisler, 2014). A post hoc analysis 
suggested that a lithium level of 0.6 mmol/L or higher was more effective than lower doses for 
lithium monotherapy maintenance in the prevention of relapse (Nolen and Weisler, 2013). There 
has been uncertainty over the years about whether single daily dosing is safer than more 
frequent dosing regimes. Twice daily, versus once-daily dosing of lithium gives sustained higher 
minimum concentrations and this has been linked to more pathological renal changes on biopsy 
(and a higher risk of polyuria (Carter et al., 2013)). Given the advantage for adherence of once-
daily dosing, we recommend once-daily night-time dosing for lithium (IV). 
Lithium concentrations in blood should be regularly monitored. How regularly is open to debate. 
This is problematic because failure to follow guidance may have legal implications for doctors. 
NICE2014 recommended measurement every 3 months for the first year of treatment and every 
6 months there-after (with a number of exceptions). Doctors should probably try to adhere to 
this recommendation. In reality, however, an annual check of all relevant blood indices is 
probably adequate in stable, physically healthy patients (McKnight et al., 2012). It is unclear 
whether the common failure to do any monitoring at all in some services is affected by what 
frequency is actually recommended. 
Vigilance and increased monitoring is required when patients become physically ill or when they 
add medications with the potential to modify the clearance of lithium (non-steroidal anti-
inflammatory drugs, for example). 
Long-term treatment with anticonvulsants. There is no basis as yet for equating anticonvulsant 
aĐtioŶ ǁith ͚ŵood staďilizatioŶ͛, as has soŵetiŵes ďeeŶ Đlaiŵed ;Post et al., ϭϵϵϴͿ. 
Anticonvulsants have a heterogeneous pharmacology and there is no evidence to suggest a class 
effect, such that anticonvulsants stabilize mood. Thus, valproate, carbamazepine, lamotrigine, 
gabapentin and topiramate are all anticonvulsants with different modes of action. In the case of 
the latter two com-pounds, there is almost no reliable evidence at all favouring their use either 
in acute mood episodes or to prevent relapse. Specifically, for gabapentin and topiramate 
controlled studies in acute mania were negative (gabapentin II, (Pande et al., 2000); topiramate 
II, (Kushner et al., 2006)). There remains some interest in using topiramate for weight reduction 
in obese bipolar patients (Chengappa et al., 2006). 
Valproate. Valproate is often referred to, with lithium, as a mood stabilizer. Data on valproate 
are much more limited than that for lithium, however. The comparison with placebo is driven by 
a single RCT of valproate (as valproate semisodium, ®Depa-kote), which showed rates for all 
relapse of 24% against placebo at 38%. This suggests an absolute risk reduction of about 15%, 
numerically comparable with lithium (22%) but statistically non-significant. In fact, the effect for 
depressive relapse was higher than for mania in this study (Cipriani et al., 2013c). The BALANCE 
trial specifically compared valproate, lithium and the combination in a randomized, non-blind 
maintenance study with a run in on the combination treatment to minimize drop-outs after 
randomization. Lithium alone and in combination with valproate was superior to valproate alone 
(Geddes et al., 2010). 
Nevertheless, observatioŶal data suppoƌt aŶ effeĐt foƌ ǀalpƌoate Ŷot ŵuĐh less thaŶ lithiuŵ͛s iŶ 
practice. 
Carbamazepine. Carbamazepine was the first agent after lithium to be advocated for long-term 
treatment of bipolar disorder (II, review by (Okuma and Kishimoto, 1998)). It has been re-
examined in two other trials, which showed a substantial benefit with lithium compared with 
carbamazepine in preventing relapse (II, (Greil et al., 1997; Hartong et al., 2003)). 
Lamotrigine. Two maintenance trials of lamotrigine as monotherapy supported an effect against 
depression, not mania (I, (Goodwin et al., 2004)). The samples were enriched for lamotrigine 
responders, and compared lamotrigine, lithium and placebo. In one, the index episode was 
mania and, in the other, depression. The results from both trials are mutually supportive in 
showing an advantage for lamotrigine in the prophylaxis of depression. There was a comparable 
advantage to lithium for prophylaxis of mania. There was no excess of depressive episodes in 
lithium-treated patients nor manic episodes in lamotrigine-treated patients compared with 
placebo. Indeed, for both agents there was a trend towards effects against the opposite pole of 
the ill-ness. Thus, neither provoked mood instability to the opposite polarity. CEQUEL also 
demonstrated benefit over 12 months for combination treatment with lamotrigine (Geddes et 
al., 2016). 
Long-term treatment with dopamine antagonists/partial agonists. Dopamine antagonists/partial 
agonists have long been used in bipolar outpatients as long-term treatment. They have been 
prescribed for some patients in depot formulations, either as monotherapy or in combination 
with other agents. Before the development of the newer dopamine/serotonin antagonists and 
partial agonists, their use was poorly supported by formal evidence for patient benefit. There is 
a clinical impression that the newer agents offer advantages because they are less likely to pro-
duce dysphoria or provoke depressive relapse. 
Most of the newer, so-called second-generation dopamine antagonists/partial agonists have 
been studied in relapse prevention trial designs. Such studies enrich the study sample for acute 
responders to the drug of interest, and the active drug may be withdrawn abruptly, which risks 
amplifying any drug/placebo difference with withdrawal effects. This can be inferred from an 
excess of early relapses seen for example in a study of this design with olanzapine (Tohen et al., 
2006). Therefore such studies, with occasional exception, primarily support short to medium-
term use. 
Use in the longer term is mainly an extrapolation, albeit sup-ported by strong naturalistic data. 
Comparison of rates of hospital admission on and off treatment over 4 years are strongly 
supportive of efficacy for lithium (HR: 0.66, 95% CI: 0.62–0.70), valproate (HR: 0.72, 95% CI: 
0.67–0.79), lamotrigine (HR: 0.79, 95% CI: 0.73–0.84), olanzapine (HR: 0.77, 95% CI: 0.71–0.82), 
and quetiapine (HR: 0.82, 95% CI: 0.75–0.89) (Joas et al., 2015). Lithium, valproate, lamotrigine, 
carbamazepine, olanzapine and quetiapine treatment periods were associated with reduced 
rates of manic episodes. Lithium, valproate, lamotrigine, quetiapine and olanzapine were 
associated with reduced rates of depressive episodes. Lithium only was associated with reduced 
rates of mixed episodes. 
Olanzapine. Olanzapine has been studied as a comparator to depot risperidone and showed a 
reduction in manic and depressive relapse (Vieta et al., 2012). There was no enrichment for 
olanzapine responders so, notwithstanding a drop-out rate of 40–50% over 18 months, this trial 
offers good evidence for patient benefit as a maintenance treatment. Olanzapine was also 
slightly superior to lithium as monotherapy after acute response to the combination of lithium 
with olanzapine, but produced significant excess weight gain (Tohen et al., 2005; Zarate and 
Tohen, 2004). This study suggests that olanzapine prevents early manic relapse after lithium 
withdrawal, although the lithium dose was tapered over 4 weeks to prevent very early 
withdrawal effects. 
Quetiapine. Quetiapine has been shown to be effective as monotherapy, and in combination 
with lithium or valproate (Sup-pes et al., 2009), in the prevention of relapse to either pole of the 
illness. These findings are consistent for patients entering treatment from either pole of the 
illness. The doses employed in trials were high (300–600 mg/day) and in the monotherapy trial 
the median dose was 546 mg/day (Weisler et al., 2011). 
Lurasidone. Lurasidone may prove useful in bipolar depression (see above). Its long-term use is 
supported by a relapse prevention study in which 28 weeks of continued treatment with 
adjunctive lurasidone was associated with a trend significant risk reduction in time to recurrence 
of any mood event compared with placebo plus lithium or valproate, and a significant reduction 
in time to recurrence of a depressive episode. Patients entered the study and were stabilized 
from either pole of the illness (Calabrese et al., 2015). 
Aripiprazole, ziprasidone, paliperidone. Aripiprazole was more effective than placebo after acute 
and continuation treatment of mania: acute withdrawal of the aripiprazole did not produce an 
excess of early relapse in this study (Keck et al., 2007). Ziprasidone has positive adjunctive data 
(Bowden et al., 2010) and paliperidone only proved effective preventing mania (Berwaerts et al., 
2012). 
Dopamine antagonists/partial agonists may be appropriate for the long-term management of 
bipolar patients especially where non-mood-congruent psychotic features are prominent. 
Dopamine antagonists/partial agonists may be useful in difficult-to-treat cases of rapid cycling 
(III, (Carvalho et al., 2014; Lowe and Batchelor, 1986)). When added to usual treatment, 
principally with lithium or anticonvulsants, combination with clozapine was superior to usual 
treatment alone over 1 year in treatment-resistant bipolar patients including those with rapid 
cycling and mixed states (II, (Suppes et al., 1999)), but rapid cycling remains a major clinical 
challenge. Secondary analysis of the acute depression studies with quetiapine suggest efficacy in 
the short term for rapid cyclers (Vieta et al., 2007), but the real problem is long-term stability. 
Long-acting dopamine antagonists. Various LAI antipsychotics are available, including 
fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, 
paliperidone palmitate and aripiprazole monohydrate. Their primary indication is in the 
treatment of psychosis, but logically, LAIs could be used in bipolar patients where the treatment 
plan  is continuation of treatment with dopamine antagonists, but adherence to oral medication 
is poor. Evidence to support their use in bipolar disorder is very limited (Bond et al., 2007; 
Gigante et al., 2012). The data for LAI risperidone is consistent in being positive for preventing 
mania, not depression (Quiroz et al., 2010; Vieta et al., 2012). 
When switching from an oral drug to an LAI form, it is good practice to start with the oral 
antipsychotic for the length of time required to establish the effective, best tolerated dose 
before switching to the LAI form (Llorca et al., 2013). 
Long-term treatment with antidepressants. Whether or not antidepressants should be used long 
term in bipolar disorder remains uncertain. One small maintenance study (II, (Prien et al., 1984)) 
has had an important influence because it suggested that the treatment of bipolar patients with 
imipramine alone resulted in an unacceptable number of manic relapses over a 1–2-year follow-
up period. This effect was prevented by co-treatment with lithium. It supports the 
recommendation that monotherapy with antidepressants is unwise in patients with bipolar I 
disorder. 
Long-term treatment of bipolar I patients with antidepressants is common in clinical practice. 
Given the significant burden of disease imposed by chronic depressive symptoms and recurrent 
depressive episodes, this may not be surprising. The evidence supporting their use in the long-
term prophylaxis of unipolar depression is strong (I, (Geddes et al., 2003)). The equivalent evi-
dence for bipolar patients is almost non-existent. There is non-random evidence for successful 
short-term prophylaxis with antidepressants drugs in bipolar patients also receiving combina-
tion treatments such as lithium, valproate, carbamazepine and antipsychotics (Altshuler et al., 
2001, 2003). But the patients in whom this is evident are about 10% of the total sample 
included. These and the few other relevant findings are far from compel-ling (Ghaemi et al., 
2001; Pacchiarotti et al., 2013). Clinicians will have to use clinical judgement in deciding whether 
an individual patient should continue with an antidepressant. 
The uncontrolled and audit experience of using antidepressants is substantial, and, of course, 
applies to real clinical populations. As others have commented, some guidelines for the 
treatment of acute bipolar depression have gone too far in their proscription (Moller and 
Grunze, 2000). 
Bipolar II patients and, in particular, patients with bipolar spectrum depression have not been 
sufficiently investigated. Anecdotally, it is possible that effective treatment with antide-
pressants is possible without an additional anti-manic drug (Parker et al., 2006). This is an area 
that merits further investigation, as the diagnostic issues become more widely understood. 
The comparative efficacy and acceptability of different drugs for long-term treatment. Network 
meta-analysis of long-term treatments suggests comparable efficacy for most of the drugs 
described above (Miura et al., 2014). However, the value of the quantitative comparisons was 
limited by the design weaknesses already described. Lithium, olanzapine, quetiapine, risperidone 
LAI and valproate prevented manic relapse. Only lamotrigine, lithium and quetiapine were 
convincingly shown to prevent depressive relapse. 
Long-term treatment: winning combinations. For perhaps too long, monotherapy with lithium 
was believed to be the best treatment for bipolar disorder. It was speculated in previous editions 
of this guideline that effective prevention of progression to frequent relapse or chronicity may 
require combination treatment from quite early in the illness course. Increasingly, combi-nations 
of agents are being prescribed for the majority of patients who fail on monotherapy. They will 
derive from apparently effective combinations used to control acute symptoms. Indeed, there is 
a strong evidence base to support the combination of a dopamine antagonist/partial agonist 
plus lithium or valproate to treat acute mania that has not responded adequately to lithium or 
valproate in monotherapy (Ogawa et al., 2014). However, there are only a limited number of 
studies that compare long-term monotherapy versus combination treatment. 
Two RCTs have shown that, when acute mania or depression responds to the combination of 
quetiapine with valproate or lithium, then continuing the combination, versus switching to lith-
ium/valproate monotherapy, is associated with a lower rate of relapse of both depression and 
mania (Suppes et al., 2009; Vieta et al., 2008). For olanzapine (Tohen et al., 2004) and 
aripiprazole (Marcus et al., 2011), a single RCT has shown that when the combination of either 
drug with lithium or valproate is effective in treating acute mania, then continuing the 
combination is associated with a lower risk of manic relapse than switching to lithium or 
valproate alone. The BALANCE study showed that over 2 years valproate monotherapy was 
inferior to both lithium monotherapy and valproate/lithium combination in terms of total 
relapses (Geddes et al., 2010). However, combination treatment, compared with monotherapy, 
carries a greater risk of medication side effects. 
Maintenance ECT. Continuation and maintenance ECT is some-times currently employed in 
patients who have failed pharmacotherapy but responded to an acute course of ECT. The 
evidence for this approach consists of case reports and retrospective chart reviews, with little 
focus on bipolar disorder per se (Frederikse et al., 2006; Petrides et al., 2011). There are 
supportive chart reviews for patients with bipolar disorder (Santos Pina et al., 2016). A small 
pilot study of vagal nerve stimulation is also compatible with some benefit in resistant rapid 
cycling patients, a very disabled group (Marangell et al., 2008). 
Suicide. As a rule, suicide is associated with depression, and risk assessment should always be 
emphasized during acute episodes of depression in bipolar patients. Assessment of suicide risk 
should be as for other depression diagnoses and should follow widely accepted principles of 
good clinical practice (Haw-ton, 1987). Suicidality will often be related to illness severity and may 
guide the need for admission. Suicide in bipolar patients is a risk that persists across the lifespan. 
There have been reports of suicidal acts in association with antidepressant treatment in younger 
people. Whether these are caused by antidepressants has been the subject of considerable 
hype, but appears unlikely (Gibbons et al., 2015). One speculation was that this might be more 
likely in undiagnosed bipolar depression. However, the onset of suicidality in bipolar patients 
was not associated with the use of antidepressants in the STEP-BD study, although the numbers 
were small (Bauer et al., 2006c). 
Adverse reactions to long-term treatment. Weight gain is a major problem associated with the 
use of many of the medicines offered long term to bipolar patients (Torrent et al., 2008). The use 
of olanzapine and quetiapine is particularly associated with unfavourable metabolic indices, 
especially when the patient population is obese (Lieberman et al., 2005). Efforts are necessary to 
alert patients to the need both to maintain normal levels of exercise and moderate calorie 
intake. While this has traditionally been a cosmetic concern, strongly felt by patients, it has 
important medical implications particularly related to the risk of future cardiovascular disease 
(see BAP guideline on the management of weight gain and metabolic disturbances associated 
with psycho-sis and antipsychotic drug treatment). 
A rise in serum prolactin caused by dopamine receptor antagonism is a frequent and neglected 
problem (Pacchiarotti et al., 2015). It may lead to secondary hypogonadism (Howes et al., 2007) 
and low bone mineral density (BMD), the most important risk factor for osteoporotic fractures. 
Lifetime risk of such fractures for women in the general population is already high at 
approximately 50%. Decreased BMD and increased fracture risk have been shown in patients 
with severe mental illness (Howard et al., 2007; Lehman and Meyer, 2005; Meyer and Koro, 
2004). Prolactin and gonadal function are hardly ever assessed in women on dopamine 
antagonists, BMD is not measured, and osteoporosis remains undiagnosed, let alone prevented 
or treated. All pre-menopausal women on amisulpride and most on risperidone (including at low 
doses) are at risk of amenorrhoea, low or undetectable oestradiol concentrations and many will 
also have low BMD. Hence, prevention and treatment of osteoporosis must become a target for 
improvement in physical health of potentially neglected populations of patients. 
Tardive dyskinesia (TD) remains a concern for patients treated long term with dopamine 
antagonists/partial agonists (Keck et al., 2000). Acute extrapyramidal symptoms are still 
regarded as a predictor of subsequent TD, and are probably more common in bipolar patients 
(Gao et al., 2008). Hence the lower extrapyramidal symptoms associated with the use of the 
lower potency dopamine/serotonin antagonists and the use of the drugs like haloperidol at 
lower doses should reduce the long-term risk. Current data on TD are supportive if not 
ĐoŶĐlusiǀe of ŵuĐh ƌeduĐed ƌisks ǁith the Ŷeǁeƌ ageŶts ;O͛BƌieŶ, ϮϬϭϱͿ. 
Conclusions 
Like NICE2014, the group highlighted the superior evidence base for lithium and the need for its 
advantages to be emphasized in training and practice. 
In view of the long-term problem of depressive symptoms in bipolar patients, the potential role 
of lamotrigine and its currently low rates of utilization in most NHS centres have been high-
lighted. In contrast, the common long-term use of antidepressants appears less easy to justify on 
the basis of the evidence. 
NICE2014 was more restrictive in its recommendations for long-term treatment with dopamine 
antagonists/partial agonists (Table 7). Naturalistic data supports a broad range of efficacy for 
these medicines. Moreover, in an individual patient, if a medicine leads to prompt remission 
from the most recent manic or depressive episode, this may be considered evidence favouring 
long-term use as monotherapy (IV). Because effective in the short term, this may lead to their 
preferential use; active consideration of lithium as a better alternative should be promoted. 
However, the greatest challenge is the early adoption of a long-term treatment strategy 
acceptable to patient and family. The complex need for access to a responsive and intelligent 
clinical service, psychoeducation and relevant behavioural change, adherence to prescribed 
medicines and informed prescribing is difficult to meet within current services for too many 
patients. 
“peĐifiĐ psǇĐhologiĐal iŶteƌǀeŶtioŶs foƌ ƌelapse pƌeǀeŶtioŶ iŶ ďipolaƌ disoƌdeƌ •฀
 PsǇĐhoeduĐatioŶ is the pƌefeƌƌed oƌ ͚fiƌst-liŶe͛ psǇĐho-logical intervention. 
•Uncritical endorsement of CBT as a generic method for relapse prevention in bipolar disorder is 
not justified. 
•In general, psychological interventions appear to demonstrate efficacy most convincingly with 
patients early in their illness course. 
 
Key uncertainties 
• Whether psychological interventions can be modified to be efficacious in patients with 
many previous episodes. 
• Efficacy and feasibility of on line psychological intervention. 
 Group and individual psychoeducation. As already indicated, we recommend 
psychoeducation as the preferred or first-line psychological intervention. 
Cognitive behaviour therapy. While bipolar patients share many of the common cognitive 
distortions and attitudes described in unipolar patients (II, (Scott et al., 2000)), a cognitive model is 
not convincing as a complete theory of the illness. Nevertheless, cognitive theories can fruitfully 
address some specific problems bipolar patients bring to treatment. Therapy derives pragmatically 
from clinical experience with bipolar patients (review by (Scott, 1996)). A preliminary trial in 42 
subjects suggested that CBT could speed recovery from depression and prevents the cascade of 
isolated manic symptoms into full-blown episodes (Scott et al., 2001). A formal trial of CBT for 
currently euthymic bipolar patients produced important reductions in rates of syndromal relapse, 
depression symptom reduction, less mania symptom fluctuation and higher social functioning over a 
1-year period compared with treatment as usual (Lam et al., 2003). The study targeted patients who 
had taken mood stabilizers and were still suffering from frequent relapses. Compared with 
treatment as usual, such enhancement of clinical care appeared to be helpful. Treatment included 
components of education, motivation to take medicines reliably, self-monitoring, active relapse 
prevention measures and problem solving. Action plans and modification of behaviours often do not 
depend solely on the patient to recognize abnormal mood states. Disappointingly, the findings from 
the Lam study were not replicated in a larger, more pragmatic CBT study, which showed no benefit 
at all for a large sample of patients versus treatment as usual (Scott et al., 2006). A secondary 
analysis suggested that patients earlier in their illness course were slightly more likely to show 
benefit – as for psychoeducation (see below). Pilot data in an early-onset group also weakly support 
this conclusion (Jones et al., 2015b). Negative findings for CBT include evidence for equivalence to a 
cheaper group psychoeducational approach (Parikh et al., 2012) and a simpler supportive individual 
approach (Meyer and Hautzinger, 2012). 
Resources for complex psychotherapy are always likely to be limited and provision should be 
focused on those patients most likely to benefit. Patients with particularly severe personal and social 
disturbance early in their illness course should probably be given priority access. Uncritical 
endorsement of CBT as a generic method for relapse prevention in bipolar disorder is not justified. 
Interpersonal and social rhythm therapy. The principles of IPSRT derive from interpersonal 
therapy, which has never itself been studied in bipolar patients (Frank et al., 2000). It places a 
particular emphasis on preserving sleep and regular daily activities. A comparison of IPSRT with 
͚iŶteŶsiǀe ĐliŶiĐal ŵaŶageŵeŶt͛ suggested benefit from this approach. Patients assigned to IPSRT in 
the acute treatment phase developed greater regularity of social rhythms at the end of acute 
treatment and survived longer without a new affective episode over 2-year follow-up (Frank et al., 
2005). IPSRT is of particular interest because it has obvious potential to be adapted for automatic 
monitoring and feedback of diurnal activity from mobile phone apps (Nicholas et al., 2015). If it 
works, a personalized approach to IPSRT-derived self-management could be made widely available 
and integrated into clinical care. 
Family/caregiver interventions. Family interventions are effective in the short and long-term 
treatment of bipolar disorder (Miklowitz et al 2008; Reinares et al, 2008), although not all patients 
are candidates for those treatments. They are mostly based on psychoeducational and CBT 
paradigms with some extra emphasis on expressed emotions. Involvement of family members is 
clearly of most value in younger patients. The key components are psychoeducation about bipolar 
disor-der, communication skills training and problem-solving skills training. 
Cognitive and functional remediation. Even those patients who achieve full clinical remission 
present, in many cases, with long-term cognitive problems and social dislocation. Cognitive and 
functional remediation, as prescribed in group format (Vieta et al., 2014), may be helpful to improve 
global as well as interpersonal and occupational functioning (Torrent et al., 2013). 
Further work is required to determine whether there are real differences between therapies 
and whether simpler interventions are worthwhile. The provision of greatly increased levels of psy-
chotherapy to vulnerable patients is not without its risks, most notably of sexual or financial 
exploitation by the therapist (Nutt and Sharpe, 2008). The disinhibition of bipolar patients in a manic 
state poses a particular hazard. 
Comparison with NICE guidelines: specific psychological treatments. The primary focus of 
the BAP guideline is a balanced recommendation for the use of medicines in the context of a 
coherent and integrated psychoeducational framework. The consensus around the common 
elements of promising psycho-logical interventions seems more convincing than specific therapies, 
and more immediately applicable through a broadly understood goal of psychoeducation for all 
patients. 
NICE2014 made more specific recommendations for psycho-logical treatment of bipolar 
depressive episodes: a psychological intervention that has been developed specifically for bipolar 
disorder and has a published evidence-based manual describing how it should be delivered or a 
high-intensity psychological intervention (cognitive behavioural therapy, interpersonal therapy or 
behavioural couples therapy) in line with the NICE clinical guideline on depression. 
We are not convinced that extrapolation from unipolar depression is justified (IV). 
4. Treatment of alcohol and substance use disorder 
The commonest co-morbidity of bipolar disorder is alcohol or substance use disorder. Patients 
appear more likely to present with dysphoric manic states and so bipolar disorder should be 
considered in the differential diagnosis of such presentations. The co-morbidity is often present at 
the first episode. 
It is now a clinical consensus that alcohol and substance use co-morbidity should not be seen as a 
secondary phenomenon that will remit with treatment of the bipolar disorder. The treatment of 
alcohol and substance use disorder should be planned in its own right. Contemporary approaches 
are summarized in another BAP guideline and will not be repeated at length here. 
Thus, ǁe suppoƌt NICE͛s ƌeĐoŵŵeŶdatioŶ to Discuss the use of alcohol, tobacco, prescription and 
non-prescription medication and illicit drugs with the person, and their carer if appropriate. Explain 
the possible interference of these substances with the therapeutic effects of prescribed medication 
and psychological interventions. 
It will be helpful to clarify the treatment target choosing from among assisted withdrawal, reduction, 
relapse prevention or maintenance of controlled drinking. In very heavy drinkers, even modest 
reductions in consumption will significantly reduce the potential physical harms. 
As described in full in the BAP guideline, naltrexone or nalmefene may help patients to reduce their 
alcohol consumption (III). Acamprosate should be offered if naltrexone has not been effective (IV). 
Disulfiram may be considered if the patient wants abstinence and acamprosate and naltrexone have 
failed. The patient must be able to understand the risks of taking disulfiram and have their mood 
monitored (IV). 
It may be helpful also to specify caffeine use and treat its reduction as a valid target in sensitive 
patients. 
There is a paucity of studies on which to shape a specific approach to treatment of bipolar disorder 
in patients with alcohol or substance use disorder. One small trial in a relevant population supports 
the combination of valproate with lithium rather than lithium alone (Kemp et al., 2009). 
5. Treatment of borderline personality disorder 
There is very limited evidence on the treatment of borderline personality disorder especially when 
co-morbid with bipolar disorder. The NICE guideline on borderline personality disorder 
(https://www.nice.org.uk/guidance/cg78) understandably addresses the stigmatization and barriers 
to treatment of this patient group. However, it is dogmatic about the use of medication: 
1.3.5.1 Drug treatment should not be used specifically for borderline personality disorder or for the 
individual symptoms or behaviour associated with the disorder (for example, repeated self-harm, 
marked emotional instability, risk-taking behaviour and transient psychotic symptoms) and 1.3.5.6 
Review the treatment of people with borderline personality disorder who do not have a diagnosed 
comorbid mental or physical illness and who are currently being prescribed drugs, with the aim of 
reducing and stopping unnecessary drug treatment. 
 Despite these recommendations, patients with borderline symptoms are not uncommonly offered 
medication in part as an extrapolation from practice in bipolar patients or as treatment for 
depression. Such practice is supported by poor-quality studies of lamotrigine, lithium, olanzapine, 
risperidone, aripiprazole and quetiapine, which suggest some symptomatic benefit in border-line 
samples (III, (Lieb et al., 2010)). 
The data from patients co-morbid for borderline and bipolar disorders, again very limited, also 
suggest improvement from lamotrigine and valproate on borderline symptoms (Frankenburg and 
Zanarini, 2002; Preston et al., 2004). In the lamotrigine study this appeared to be associated with, 
and so perhaps secondary to, improved control of bipolar symptoms. 
There are four approaches to psychological treatment of borderline personality; two are considered 
psychodynamic in nature: mentalization-based treatment and transference-focused psycho-therapy. 
The other two are considered to be cognitive-behavioural in nature: dialectical behavioural therapy 
and schema-focused therapy (Zanarini, 2009). They have been investigated in poor-quality clinical 
trials (III or less). In terms of an evidence base, there is less to choose between medication and 
psychological treatment than the NICE guidance suggests. 
While the NICE borderline guideline acknowledges in passing that the condition is commonly co-
morbid with bipolar disorder, and implicitly acknowledges that its treatment should continue, this 
probably needs emphasis so as to avoid a polarizing approach in the services caring for patients with 
borderline problems. In fact NHS audit suggests that borderline patients with bipolar disorder 
usually do receive appropriate medication as much as 80% of the time (Paton et al., 2015). 
6. Treatment of anxiety 
The NICE Bipolar disorder clinical guideline (185: 2014. p. 108) states: 
Offer people with bipolar disorder and coexisting disorders, such as personality disorder, attention 
deficit hyperactivity disorder, anxiety disorders or substance misuse, treatment in line with the 
relevant NICE clinical guideline, in addition to theiƌ tƌeatŵeŶt foƌ ďipolaƌ disoƌdeƌ …. ďe aleƌt to the 
potential for drug interactions and use clinical judgement. 
We recommend the corresponding BAP guidelines for attention deficit hyperactivity disorder (Bolea-
Alamanac et al., 2014), anxiety disorders (Baldwin et al., 2014) or substance misuse (Lingford-Hughes 
et al., 2012). 
Anxiety disorders should be routinely assessed alongside mood symptoms in patients with bipolar 
disorder. The anxiety co-morbidity in bipolar disorder is widely distributed: approximate proportions 
are social anxiety (22%), generalized anxiety disorder (18%), PTSD (17%), panic disorder with / 
without agoraphobia (17%), obsessive–compulsive disorder (10%), and agoraphobia without panic 
(9%) (McIntyre et al., 2006). The NICE and BAP guidelines for these primary anxiety disorders detail 
the specific pharmacological approaches. In bipolar patients there is need for caution in the use of 
dual-action monoamine re-uptake inhibitors such as venlafaxine and duloxetine because of the risk 
of switch to mania: pregabalin may have advantages because of its mode of action (via calcium 
channels, not GABA receptors as its structure and name might lead one to expect). Specific anxiety-
focused psychological treatments – such as trauma-focused CBT and CBT for social anxiety – are 
ƌeĐoŵŵeŶded ƌatheƌ thaŶ ͚geŶeƌiĐ CBT͛. IŶ geŶeƌal, effeĐt sizes foƌ dƌug tƌeatŵeŶt of aŶǆietǇ 
disorders appear to be greater than for psychological treatments (Bandelow et al., 2015). 
Psychological treatments do potentially offer adjunctive approaches for addressing anxiety in bipolar 
disorder where anxiety-specific medication is contra-iŶdiĐated aŶd/oƌ iŶ liŶe ǁith a patieŶt͛s 
preference. However, bipolar disorder is typically an exclusion criterion in the trials of psychological 
treatments so such recommendations represent extrapolation. Moreover, only 22 psychological 
treatment studies had been published by 2014 with an anxiety-related outcome measure in adults 
with bipolar disorders (Stratford et al., 2015). Thus, few psychological treatment studies have 
explicitly targeted anxiety, since historically depression has been the focus. Stratford et al. conclude 
that preliminary data are promising for CBT for PTSD and generalized anxiety disorder in bipolar 
disorders. There was no evidence that psychoeducation alone reduced anxiety. There is early 
evidence that when CBT incorporated an anxiety treatment component, anxiety symptoms were 
ƌeduĐed iŶ ĐǇĐlothǇŵia, ͚ƌefƌaĐtoƌǇ͛ aŶd ƌapid ĐǇĐliŶg ďipolaƌ disoƌdeƌ, ǁheƌeas staŶdaƌd ďipolaƌ CBT 
treatments had only a modest effect on anxiety. CBT during euthymic phases had the greatest 
weight of evidence, although still there is only relatively weak evidence and for limited bene-fit. The 
preliminary evidence for mindfulness-based cognitive therapy was mixed. Where reported, 
psychological therapy appeared acceptable and safe, but more systematic collection and reporting 
of safety and acceptability information is needed. 
Development of specific psychological models and treatment protocols for anxiety in bipolar 
disorders may help improve out-comes. However, separate parallel approaches to bipolar patients 
with different anxiety disorders will be unwieldy and restrictive. A current theŵe is that ͚ďipolaƌ 
aŶǆietǇ͛ is peƌĐeiǀed to ďe a Đoŵ-mon clinical problem even if its intensity and structure do not 
make an anxiety diagnosis. Moreover, anxiety symptoms can be argued to have many core features 
across anxiety diagnoses. The challenge is how to develop such a generic approach for bipolar 
patients. One proposal is to take a highly patient-led approach based on qualitative interview and 
patient experience (Jones et al., 2013) from which, if effective, generalizability may be difficult. A 
more mechanistic approach might identify specific psychological treatment components responsible 
for reducing anxiety in bipolar disorder, like the intensity of imagery (i.e. experience-like perception 
in the absence of a percept, such as intrusive images of traumatic events, or images of performing 
badly in a social situation, relevant to PTSD/social anxiety, respectively) (Holmes et al., 2008, 2011). 
Anxiety requires treatment in its own right, and since anxiety may exacerbate other mood 
symptoms, its treatment may contribute to overall improved mood stability. There is wide 
consensus that research and development is required (Mitchell, 2015). 
As discussed above, in youth prodromes the earliest symptoms may be anxiety (NICE2014, p. 91). 
Further research is especially warranted for prodromal phases and youth populations in which 
anxiety is prominent. We agree with the NICE guide-liŶes ϮϬϭϰ ;p. ϯϬϰͿ ͞it is iŵpoƌtaŶt to kŶoǁ the 
form of psycho-logical therapy that can benefit young people with bipolar disordeƌ͟. EǀideŶĐe-based 
psychological therapy – even, for example, within CBT – takes disorder-specific forms and may need 
to be targeted to bipolar-specific features as well delivered in forms acceptable to youth. 
There is a widely perceived need for closer integration between psychological and pharmacological 
approaches, with psychological intervention a potential adjunctive treatment for anxiety in the 
context of long-term maintenance pharmacotherapy for mood symptoms. The NICE clinical guideline 
185: 2014 p. 264 suggests that psychological therapists applying anxiety (or depression) treatment 
pƌotoĐol to ďipolaƌ disoƌdeƌ ͞should haǀe eǆpeƌieŶĐe of ďipolaƌ͟. Fuƌtheƌ ǁoƌk Ŷeeds to ďe doŶe oŶ 
standards of training and gaining experience of this clinical group. Reading these BAP guidelines 
should be part of this (see comment above in Scope of this Guidance). In addition it is recommended 
that psychological therapists and those pre-scribing maintain and active clinical links when working 
with the same patient. 
7. Treatment in special situations 
Children and young adults. In previous versions of this guide-line there was little attempt to make 
specific recommendations for children and young people, so one inference could have been that 
treatment options for this group should be extrapolated from adult data. One worry has been such 
eǆtƌapolatioŶ to ĐhildƌeŶ falselǇ diagŶosed ǁith ͚ďipolaƌ disoƌdeƌ͛. IŶ the aďseŶĐe of iŶdepeŶdeŶt 
evidence of benefit and from appropriate trials in such children, the extrapolation could not be 
encouraged. A more conservative consensus about diagnosis has emerged and there has been some 
increase in information available since the last edition on both efficacy and adverse reactions. Most 
new studies were conducted in the USA and will have included patients with broadly defined bipolar 
disorder, so the diagnosis of mania may have had limited validity. There are studies showing 
advantages compared with placebo of aripiprazole, olanzapine, quetiapine, risperidone (and 
ziprasidone) and further evidence that effect sizes for these medicines is greater than lithium or 
valproate (Correll et al., 2010). Adverse effects on weight were very prominent for olanzapine, 
quetiapine and risperidone (in descending order of harm). Aripiprazole, lithium and valproate were 
better (Singh et al., 2010). 
Currently only aripiprazole (for 12 weeks) and lithium are licensed for treatment of mania in the UK 
(children of 12 years and older). 
Medications approved by the US Food and Drug Administration (FDA) to treat youth with bipolar 
disorder are risperidone, aripiprazole, quetiapine and olanzapine. Specifically, short-term treatment 
with risperidone can help reduce symptoms of mania or mixed mania in children ages 10 and up. 
Some research has indicated that risperidone is more effective in treating mania in young children 
than other medications. Aripiprazole and quetiapine are approved to treat mania symptoms in 
children 10–17 years old who have bipolar I, while olanzapine is approved for use in children ages 
13–17. (http://www.nimh.nih.gov/health/publications/bipolar-disorder-in-children-and-
adolescents/index. shtml#pub7 ). 
Empirical data on the treatment of bipolar depression in children and young people are scarce. Thus, 
no trials of SSRIs have been conducted in bipolar depression, a study of quetiapine did not separate 
from placebo and there is only low-quality evidence from open trials for lithium (Patel et al., 2006) 
and lamotrigine (Chang et al., 2006). 
NICE suggested a structured psychological intervention (individual CBT or interpersonal therapy) of 
at least ϯ ŵoŶths͛ duƌatioŶ foƌ ďipolaƌ depƌessioŶ. This is a siŵple eǆtƌapolatioŶ fƌoŵ uŶipolaƌ 
practice. Child and adolescent mental health professionals usually take a family-based approach (in 
the sense of non-specific support and psychoeducation) and we note a further need to support the 
education of these patients because manic episodes are easily misunderstood. 
Most of the trial data in young people come from family therapy or multi-family psychoeducation 
groups with a focus on relapse prevention, so a more balanced view of this alternative would be 
appropriate. Family-focused psychotherapy is currently the most relevant manualized approach to 
the problem (Miklowitz, 2015; Vallarino et al., 2015). 
The recommendation to treat co-morbidities in accordance with other guidelines could imply 
additional treatment approaches. An integrated treatment that addresses multiple presentations of 
the illness may be more relevant in young peple (IV). 
For bipolar depression that is moderate to severe, we would consider a pharmacological 
intervention that follows the recommendations for pharmacological interventions for adults with 
appropriate consideration of dosing and potential harms. 
Elderly patients. Patients with bipolar disorder grow old, and older people may develop bipolar 
disorder de novo. Indeed, up to 10% of individuals develop bipolar disorder over the age of 50, an 
increasing number as population longevity increases (Sajatovic, 2002). Treatment follows the same 
principles as for other patient groups, although few studies have been directed specifically at the 
elderly. As a group they are more susceptible to adverse reactions, owing increased end-organ 
sensitivity, impaired circulation, and reduced hepatic and renal clearance. This may be especially the 
case with lithium (Sproule et al., 2000). In general, treatment doses are lower than those used in 
younger adults and should be more carefully titrated (Naranjo et al., 1995). 
Bipolar disorder and pregnancy. Bipolar patients may wish to get pregnant. Some psychotropic 
medicines may reduce fertility. Thus, an increased incidence of polycystic ovarian syndrome (Joffe, 
2007), putatively associated with valproate use, may reduce fertility but be reversible on stopping 
medication. Some dopamine antagonists may impair ovulation by causing hyperprolactinaemia and 
disruption of the hypothalamic–gonadal axis. Conversely, switching to a prolactin-sparing dopamine 
antagonist/partial agonist may cause return of fertility and unplanned pregnancy. Carbamazepine 
reduces the effectiveness of oral contraceptives by enzyme induction: double dosing of the oral con-
traceptive is one practical solution. 
Risks of discontinuation of medication. There appears to be a high probability that women who are 
taking lithium and become pregnant will discontinue it. The figure from the UK Health Improvement 
Network primary care database was almost 70% by the 6th week of pregnancy. There is a high risk of 
relapse in affective disorder if medication is discontinued. Thus, 52% of women who discontinued 
lithium during pregnancy relapsed and 70% of the women who remained stable after lithium 
discontinuation during pregnancy relapsed in the post-partum period (Meyer and Koro, 2004; 
Viguera et al., 2000). A systematic review of over 4000 women with bipolar disorder or post-partum 
psychosis con-firmed that post-partum relapse rates were significantly higher among those who 
were medication free during pregnancy (66%, 95% CI 57–75) than those who used prophylactic 
medication (23%, 95% CI 14–37) (Wesseloo et al., 2016). Risk of post-par-tum illness is especially 
high in women with a history of previous post-partum psychosis. Treatment may involve exposure to 
higher doses of psychotropic medicines than would be implied by long-term maintenance treatment. 
Maternal depression has a negative effect on child development (Rice et al., 2007). 
Risk of medication harms. The risk of major congenital malformations in the general population is 
surprisingly high at 2–4% and increases with maternal age. Cohort studies have shown that the risk 
increases to 11% in valproate-exposed babies (II, (Kaneko et al., 1999)), and 6% in those exposed to 
carbamazepine (II, (Rosa, 1991)), and these risks are usually unacceptable. Of course, the great 
majority of women who conceive while taking either drug will still deliver a normal baby. 
Carbamazepine and valproate are associated with a range of congenital abnormalities, including 
neural tube defects (incidence 1% with carbamazepine and 1–2% with valproate (Omtzigt et al., 
1992)) and the foetal hydantoin syndrome (facial dysmorphophobia, cleft lip and palate, cardiac 
defects, digital hypoplasia, and nail dysplasia), which was originally described with phenytoin. The 
risk of congenital abnormalities is dose related with valproate (blood concentrations over 70 µg/mL 
are implicated) and increases with the number of antiepileptic agents prescribed (II, (Samren et al., 
1999)). Valproate has been particularly singled out for concern because of apparently higher risks of 
developmental impairments when compared with women taking other anticonvulsants (for 
epilepsy) (see https://www.gov.uk/drug-safety-update/medicines-related-to-valproate-risk-of-
abnormal-pregnancy-out-comes). The problems describe include lowered IQ and development 
disorders. 
Lamotrigine appears not to increase the risk of foetal malformation in the epilepsy population (Vajda 
et al., 2014). 
Lithiuŵ͛s poteŶtial teƌatogeŶiĐitǇ ƌeŵaiŶs less ǁell ĐhaƌaĐteƌized, ďeĐause it is a less ĐoŵŵoŶ 
prescription (and is pƌoďaďlǇ ofteŶ aǀoided iŶ pƌegŶaŶĐǇͿ. IŶ the past, lithiuŵ͛s ͚speĐifiĐ assoĐiatioŶ͛ 
ǁith EďsteiŶ͛s aŶoŵalǇ ǁas ďelieǀed to ƌepƌeseŶt a high ƌisk. But ƌeĐeŶt aŶalǇsis suggests that fiƌst 
trimester exposure to lithium is actually associated with a 0.05–0.1% risk of cardiovascular 
anomalies (a low absolute risk but perhaps still higher than in the general population) (I, (Cohen et 
al., 1994)). Some studies are still interpreted to justify echocardiography to check for cardiac 
problems in exposed babies (DiavCitrin et al., 2014). However, studies have never been large enough 
(and so included too few cases) to be decisive (McKnight et al., 2012). 
Many of the risks for bipolar patients may be unavoidable, because population figures of 30% are 
given for unplanned pregnancy, and this rate may be higher again in patients with mania. Most of 
the danger for organ development is in the first 2 months, which may be before a woman is aware 
that she is pregnant. Consequently, all female patients of child-bearing age should be advised about 
the importance of effective contraception (II, (Smith and Whitfield, 1995)). Pregnancy should be 
planned in consultation with the psychiatrist and should include a full explanation of the treatment 
options and their benefit to harm balance. Treatment options include continuing the existing 
medication throughout pregnancy, switching to alternative medicines associated with lower foetal 
risk before conception, withdrawing some or all medication before conception, and reintroducing it 
either after the first trimester or immediately after birth. The chosen option will depend on the 
patieŶt͛s past histoƌǇ, ƌespoŶse to tƌeatŵeŶt aŶd the patieŶt͛s aŶd ĐliŶiĐiaŶ͛s pƌefeƌeŶĐes. If lithiuŵ 
or valproate is continued during pregnancy, prescribing slow-release formulations twice or more 
times daily can minimize high peak concentrations. Some authorities consider withdrawal or 
reduction of lithium before (planned) delivery and re-establishing the original dose as before 
pregnancy immediately after delivery (see NICE2014). 
Patients who take lithium, valproate, or carbamazepine during the first trimester should be advised 
about prenatal diagnosis and offered maternal alpha-fetoprotein screening and a high-resolution 
ultrasound scan at 16–18 weeks gestation. Folate supple-mentation is advised for all pregnant 
women, but it is unclear whether this reduces the increased risk of neural tube defects associated 
with carbamazepine and valproate. 
Maternal physiological changes during pregnancy may necessitate dosage adjustments. For example, 
the glomerular filtration rate increases during pregnancy, causing many medications to be excreted 
more rapidly. As a result serum concentrations may fall and the mother may require higher doses to 
prevent a relapse. After birth these changes reverse and there is a risk that higher serum 
concentrations will results in adverse reactions, unless doses are reduced. These issues are most 
relevant to lithium, given its low therapeutic index. 
ECT can be administered to pregnant women without immediate adverse reactions or effects but 
primary data is very sparse and confounding prevents any comment about the safety for the unborn 
child (Leiknes et al., 2015). 
Neurotoxicity of maternal psychotropic medication after birth. In patients who have taken medicines 
up to childbirth, both toxic effects and withdrawal effects have been described in clinical case 
reports/series, although proving causality is often difficult (Ebbesen et al., 2000). Vigilance in caring 
for babies of mothers taking psychotropic agents is recommended. Pre-term babies are at particular 
risk if breast-fed due to reduced hepatic capacity. Benzodiazepines may depress neonatal respiration 
or cause drowsiness, hypertonia or withdrawal symptoms. Dopamine antagonists/partial agonists 
can cause extrapyramidal symptoms. Tricyclics can cause urinary retention and functional bowel 
obstruction. Lithium has been associated with goitre, hypotonic and cyanosis. Carbamazepine has 
caused neonatal bleeding and is an indication for prophylactic vitamin K. 
In the case of antidepressants, which are prescribed in as many as 6.5% of women delivering babies, 
revised class label-ling has emphasized an increased risk of jitteriness, poor feeding, crying and 
seizures. The mechanisms are unclear but are clearly attributable to toxicity, withdrawal or a 
combination of factors (Haddad et al., 2005). Discontinuation in pregnancy, or a switch to fluoxetine, 
whose long half-life may reduce withdrawal effects, are management options. 
Breastfeeding requires an understanding by patients of the potential risks of toxicity to the neonate 
and the need for vigilance in their care. All maternal drugs enter breast milk, but the ratio between 
infant and maternal plasma concentrations varies greatly. The rate of adverse reactions attributable 
to maternal psychotropic medicines is most uncertain and depends on sporadic reports of, for 
example, toxicity due to lithium, hepatic dysfunction due to carbamazepine, and thrombocytopenia 
or anaemia attributed to valproate. These risks need to be balanced against the benefits of 
breastfeeding (I, (Austin and Mitchell, 1998)). Owing to its narrow therapeutic index lithium is 
generally regarded as being a relative contra-indication to breastfeed-ing (I, (Chaudron and 
Jefferson, 2000)) because it is present in breast milk at 40% of the maternal serum concentration 
(American Academy of Paediatrics Committee on Drugs, 2000). 
In general, the risks to the infant are the same as those for any patient exposed to the medicine, so 
clozapine is usually regarded as contra-indicated because of the risk of agranulocytosis. Lamotrigine 
will carry the possibility of rash. Antidepressants are usually present in breast milk in low 
concentration but there is large individual variation and some infants have developed plasma 
concentrations higher than maternal plasma concentrations. Abrupt withdrawal of sertraline may 
have caused neonatal withdrawal effects. 
The BUMPS website provides a useful resource for clinical staff and pregnant mothers themselves 
concerned about the use of medicines: http://medicinesinpregnancy.org. NICE have revised their 
guidelines for antenatal and postnatal mental health (http://www.nice.org.uk/guidance/cg192). 
Bottle feeding. A pragmatic alternative to breastfeeding is bottle feeding. This obviously avoids 
concerns about drugs in breast milk and means adherence to drug treatment may be more likely. It 
also has the advantage that responsibility for night feeds may be shared. This may in turn protect 
against the deleterious impact of sleep deprivation on bipolar mood at a critical time for mother and 
infant. Unfortunately, patients may encounter an over-zealous approach to breastfeeding advice 
which assumes they ought to do so. Common sense may well dictate otherwise, and women should 
feel confident to make an informed decision that suits them (IV). 
The risk of relapse. Childbirth increases the risk of relapse in patients with bipolar I disorder in the 
post-partum period (Robertson et al., 2005). In fact, this effect is most striking in first babies and for 
first psychiatric admissions (I, (Terp and Mortensen, 1998)). The potential benefits of adherence to 
long-term treatment for a mother with bipolar affective disorder are to remain free of symptoms, 
enjoy normal bonding with her child and facilitate neonatal development. Failure to control 
symptoms will risk harm to the mother/child relationship directly or via co-morbid alcohol, drug and 
nicotine consumption. Against the benefits there are some risks. These include teratogenesis, 
neonatal adverse reactions that may reflect drug toxicity and withdrawal effects. 
Patients with bipolar II disorder are at an increased risk of mood episodes in general (and during 
pregnancy) but not particularly in the post-partum periods. A history of childhood sexual abuse is 
associated with an increased risk of post-partum depression (Robertson et al., 2005). 
Suicide is a major cause of maternal death in developed countries (Oates, 2003) and is sometimes 
associated with infanticide. It is a sombre note on which to conclude, but perhaps helps underline 
just how fatal a disease bipolar disorder sometimes is. 
Acknowledgements 
Special thanks are due to Susan Chandler and Lynne Harmer who organized the logistics. The 
expenses of the meeting itself were defrayed by BAP exclusively. GMG, PMH, INF planned the 
meeting. GMG wrote and edited the manuscript. All other contributors attended the meeting and 
contributed to the drafting. 
Declaration of Conflicting Interest 
For disclosure of competing interests for all authors, visit http://www. 
bap.org.uk/bipolardeclarations 
Funding 
The authors received no financial support for the research, authorship, and/or publication of this 
article. 
References 
Abdallah CG, Sanacora G, Duman RS, et al. (2015) Ketamine and rapid-acting antidepressants: A 
window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 66: 509–523. 
Achtyes ED, Halstead S, Smart L, et al. (2015) Validation of Computer-ized Adaptive Testing in an 
Outpatient Nonacademic Setting: The VOCATIONS Trial. Psychiatr Serv 66: 1091–1096. 
Agnew-Blais J and Danese A (2016) Childhood maltreatment and unfa-vourable clinical outcomes in 
bipolar disorder: A systematic review and meta-analysis. Lancet Psychiatry (epub ahead of print). 
Albert U, Rosso G, Maina G, et al. (2008) Impact of anxiety disorder comorbidity on quality of life in 
euthymic bipolar disorder patients: Differences between bipolar I and II subtypes. J Affect Disord 
105: 297–303. 
Allen MH, Currier GW, Hughes DH, et al. (2001) The Expert Consensus  Guideline Series. Treatment 
of behavioral emergencies. Postgrad Med 1–88. 
Altshuler L, Kiriakos L, Calcagno J, et al. (2001) The impact of anti-depressant discontinuation versus 
antidepressant continuation on 1-year risk for relapse of bipolar depression: A retrospective chart 
review. J Clin Psychiatry 62: 612–616. 
Altshuler L, Suppes T, Black D, et al. (2003) Impact of antidepressant discontinuation after acute 
bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 160: 
1252–1262. 
American Academy of Paediatrics Committee on Drugs (2000) Use of psychoactive medications 
during pregnancy and possible effects on the fetus and newborn. Pediatrics 105: 880–887.  
American Psychiatric Association (1994) Diagnostic and Statistical Manual for Mental Disorders 
(DSM-IV). Washington, DC: American Psychiatric Association. 
American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar 
disorder (revision). Am J Psychiatry 159: 1–50. 
American Psychiatric Association (2013) Diagnostic and Statistical Manual for Mental Disorders 
(DSM-5). Washington, DC: American Psychiatric Association. 
Amsterdam JD, Lorenzo-Luaces L, Soeller I, et al. (2015) Safety and effectiveness of continuation 
antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: 
A randomized, double-blind, parallel-group, prospective study. J Affect Disord 185: 31–37. 
Anderson IM (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57: 161–178. 
Andreazza AC, Kauer-“aŶt͛AŶŶa M, FƌeǇ BN, et al. ;ϮϬϬϴͿ Oǆidatiǀe stƌess ŵaƌkeƌs iŶ ďipolaƌ 
disorder: A meta-analysis. J Affect Disord 111: 135–144. 
Andreazza AC, Wang JF, Salmasi F, et al. (2013) Specific subcellular changes in oxidative stress in 
prefrontal cortex from patients with bipolar disorder. J Neurochem 127: 552–561. 
Angst F, Stassen HH, Clayton PJ, et al. (2002) Mortality of patients with mood disorders: Follow-up 
over 34-38 years. J Affect Disord 68: 167–181. 
Angst J (1998) The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 50: 
143–151. 
Angst J and Preisig M (1995) Course of a clinical cohort of unipolar, bipolar and schizoaffective 
patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr 146: 
5–16. 
 
Angst J and Sellaro R (2000) Historical perspectives and natural history of bipolar disorder. Biol 
Psychiatry 48: 445–457. 
 
Angst J, Azorin JM, Bowden CL, et al. (2011) Prevalence and characteristics of undiagnosed bipolar 
disorders in patients with a major depressive episode: The BRIDGE study. Arch Gen Psychiatry 68: 
791–798. 
 
Angst J, Gamma A, Sellaro R, et al. (2003) Recurrence of bipolar disorders and major depression. A 
life-long perspective. Eur Arch PsychiatryClin Neurosci 253: 236–240. 
 
Aronson JK (2013) Distinguishing hazards and harms, adverse drug effects and adverse drug 
reactions: Implications for drug development, clinical trials, pharmacovigilance, biomarkers, and 
monitoring. Drug Safety 36: 147–153.  
 
Ashcroft R (2000) Giving medicine a fair trial. Trials should not second guess what patients want. 
BMJ 320: 1686. 
 
Austin MP and Mitchell PB (1998) Use of psychotropic medications in breast-feeding women: Acute 
and prophylactic treatment. Aust N Z JPsychiatry 32: 778–784. 
 
Bai Y-M, Su T-P, Chen M-H, et al. (2013) Risk of developing diabetes mellitus and hyperlipidemia 
among patients with bipolar disorder, major depressive disorder, and schizophrenia: A 10-year 
nationwide population-based prospective cohort study. J Affect Disord 150: 57–62. 
 
Bain M, Juszczak E, McInneny K, et al. (2000) Obstetric complications and affective psychoses. Two 
case-control studies based on structured obstetric records. Br J Psychiatry 176: 523–526. 
 
Baldessarini RJ, Hennen J, Wilson M, et al. (2003) Olanzapine versus placebo in acute mania - 
Treatment responses in subgroups. J Clin Psychopharmacol 23: 370–376. 
 
Baldwin DS, Anderson IM, Nutt DJ, et al. (2014) Evidence-based pharmacological treatment of 
anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of 
the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28: 
403–439. 
 
Bandelow B, Reitt M, Rover C, et al. (2015) Efficacy of treatments for anxiety disorders: A meta-
analysis. Int Clin Psychopharmacol 30: 183–192. 
 
Barnes E, Simpson S, Griffiths E, et al. (2011) Developing an online psychoeducation package for 
bipolar disorder. J Ment Health 20: 21–31. 
 
Bauer MS, Biswas K and Kilbourne AM (2009) Enhancing multiyear guideline concordance for bipolar 
disorder through collaborative care. Am J Psychiatry 166: 1244–1250. 
 
Bauer MS, McBride L, Williford WO, et al. (2006a) Collaborative care for bipolar disorder: Part I. 
Intervention and implementation in a randomized effectiveness trial. Psychiatr Serv 57: 927–936. 
 
Bauer MS, McBride L, Williford WO, et al. (2006b) Collaborative care for bipolar disorder: Part II. 
Impact on clinical outcome, function, and costs. Psychiatr Serv 57: 937–945. 
 
Bauer MS, Wisniewski SR, Marangell LB, et al. (2006c) Are antidepressants associated with new-
onset suicidality in bipolar disorder? A prospective study of participants in the systematic treatment 
enhancement program for bipolar disorder (STEP-BD). J Clin Psychiatry 67: 48–55. 
 
Berk M, Hallam KT and McGorry PD (2007) The potential utility of a staging model as a course 
specifier: A bipolar disorder perspective. J Affect Disord 100: 279–281. 
 
Berwaerts J, Melkote R, Nuamah I, et al. (2012) A randomized, placebo- and active-controlled study 
of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after 
an acute manic or mixed episode. J Affect Disord 138: 247–258. 
 
Bhagwagar Z and Goodwin GM. (2002) The role of lithium in the treatment 
of bipolar depression. Clin Neurosci Res 2: 222–227. 
 
Biel MG, Peselow E, Mulcare L, et al. (2007) Continuation versus discontinuation 
of lithium in recurrent bipolar illness: A naturalistic study. Bipolar Disord 9: 435–442. 
 
Bieling PJ, Green SM and Macqueen G (2007) The impact of personality 
disorders on treatment outcome in bipolar disorder: A review. Personal Ment Health 1: 2–13. 
 
Biffin F, Tahtalian S, Filia K, et al. (2009) The impact of age at onset of bipolar I disorder on 
functioning and clinical presentation. Acta Neuropsychiatr 21: 191–196. 
 
Bjorklund L, Horsdal HT, Mors O, et al. (2015) Trends in the psychopharmacological treatment of 
bipolar disorder: A nationwide register- based study. Acta Neuropsychiatr 11: 1–10. 
 
Black DW, Winokur G and Nasrallah A (1987a) Suicide in subtypes of major affective disorder. A 
comparison with general population suicide mortality. Arch Gen Psychiatry 44: 878–880. 
 
Black DW, Winokur G and Nasrallah A (1987b) Treatment of mania – a naturalistic study of 
electroconvulsive-therapy versus lithium in 438 patients. J Clinical Psychiatry 48: 132–139. 
 
Blacker D and Tsuang MT (1992) Contested boundaries of bipolar disorder and the limits of 
categorical diagnosis in psychiatry. Am J Psychiatry 149: 1473–1483. 
 
Blader JC and Carlson GA (2007) Increased rates of bipolar disorder diagnoses among U.S. child, 
adolescent, and adult inpatients, 1996- 2004. Biol Psychiatry 62: 107–114. 
 
Blanco C, Grant J, Petry NM, et al. (2008) Prevalence and correlates of shoplifting in the United 
States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). 
Am J Psychiatry 165: 905–913. 
 
Bolea-Alamanac B, Nutt DJ, Adamou M, et al. (2014) Evidence-based 
guidelines for the pharmacological management of attention deficithyper activity disorder: Update 
on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 28: 
179–203. 
 
Bond DJ, Pratoomsri W and Yatham LN (2007) Depot antipsychotic medications in bipolar disorder: A 
review of the literature. Acta Psychiatr Scand Suppl 3–16. 
 
Bond K and Anderson IM (2015) Psychoeducation for relapse prevention in bipolar disorder: A 
systematic review of efficacy in randomized controlled trials. Bipolar Disord 17: 349–362. 
 
Bottlender R, Rudolf D, Strauss A, et al. (2001) Mood-stabilisers reduce the risk of developing 
antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect 
Disord 63: 79–83. 
 
Bourne C, Aydemir O, Balanza-Martinez V, et al. (2013) Neuropsychological testing of cognitive 
impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatr 
Scand 128: 149–162. 
 
Bourne C, Bilderbeck AC, Drennan R, et al. (2015) Verbal learning impairment in euthymic bipolar 
disorder: BDI v BDII. J Affect Disord 182: 95–100. 
 
Bowden CL, Calabrese JR, McElroy SL, et al. (1999) The efficacy of lamotrigine in rapid cycling and 
non-rapid cycling patients with bipolar disorder. Biol Psychiatry 45: 953–958. 
 
Bowden CL, Vieta E, Ice KS, et al. (2010) Ziprasidone plus a mood stabilizer in subjects with bipolar I 
disorder: A 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 71: 
130–137. 
  
Brown EB, McElroy SL, Keck PE, Jr., et al. (2006) A 7-week, randomized, double-blind trial of 
olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin 
Psychiatry 67: 1025–1033. 
 
Brown ES, Khan DA and Nejtek VA (1999) The psychiatric side effects of corticosteroids. Ann Allergy 
Asthma Immunol 83: 495–503. 
  
Brown ES, Suppes T, Khan DA, et al. (2002) Mood changes during prednisone bursts in outpatients 
with asthma. J Clin Psychopharmacol 22: 55–61. 
  
Browne R, Byrne M, Mulryan N, et al. (2000) Labour and delivery complications at birth and later 
mania. An Irish case register study. Br J Psychiatry 176: 369–372. 
 
Burgess S, Geddes J, Hawton K, et al. (2001) Lithium for maintenance treatment of mood disorders. 
Cochrane Database Syst Rev 3: CD003013. 
  
Burns T, White I, Byford S, et al. (2002) Exposure to case management: Relationships to patient 
characteristics and outcome. Report from the UK700 trial. Br J Psychiatry 181: 236–241. 
 
Button KS and Munafo MR (2015) Addressing risk of bias in trials of cognitive behavioral therapy. 
Shanghai Arch Psychiatry 27: 144–148. 
  
Calabrese JR, Bowden CL, Sachs GS, et al. (1999) A double-blind placebo Controlled study of 
lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin 
Psychiatry 60: 79–88. 
  
Calabrese JR, Keck PE, Jr., Macfadden W, et al. (2005) A randomized, double-blind, placebo-
controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162: 
1351–1360. 
 
Calabrese JR, Shelton MD, Rapport DJ, et al. (2001) Current research on rapid cycling bipolar disorder 
and its treatment. J Affect Disord 67: 241–255. 
  
Calabrese J, Pikalov A, Cucchiaro J, et al. (2015) Lurasidone adjunctive to lithium or divalproex for 
prevention of recurrence in patients with bipolar i disorder: Results of a 28-week, randomized, 
double-blind, placebo-controlled study. Neuropsychopharmacology 40: S479–480. 
 
Carter L, Zolezzi M and Lewczyk A (2013) An updated review of the optimal lithium dosage regimen 
for renal protection. Can J Psychiatry 58: 595–600. 
 
Carvalho AF, Dimellis Ds, Gonda X, et al. (2014) Rapid cycling in bipolar disorder: A systematic 
review. J Clin Psychiatry 75: e578–e586. 
 
Carvalho AF, Quevedo J, McIntyre RS, et al. (2015) Treatment implications of predominant polarity 
and the polarity index: A comprehensive review. Int J Neuropsychopharmacol 18: pyu079. 
 
Cassano GB, Rucci P, Frank E, et al. (2004) The mood spectrum in unipolar and bipolar disorder: 
Arguments for a unitary approach. Am J Psychiatry 161: 1264–1269. 
 
Cassidy F, Forest K, Murry E, et al. (1998) A factor analysis of the signs and symptoms of mania. Arch 
Gen Psychiatry 55: 27–32. 
  
Cassidy F, Pieper CF and Carroll BJ (2001) Subtypes of mania determined by grade of membership 
analysis. Neuropsychopharmacology 25: 373–383. 
  
Castberg I, Skogvoll E and Spigset O (2007) Quetiapine and drug interactions: Evidence from a 
routine therapeutic drug monitoring service. J Clin Psychiatry 68: 1540–1545. 
 
Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. (2006) Comparison of treatment-emergent 
extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical 
trials. J Clin Psychiatry 67: 107–113. 
 
Chang K, Saxena K and Howe M (2006) An open-label study of lamotrigine adjunct or monotherapy 
for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 45: 
298–304. 
 
Chaudron LH and Jefferson JW (2000) Mood stabilizers during breastfeeding: A review. J Clin 
Psychiatry 61: 79–90. 
 
Chen YW and Dilsaver SC (1996) Lifetime rates of suicide attemptsamong subjects with bipolar and 
unipolar disorders relative to subjects with other axis I disorders. Biol Psychiatry 39: 896–899. 
 
Chengappa KNR, Schwarzman LK, Hulihan JF, et al. (2006) Adjunctive topiramate therapy in patients 
receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin 
Psychiatry 67: 1698–1706. 
 
Chesney E, Goodwin GM and Fazel S (2014) Risks of all-cause and suicide mortality in mental 
disorders: A meta-review. World Psychiatry 13: 153–160. 
 
Cipriani A, Barbui C, Salanti G, et al. (2011) Comparative efficacy andacceptability of antimanic drugs 
in acute mania: A multiple-treatments meta-analysis. Lancet 378: 1306–1315. 
 
Cipriani A, Furukawa TA, Salanti G, et al. (2009) Comparative efficacyand acceptability of 12 new-
generation antidepressants: A multipletreatments meta-analysis. Lancet 373: 746–758. 
 
Cipriani A, Hawton K, Stockton S, et al. (2013a) Lithium in the prevention of suicide in mood 
disorders: Updated systematic review and meta-analysis. BMJ 346: f3646. 
  
Cipriani A, Higgins JPT, Geddes JR, et al. (2013b) Conceptual and technical challenges in network 
meta-analysis. Ann Intern Med 159: 130–137. 
  
Cipriani A, Reid K, Young AH, et al. (2013c) Valproic acid, valproate and divalproex in the 
maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 10: CD003196. 
 
Clark L, Iversen SD and Goodwin GM (2002) Sustained attention deficit in bipolar disorder. Br J 
Psychiatry 180: 313–319. 
 
Clatworthy J, Bowskill R, Parham R, et al. (2009) Understanding medication non-adherence in bipolar 
disorders using a Necessity-Concerns Framework. J Affect Disord 116: 51–55. 
  
Cleare A, Pariante CM, Young AH, et al. (2015) Evidence-based guidelines for treating depressive 
disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology 
guidelines. J Psychopharmacol 29: 459–525. 
  
Clements C, Morriss R, Jones S, et al. (2013) Suicide in bipolar disorder in a national English sample, 
1996-2009: Frequency, trends and characteristics. Psychol Med 43: 2593–2602. 
  
Clyburn LD, Stones MJ, Hadjistavropoulos T, et al. (2000) Predicting caregiver burden and depression 
iŶ Alzheiŵeƌ͛s disease. J Gerontol B Psychol Sci Soc Sci 55: S2–S13. 
 
Cohen LS, Friedman JM, Jefferson JW, et al. (1994) A reevaluation of risk of in utero exposure to 
lithium. JAMA 271: 146–150. 
  
Colom F and Vieta E (2006) Psychoeducation Manual for Bipolar Disorder. Cambridge: Cambridge 
University Press. 
 
Colom F, Vieta E, Daban C, et al. (2006) Clinical and therapeutic implications of predominant polarity 
in bipolar disorder. J Affect Disord 93: 13–17. 
  
Colom F, Vieta E, Martinez-Aran A, et al. (2000) Clinical factors associated with treatment 
noncompliance in euthymic bipolar patients. J Clin Psychiatry 61: 549–555. 
  
Colom F, Vieta E, Martinez-Aran A, et al. (2003) A randomized trial on the efficacy of group 
psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. 
Arch Gen Psychiatry 60: 402–407. 
 
Colom F, Vieta E, Sanchez-Moreno J, et al. (2009) Group psychoeducation for stabilised bipolar 
disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry 194: 260–265. 
 
Correll CU, Sheridan EM and DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and 
tolerability in pediatric and adult patients with bipolar I mania: A comparative analysis of acute, 
randomized, placebo-controlled trials. Bipolar Disord 12: 116–141. 
  
Coryell W, Fiedorowicz J, Leon AC, et al. (2013) Age of onset and the prospectively observed course 
of illness in bipolar disorder. J Affect Disord 146: 34–38. 
  
Craddock N and Owen MJ (2010) The Kraepelinian dichotomy – going, goiŶg… ďut still Ŷot goŶe. Br J 
Psychiatry 196: 92–95. 
  
Cross AJ, Widzowski D, Maciag C, et al. (2016) Quetiapine and its metabolite norquetiapine: 
Translation from in vitro pharmacology to in vivo efficacy in rodent models. Br J Pharmacol 173: 
155–166. 
Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, et al. (2013) Genetic 
relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genet 45: 
984–994. 
  
Crowe M, Inder M, Carlyle D, et al. (2012) Nurse-led delivery of specialist supportive care for bipolar 
disorder: A randomized controlled trial. J Psychiatr Ment Health Nurs 19: 446–454. 
  
Crump C, Sundquist K, Winkleby MA, et al. (2013) Comorbidities and mortality in bipolar disorder: A 
Swedish national cohort study. JAMA Psychiatry 70: 931–939. 
  
Cummings JL and Mendez MF (1984) Secondary mania with focal cerebrovascularlesions. Am J 
Psychiatry 141: 1084–1087. 
 
de Barros Pellegrinelli K, de O Costa LF, Silval KI, et al. (2013) Efficacy of psychoeducation on 
symptomatic and functional recovery in bipolar disorder. Acta Psychiatr Scand 127: 153–158. 
 
Dell͛Osso B aŶd Ketteƌ TA ;ϮϬϭϯͿ Assessing efficacy/effectiveness and safety/tolerability profiles of 
adjunctive pramipexole in bipolar depression: Acute versus long-term data. Int Clin Psychopharmacol 
28: 297–304. 
 
Denicoff KD, Leverich GS, Nolen WA, et al. (2000) Validation of the prospective NIMH-Life-Chart 
Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 30: 1391–1397. 
 
Department of Health (1999) A National Service Framework for Mental Health. London: Department 
of Health. 
  
Di Simplicio M, McInerney JE, Goodwin GM, et al. (2012) Revealing the ŵiŶd͛s eǇe: BƌiŶgiŶg ;ŵeŶtalͿ 
images into psychiatry. Am J Psychiatry 169: 1245–1246. 
 
Diav-Citrin O, Shechtman S, Tahover E, et al. (2014) Pregnancy outcome following in utero exposure 
to lithium: A prospective, comparative, observational study. Am J Psychiatry 171: 785–794. 
  
Diflorio A and Jones I (2010) Is sex important? Gender differences in bipolar disorder. Int Rev 
Psychiatry 22: 437–452. 
  
Dols A, Kupka RW, van Lammeren A, et al. (2014) The prevalence of late-life mania: A review. Bipolar 
Disord 16: 113–118. 
  
Dragioti E, Dimoliatis I and Evangelou E (2015) Disclosure of researcher allegiance in meta-analyses 
and randomised controlled trials of psychotherapy: A systematic appraisal. BMJ Open 5: e007206. 
  
Dunayevich E and Keck PE, Jr (2000) Prevalence and description of psychotic features in bipolar 
mania. Curr Psychiatry Rep 2: 286–290. 
  
Duncan S (2001) Polycystic ovarian syndrome in women with epilepsy: A review. Epilepsia 42(Suppl 
3): 60–65. 
  
Durgam S, Earley W, Lipschitz A, et al. (2016) An 8-week randomized, double-blind, placebo-
controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar i depression. 
Am J Psychiatry 173: 271–281. 
  
Durgam S, Starace A, Li D, et al. (2015) The efficacy and tolerability of cariprazine in acute mania 
associated with bipolar I disorder: A phase II trial. Bipolar Disord 17: 63–75. 
  
Ebbesen F, Joergensen A, Hoseth E, et al. (2000) Neonatal hypoglycaemia and withdrawal symptoms 
after exposure in utero to valproate. Arch Dis Child Fetal Neonatal Ed 83: F124–F129. 
  
Fadden G, Bebbington P and Kuipers L (1987) The burden of care: The impact of functional 
psǇĐhiatƌiĐ illŶess oŶ the patieŶt͛s faŵilǇ. Br J Psychiatry 150: 285–292. 
  
Fagiolini A, Frank E, Rucci P, et al. (2007) Mood and anxiety spectrum as a means to identify clinically 
relevant subtypes of bipolar I disorder. Bipolar Disord 9: 462–467. 
 
Faurholt-Jepsen M, Ritz C, Frost M, et al. (2015) Mood instability in bipolar disorder type I versus 
type II – continuous daily electronic self-monitoring of illness activity using smartphones. J Affect 
Disord 186: 342–349. 
  
Fazel S and Seewald K (2012) Severe mental illness in 33,588 prisoners worldwide: Systematic review 
and meta-regression analysis. Br J Psychiatry 200: 364–373. 
  
Fazel S, Singh JP, Doll H, et al. (2012) Use of risk assessment instruments to predict violence and 
antisocial behaviour in 73 samples involving 24 827 people: Systematic review and meta-analysis. 
BMJ 345: e4692. 
  
Fazel S, Wolf A and Geddes JR (2013) Suicide in prisoners with bipolar disorder and other psychiatric 
disorders: A systematic review. Bipolar Disord 15: 491–495. 
  
Fazel S, Zetterqvist J, Larsson H, et al. (2014) Antipsychotics, mood stabilisers, and risk of violent 
crime. Lancet 384: 1206–1214. 
  
Ferner RE, Coleman J, Pirmohamed M, et al. (2005) The quality of information on monitoring for 
haematological adverse drug reactions. Br J Clin Pharmacol 60: 448–451. 
  
Fiander M, Burns T, McHugo GJ, et al. (2003) Assertive community treatment across the Atlantic: 
Comparison of model fidelity in the UK and USA. Br J Psychiatry 182: 248–254. 
  
Flint J, Cuijpers P, Horder J, et al. (2015) Is there an excess of significant findings in published studies 
of psychotherapy for depression? Psychol Med 45: 439–446. 
  
Frangou S, Donaldson S, Hadjulis M, et al. (2005) The Maudsley Bipolar Disorder Project: Executive 
dysfunction in bipolar disorder I and its clinical correlates. Biol Psychiatry 58: 859–864. 
  
Frank E, Kupfer DJ, Thase ME, et al. (2005) Two-year outcomes for interpersonal and social rhythm 
therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 62: 996–1004. 
  
Frank E, Swartz HA and Kupfer DJ (2000) Interpersonal and social rhythm therapy: Managing the 
chaos of bipolar disorder. Biol Psychiatry 48: 593–604. 
  
Frankenburg FR and Zanarini MC (2002) Divalproex sodium treatment of women with borderline 
personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J Clin 
Psychiatry 63: 442–446. 
  
Franks MA, Macritchie KAN, Mahmood T, et al. (2008) Bouncing back: Is the bipolar rebound 
phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol 22: 452–456. 
  
Frederikse M, Petrides G and Kellner C (2006) Continuation and maintenance electroconvulsive 
therapy for the treatment of depressive illness: A response to the National Institute for Clinical 
Excellence report. J ECT 22: 13–17. 
 
Freedman R, Lewis DA, Michels R, et al. (2013) The initial field trials of DSM-5: New blooms and old 
thorns. Am J Psychiatry 170: 1–5. 
 
Freeman MP, Freeman SA and McElroy SL (2002) The comorbidity of bipolar and anxiety disorders: 
Prevalence, psychobiology, and treatment issues. J Affect Disord 68: 1–23. 
  
Frye MA, Ketter TA, Kimbrell TA, et al. (2000) A placebo-controlled study of lamotrigine and 
gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20: 607–614. 
  
Gao KM, Kemp DE, Ganocy SJ, et al. (2008) Antipsychotic-induced extrapyramidal side effects in 
bipolar disorder and schizophrenia: A systematic review. J Clin Psychopharmacol 28: 203–209. 
  
Geddes JR, Calabrese J and Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: 
Independent meta-analysis and metaregression of individual patient data from five randomized 
trials. Br J Psychiatry 194: 4–9. 
  
Geddes JR, Carney SM, Davies C, et al. (2003) Relapse prevention with antidepressant drug 
treatment in depressive disorders. Lancet 361: 643–651. 
  
Geddes JR, Gardiner A, Rendell J, et al. (2016) Comparative evaluation of quetiapine plus lamotrigine 
combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression 
(CEQUEL): A 2 x 2 factorial randomised trial. Lancet Psychiatry 3: 31–39. 
  
Geddes JR, Goodwin GM, Rendell J, et al. (2010) Lithium plus valproate combination therapy versus 
monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. 
Lancet 375: 385–395. 
  
Geddes JR and Miklowitz DJ (2013) Treatment of bipolar disorder. Lancet 381: 1672–1682. 
  
Geller B, Sun K, Zimerman B, et al. (1995) Complex and rapid-cycling in bipolar children and 
adolescents: A preliminary study. J Affect Disord 34: 259–268. 
  
George EL, Miklowitz DJ, Richards JA, et al. (2003) The comorbidity of bipolar disorder and axis II 
personality disorders: Prevalence and clinical correlates. Bipolar Disord 5: 115–122. 
  
Gershon ES, Hamovit J, Guroff JJ, et al. (1982) A family study of schizoaffective, bipolar-i, bipolar-ii, 
unipolar, and normal control probands. Arch Gen Psychiatry 39: 1157–1167. 
  
Ghaemi SN, Lenox MS and Baldessarini RJ (2001) Effectiveness and safety of long-term 
antidepressant treatment in bipolar disorder. J Clin Psychiatry 62: 565–569. 
  
Gibbons RD, Coca Perraillon M, Hur K, et al. (2015) Antidepressant treatment and suicide attempts 
and self-inflicted injury in children and adolescents. Pharmacoepidemiol Drug Saf 24: 208–214. 
  
Gigante AD, Lafer B and Yatham LN (2012) Long-acting injectable antipsychotics 
for the maintenance treatment of bipolar disorder. CNS Drugs 26: : 403–420. 
 
Gijsman HJ, Geddes JR, Rendell JM, et al. (2004) Antidepressants for bipolar depression: A systematic 
review of randomized, controlled trials. Am J Psychiatry 161: 1537–1547. 
  
Goldstein J, Nyberg S, Takano A, et al. (2007) PET-measured D2, 5HT2A, and NET occupancy by 
quetiapine and n-desalkyl-quetiapine (norquetiapine) in non-human primates. Int J Psychiatry Clin 
Pract 11: 322–322.  
 
Goodwin GM (1994) Recurrence of mania after lithium withdrawal. Implications for the use of 
lithium in the treatment of bipolar affective disorder. Br J Psychiatry 164: 149–152. 
  
Goodwin GM (2002) Hypomania – what͛s iŶ a Ŷaŵe? Br J Psychiatry 181: 94–95. 
  
Goodwin GM (2003) Evidence-based guidelines for treating bipolar disorder: Recommendations 
from the British Association for Psychopharmacology. J Psychopharmacol 17: 149–173. 
  
Goodwin GM (2009) Evidence-based guidelines for treating bipolar disorder: Revised second edition-
recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23: 
346–388. 
  
Goodwin GM (2012) Bipolar depression and treatment with antidepressants. Br J Psychiatry 200: 5–
6. 
 
Goodwin GM and Geddes JR (2007) What is the heartland of psychiatry? Br J Psychiatry 191: 189–
191. 
  
Goodwin GM, Bowden CL, Calabrese JR, et al. (2004) A pooled analysis of 2 placebo-controlled 18-
month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–
441. 
  
Goss AJ, Kaser M, Costafreda SG, et al. (2013) Modafinil augmentation therapy in unipolar and 
bipolar depression: A systematic review and meta-analysis of randomized controlled trials. J Clin 
Psychiatry 74: 1101–1107. 
  
Grande I, Balanza-Martinez V, Jimenez-Arriero MA, et al. (2012) Clinical factors leading to 
lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study. J Affect Disord 
143: 102–108. 
  
Green AI, Tohen M, Patel JK, et al. (2000) Clozapine in the treatment of refractory psychotic mania. 
Am J Psychiatry 157: 982–986. 
  
Greil W, Ludwig-Mayerhofer W, Erazo N, et al. (1997) Lithium versus carbamazepine in the 
maintenance treatment of bipolar disorders–a randomised study. J Affect Disord 43: 151–161. 
  
Grunze H, Kotlik E, Costa R, et al. (2015) Assessment of the efficacy and safety of eslicarbazepine 
acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, 
randomised phase II clinical studies in patients with bipolar disorder I. J Affect Disord 174: 70–82. 
 
Haddad PM, Pal BR, Clarke P, et al. (2005) Neonatal symptoms following maternal paroxetine 
treatment: Serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol 19: 554–
557. 
 
Hales SA, Deeprose C, Goodwin GM, et al. (2011) Cognitions in bipolar affective disorder and 
unipolar depression: Imagining suicide. Bipolar Disord 13: 651–661. 
  
Harmer CJ, Goodwin GM and Cowen PJ (2009) Why do antidepressants take so long to work? A 
cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195: 102–108. 
  
Harris EC and Barraclough B (1997) Suicide as an outcome for mental disorders. A meta-analysis. Br J 
Psychiatry 170: 205–228. 
  
Hartong EGTM, Moleman P, Hoogduin CAL, et al. (2003) Prophylactic efficacy of lithium versus 
carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 64: 144–151. 
  
Harvey AG, Schmidt DA, Scarna A, et al. (2005) Sleep-related functioning in euthymic patients with 
bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry 
162: 50–57. 
  
Harvey AG, Soehner AM, Kaplan KA, et al. (2015) Treating insomnia improves mood state, sleep, and 
functioning in bipolar disorder: A pilot randomized controlled trial. J Consult Clin Psychol 83: 
564–577. 
  
Hawton K (1987) Assessment of suicide risk. Br J Psychiatry 150: 145–153. 
  
Hawton K, Sutton L, Haw C, et al. (2005) Suicide and attempted suicide in bipolar disorder: A 
systematic review of risk factors. J Clin Psychiatry 66: 693–704. 
  
Hiller W, Dichtl G, Hecht H, et al. (1993) An empirical comparison of diagnoses and reliabilities in 
ICD-10 and DSM-III-R. Eur Arch Psychiatry Clin Neurosci 242: 209–217. 
  
Hirschfeld RM, Calabrese JR, Weissman MM, et al. (2003) Screening for bipolar disorder in the 
community. J Clin Psychiatry 64: 53–59. 
  
Hoertel N, Le Strat Y, Lavaud P, et al. (2013) Generalizability of clinical trial results for bipolar 
disorder to community samples: Findings from the National Epidemiologic Survey on Alcohol and 
Related Conditions. J Clin Psychiatry 74: 265–270. 
  
Holmes EA, Deeprose C, Fairburn CG, et al. (2011) Mood stability versus mood instability in bipolar 
disorder: A possible role for emotional mental imagery. Behav Res Ther 49: 707–713. 
  
Holmes EA, Geddes JR, Colom F, et al. (2008) Mental imagery as an emotional amplifier: Application 
to bipolar disorder. Behav Res Ther 46: 1251–1258. 
  
Horne R, Chapman SC, Parham R, et al. ;ϮϬϭϯͿ UŶdeƌstaŶdiŶg patieŶts͛ adherence-related beliefs 
about medicines prescribed for long-term conditions: A meta-analytic review of the Necessity-
Concerns Framework. PLoS One 8: e80633. 
  
Howard L, Kirkwood G and Leese M (2007) Risk of hip fracture in patients with a history of 
schizophrenia. Br J Psychiatry 190: 129–134. 
Howes OD, Lim S, Theologos G, et al. (2011) A comprehensive review and model of putative 
prodromal features of bipolar affective disorder. Psychol Med 41: 1567–1577. 
  
Howes OD, Wheeler MJ, Pilowsky LS, et al. (2007) Sexual function and gonadal hormones in patients 
taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 68: 
361–367. 
  
Hoyer EH, Mortensen PB and Olesen AV (2000) Mortality and causes of death in a total national 
sample of patients with affective disorders admitted for the first time between 1973 and 1993. Br J 
Psychiatry 176: 76–82. 
  
Ivins A, Di Simplicio M, Close H, et al. (2014) Mental imagery in bipolar affective disorder versus 
unipolar depression: Investigating cognitions at tiŵes of ͚positiǀe͛ ŵood. J Affect Disord 166: 234–
242. 
  
Jauhar S, McKenna PJ and Laws KR (2016) NICE guidance on psychological treatments for bipolar 
disorder: Searching for the evidence. Lancet Psychiatry 3: 386–388. 
  
Joas E, Karanti A, Lichtenstein P, et al. (2015) Effectiveness of medication in preventing psychiatric 
hospitalization in bipolar disorder—A Swedish register-based study. Effectiveness of medication in 
preventing psychiatric hospitalization in bipolar disorder—A Swedish register-based study. 
Pharmacoepidemioloy and Drug Safety 24(Suppl S1): 600.  
 
Joffe H (2007) Reproductive biology and psychotropic treatments in premenopausal women with 
bipolar disorder. J Clin Psychiatry 68: 10–15. 
  
Johnson RE and McFarland BH (1996) Lithium use and discontinuation in a health maintenance 
organization. Am J Psychiatry 153: 993–1000. 
  
Johnstone EC, Crow TJ, Frith CD, et al. (1988) The Northwick Park ͞fuŶĐtioŶal͟ psǇĐhosis studǇ: 
Diagnosis and treatment response. Lancet 2: 119–125. 
  
Jones L, Metcalf A, Gordon-Smith K, et al. (2015a) Gambling problems in bipolar disorder in the UK: 
Prevalence and distribution. Br J Psychiatry 207: 328–333. 
  
Jones S, McGrath E, Hampshire K, et al. (2013) A randomised controlled trial of time limited CBT 
informed psychological therapy for anxiety in bipolar disorder. BMC Psychiatry 13: 54. 
  
Jones SH, Smith G, Mulligan LD, et al. (2015b) Recovery-focused cognitive- behavioural therapy for 
recent-onset bipolar disorder: Randomised controlled pilot trial. Br J Psychiatry 206: 58–66. 
  
Judd LL, Akiskal HS, Schettler PJ, et al. (2002) The long-term natural history of the weekly 
symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59: 530–537. 
 
Judd LL, Schettler PJ, Akiskal HS, et al. (2003) Long-term symptomatic status of bipolar I vs. bipolar II 
disorders. Int J Neuropsychopharmacol 6: 127–137. 
  
Judd LL, Schettler PJ, Akiskal HS, et al. (2008) Residual symptom recovery from major affective 
episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 65: 
386–394. 
  
Kaneko S, Battino D, Andermann E, et al. (1999) Congenital malformations due to antiepileptic drugs. 
Epilepsy Res 33: 145–158. 
  
Kay JH, Altshuler LL, Ventura J, et al. (2002) Impact of axis II comorbidity on the course of bipolar 
illness in men: A retrospective chart review. Bipolar Disord 4: 237–242. 
  
Keck P-EJ, McElroy SL, Strakowski SM, et al. (2000) Antipsychotics in the treatment of mood 
disorders and risk of tardive dyskinesia. J Clin Psychiatry 61(Suppl 4): 33–38. 
  
Keck PE, Calabrese JR, McIntyre RS, et al. (2007) Aripiprazole monotherapy for maintenance therapy 
in bipolar I disorder: A 100- week, double-blind study versus placebo. J Clin Psychiatry 68: 1480–
1491. 
  
Kemp DE, Gao KM, Ganocy SJ, et al. (2009) A 6-month, double-blind,maintenance trial of lithium 
monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and 
co-occurring substance abuse or dependence. J Clin Psychiatry 70: 113–121. 
  
Kemp R, Kirov G, Everitt B, et al. (1998) Randomised controlled trial of compliance therapy. 18-
month follow-up. Br J Psychiatry 172: 413–419. 
  
Kendell RE (1987) Diagnosis and classification of functional psychoses. Br Med Bull 43: 499–513. 
  
Kendell RE and Gourlay J (1970) The clinical distinction between the affective psychoses and 
schizophrenia. Br J Psychiatry 117: 61–266. 
  
Kessing L (2015) Treatment options in bipolar disorder: Lessons from population-based registers 
with focus on lithium. Curr Treat Options Psych 2: 218–228. 
  
Kessing LV, Hansen HV, Hvenegaard A, et al. (2013) Treatment in a specialised out-patient mood 
disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: Randomised 
clinical trial. Br J Psychiatry 202: 212–219. 
  
Kessing LV, Sondergard L, Kvist K, et al. (2007) Adherence to lithium in naturalistic settings: Results 
from a nationwide pharmacoepidemiological study. Bipolar Disord 9: 730–736. 
  
Kessing LV, Vradi E and Andersen PK (2014) Starting lithium prophylaxis early v. late in bipolar 
disorder. Br J Psychiatry 205: 214–220. 
  
Kessler RC, Rubinow DR, Holmes C, et al. (1997) The epidemiology of DSM-III-R bipolar I disorder in a 
general population survey. Psychol Med 27: 1079–1089. 
  
Ketter TA, Wang PW, Chandler RA, et al. (2006) Adjunctive aripiprazole in treatment-resistant bipolar 
depression. Ann Clin Psychiatry 18: 169–172. 
  
Kieseppa T, Partonen T, Haukka J, et al. (2004) High concordance of bipolar I disorder in a nationwide 
sample of twins. Am J Psychiatry 161: 1814–1821. 
  
Kilbourne AM, Goodrich DE, Lai Z, et al. (2013) Randomized controlled trial to assess reduction of 
cardiovascular disease risk in patients with bipolar disorder: The Self-Management Addressing Heart 
Risk Trial (SMAHRT). J Clin Psychiatry 74: e655–e662. 
  
Kripalani M, Shawcross J, Reilly J, et al. (2009) Lithium and chronic kidney disease. BMJ 339: b2452. 
  
Kupka RW, Altshuler LL, Nolen WA, et al. (2007) Three times more days depressed than manic or 
hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9: 531–535. 
  
Kushner SF, Khan A, Lane R, et al. (2006) Topiramate monotherapy in the management of acute 
mania: Results of four double-blind placebo- controlled trials. Bipolar Disord 8: 15–27. 
  
Lam D, Watkins E, Hayward P, et al. (2003) A randomised controlled study of cognitive therapy of 
relapse prevention for bipolar affective disorder – outcome of the first year. Arch Gen Psychiatry 60: 
145–152. 
  
Lasser K, Boyd JW, Woolhandler S, et al. (2000) Smoking and mental illness - A population-based 
prevalence study. JAMA 284: 2606–2610. 
  
Laursen TM and Nordentoft M (2011) Heart disease treatment and mortality in schizophrenia and 
bipolar disorder - Changes in the Danish population between 1994 and 2006. J Psychiatr Res 45: 29–
35. 
  
Lebensohn ZM (1999) The history of electroconvulsive therapy in the United States and its place in 
American psychiatry: A personal memoir. Compr Psychiatry 40: 173–181. 
  
Leclerc E, Mansur RB and Brietzke E (2013) Determinants of adherence to treatment in bipolar 
disorder: A comprehensive review. J Affect Disord 149: 247–252. 
  
Lehman D and Meyer JM (2005) Decreased bone mineral density in male schizophrenia patients. 
Schizophrenia Res 76: 131–133. 
  
Leiknes KA, Cooke MJ, Jarosch-von Schweder L, et al. (2015) Electroconvulsive therapy during 
pregnancy: A systematic review of case studies. Arch Womens Ment Health 18: 1–39. 
  
Lembke A, Miklowitz D, Otto M, et al. (2003) Psychosocial service utilization by patients with bipolar 
disorder. Biol Psychiatry 53: 52s–52s. 
  
Leon AC, Mallinckrodt CH, Chuang-Stein C, et al. (2006) Attrition in randomized controlled clinical 
trials: Methodological issues in psychopharmacology. Biol Psychiatry 59: 1001–1005. 
  
Leucht S, Cipriani A, Spineli LM, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic 
drugs in schizophrenia: A multipletreatments meta-analysis. Lancet 382: 951–962. 
  
Leucht S, Hierl S, Kissling W, et al. (2012) Putting the efficacy of psychiatric and general medicine 
medication into perspective: Review of meta-analyses. Br J Psychiatry 200: 97–106. 
  
Leverich GS, Altshuler LL, Frye MA, et al. (2003) Factors associated with suicide attempts in 648 
patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 64: 
506–515. 
  
Li C-T, Bai Y-M, Huang Y-L, et al. (2012) Association between antidepressant resistance in unipolar 
depression and subsequent bipolar disorder: Cohort study. Br J Psychiatry 200: 45–51. 
  
Li XB, Tang YL, Wang CY, et al. (2015) Clozapine for treatmentresistant bipolar disorder: A systematic 
review. Bipolar Disord 17: 235–247. 
  
Lieb K, Vollm B, Rucker G, et al. (2010) Pharmacotherapy for borderline personality disorder: 
Cochrane systematic review of randomised trials. Br J Psychiatry 196: 4–12. 
  
Lieberman JA, Stroup TS, Mcevoy JP, et al. (2005) Effectiveness of antipsychotic drugs in patients 
with chronic schizophrenia. N Engl J Med 353: 1209–1223. 
  
Lingam R and Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 
105: 164–172. 
  
Lingford-Hughes AR, Welch S, Peters L, et al. (2012) BAP updated guidelines: Evidence-based 
guidelines for the pharmacological management of substance abuse, harmful use, addiction and 
comorbidity: recommendations from BAP. J Psychopharmacol 26: 899–952. 
  
Lish JD, Dime-Meenan S, Whybrow PC, et al. (1994) The National Depressive and Manic-depressive 
Association (DMDA) survey of bipolar members. J Affect Disord 31: 281–294. 
  
Llorca P-M, Abbar M, Courtet P, et al. (2013) Guidelines for the use and management of long-acting 
injectable antipsychotics in serious mental illness. BMC Psychiatry 13: 340. 
  
Lloyd J, Doll H, Hawton K, et al. (2010) How psychological symptoms relate to different motivations 
for gambling: An online study of internet gamblers. Biol Psychiatry 68: 733–740. 
  
LloǇd T aŶd JoŶes PB ;ϮϬϬϮͿ Τhe epideŵiologǇ of fiƌst-onset mania. In: Tsuang MT and Tohen M (eds) 
Textbook in Psychiatric Epidemiology. New York, Chichester: Wiley-Liss, pp.445–458. 
 
Lobban F, Taylor L, Chandler C, et al. (2010) Enhanced relapse prevention for bipolar disorder by 
community mental health teams: Cluster feasibility randomised trial. Br J Psychiatry 196: 59–63. 
  
Loebel A, Cucchiaro J, Silva R, et al. (2014a) Lurasidone monotherapy in the treatment of bipolar I 
depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry 171: 160–168. 
  
Loebel A, Cucchiaro J, Silva R, et al. (2014b) Lurasidone as adjunctive therapy with lithium or 
valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled 
study. Am J Psychiatry 171: 169–177. 
  
Lowe MR and Batchelor DH (1986) Depot neuroleptics and manic depressive psychosis. Int Clin 
Psychopharmacol 1(Suppl 1): 53–62. 
  
Lundh A, Sismondo S, Lexchin J, et al. (2012) Industry sponsorship and research outcome. Cochrane 
Database Syst Rev 12: MR000033. 
  
MacCabe JH, Lambe MP, Cnattingius S, et al. (2010) Excellent school performance at age 16 and risk 
of adult bipolar disorder: National cohort study. Br J Psychiatry 196: 109–115. 
  
MacQueen GM, Young LT and Joffe RT (2001) A review of psychosocial outcome in patients with 
bipolar disorder. Acta Psychiatr Scand 103: 163–170. 
  
Macritchie K, Geddes JR, Scott J, et al. (2003) Valproate for acute mood episodes in bipolar disorder 
(Cochrane Review). Cochrane Database Syst Rev: CD004052. 
  
Maj M, Pirozzi R, Formicola AM, et al. (1999) Reliability and validity of four alternative definitions of 
rapid-cycling bipolar disorder. Am J Psychiatry 156: 1421–1424. 
  
Maj M, Pirozzi R, Formicola AM, et al. (2000) Reliability and validity of the DSM-IV diagnostic 
category of schizoaffective disorder: Preliminary data. J Affect Disord 57: 95–98. 
  
Marangell LB, Suppes T, Zboyan HA, et al. (2008) A 1-year pilot study of vagus nerve stimulation in 
treatment-resistant rapid-cycling bipolar disorder. J Clin Psychiatry 69: 183–189. 
  
Marcus R, Khan A, Rollin L, et al. (2011) Efficacy of aripiprazole adjunctive to lithium or valproate in 
the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium 
or valproate monotherapy: A multicenter, double-blind, randomized study. Bipolar Disord 13: 133–
144. 
  
Martinez-Aran A, Vieta E, Reinares M, et al. (2004) Cognitive function across manic or hypomanic, 
depressed, and euthymic states in bipolar disorder. Am J Psychiatry 161: 262–270. 
  
Matthews M, Abdullah S, Gay G, et al. (2014) Tracking mental wellbeing: Balancing rich sensing and 
patient needs. Computer 47: 36–43. 
  
McCombs JS, Ahn J, Tencer T, et al. (2007) The impact of unrecognized bipolar disorders among 
patients treated for depression with antidepressants in the fee-for-services California Medicaid 
(Medi- Cal) program: A 6-year retrospective analysis. J Affect Disorders 97: 171–179. 
 
McCloud TL, Caddy C, Jochim J, et al. (2015) Ketamine and other glutamate receptor modulators for 
depression in bipolar disorder in adults. Cochrane Database Syst Rev 29: 9. DOI: 10.1002/14651858. 
CD011611.pub2. 
 
McElroy SL, Keck P-EJ and Strakowski SM (1996) Mania, psychosis, and antipsychotics. J Clin 
Psychiatry 57(Suppl 3): 14–26. McElroy SL, Weisler RH, Chang W, et al. (2010) A double-blind, 
placebo- controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar 
depression (EMBOLDEN II). J Clin Psychiatry 71: 163–174. 
 
McGorry PD, Tanti C, Stokes R, et al. ;ϮϬϬϳͿ headspaĐe: Austƌalia͛s National Youth Mental Health 
Foundation–where young minds come first. Med J Aust 187: S68–S70. 
 
McInerney SJ and Kennedy SH (2014) Review of evidence for use of antidepressants in bipolar 
depression. Prim Care Companion CNS Disord 16. doi: 10.4088/PCC.14r01653 (eCollection 2014). 
 
McIntyre RS, Soczynska JK, Bottas A, et al. (2006)  Anxiety disorders and bipolar disorder: A review. 
Bipolar Disord 8: 665–676. 
 
McKnight RF, Adida M, Budge K, et al. (2012) Lithium toxicity profile: A systematic review and meta-
analysis. Lancet 379: 721–728. 
 
Medda P, Toni C, Mariani MG, et al. (2015) Electroconvulsive therapy in 197 patients with a severe, 
drug-resistant bipolar mixed state: Treatment outcome and predictors of response. J Clin Psychiatry 
76:1168–1173. 
 Mendez MF (2000) Mania in neurologic disorders. Curr Psychiatry Rep 
2: 440–445. 
 
Merikangas KR, Akiskal HS, Angst J, et al. (2007) Lifetime and12-month prevalence of bipolar 
spectrum disorder in the NationalComorbidity Survey replication. Arch Gen Psychiatry 64: 543–552. 
 
Merikangas KR and Lamers F (2012) The ͚tƌue͛ pƌeǀaleŶĐe of ďipolaƌ IIdisorder. Curr Opin Psychiatry 
25: 19–23. 
 
Meyer JM and Koro CE (2004) The effects of antipsychotic therapy on serum lipids: A comprehensive 
review. Schizophrenia Res 70: 1–17. 
 
Meyer TD, Hammelstein P, Nilsson LG, et al. (2007) The Hypomania Checklist (HCL-32): Its factorial 
structure and association to indices of impairment in German and Swedish nonclinical samples. 
Compr Psychiatry 48: 79–87. 
 
Meyer TD and Hautzinger M (2012) Cognitive behaviour therapy and supportive therapy for bipolar 
disorders: Relapse rates for treatment period and 2-year follow-up. Psychol Med 42: 1429–1439. 
 
Michl J, Scharinger C, Zauner M, et al. (2014) A multivariate approach 
linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding 
affinities. Eur Neuropsychopharmacol 24: 1463–1474. 
 
Miklowitz DJ (2015) Intervening early in children with bipolar disorder: 
Is there a pot at the end of the Rainbow? Evid Based Mental Health 18: 65–66. 
 
Miklowitz DJ, Goodwin GM, Bauer MS, et al. (2008) Common and 
specific elements of psychosocial treatments for bipolar disorder: A survey of clinicians participating 
in randomized trials. J Psychiatr Pract 14: 77–85. 
 
Miklowitz DJ, Price J, Holmes EA, et al. (2012) Facilitated integrated mood management for adults 
with bipolar disorder. Bipolar Disord 14: 185–197. 
 
Mitchell PB (2015) Bipolar disorder and anxiety: A comorbidity needing better treatments. Lancet 
Psychiatry 2: 671–672. 
 
Mitchell PB, Goodwin GM, Johnson GF, et al. (2008) Diagnostic guidelines for bipolar depression: A 
probabilistic approach. Bipolar Disord 10: 144–152. 
 
Mitchell PB, Wilhelm K, Parker G, et al. (2001) The clinical features of bipolar depression: A 
comparison with matched major depressive disorder patients. J Clin Psychiatry 62: 212–216. 
 
Miura T, Noma H, Furukawa TA, et al. (2014) Comparative efficacy and tolerability of 
pharmacological treatments in the maintenance treatment of bipolar disorder: A systematic review 
and network metaanalysis. Lancet Psychiatry 1: 351–359. 
 
Mizrahi R, Rusjan P, Agid O, et al. (2007) Adverse subjective experience with antipsychotics and its 
relationship to striatal and extrastriatal D-2 receptors: A PET study in schizophrenia. Am J Psychiatry 
164: 630–637. 
 
Modabbernia A, Taslimi S, Brietzke E, et al. (2013) Cytokine alterations in bipolar disorder: A meta-
analysis of 30 studies. Biol Psychiatry 74: 15–25. 
 
Moller HJ and Grunze H (2000) Have some guidelines for the treatment of acute bipolar depression 
gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 250: 57–68. 
 
Moller HJ, Bottlender R, Grunze H, et al. (2001) Are antidepressants less effective in the acute 
treatment of bipolar I compared to unipolar depression? J Affect Disord 67: 141–146. 
 
Monaco F and Cicolin A (1999) Interactions between anticonvulsant and psychoactive drugs. 
Epilepsia 40(Suppl 10): S71–S76. 
 
Montgomery SA, Schatzberg AF, Guelfi JD, et al. (2000) Pharmacotherapy of depression and mixed 
states in bipolar disorder. J Affect Disord 59(Suppl 1): S39–S56. 
 
Moreno C, Hasin DS, Arango C, et al. (2012) Depression in bipolar disorder versus major depressive 
disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar 
Disord 14: 271–282. 
 
Moreno C, Laje G, Blanco C, et al. (2007) National trends in the outpatient diagnosis and treatment 
of bipolar disorder in youth. Arch Gen Psychiatry 64: 1032–1039. 
 
Morriss R, Marshall M and Harris A (2002) Bipolar affective disorder left out in the cold. Too late for 
the national service framework butlocal initiatives may be possible. BMJ 324: 61–62. 
 
Morriss RK, Faizal MA, Jones AP, et al. (2007) Interventions for helping people recognise early signs 
of recurrence in bipolar disorder. Cochrane Database Syst Rev CD004854. 
 
Mt-Isa S, Hallgreen CE, Wang N, et al. (2014) Balancing benefit and risk of medicines: A systematic 
review and classification of available methodologies. Pharmacoepidemiol Drug Saf 23: 667–678. 
 
Mukherjee S, Sackeim HA and Schnur DB (1994) Electroconvulsive therapy of acute manic episodes: 
A ƌeǀieǁ of ϱϬ Ǉeaƌs͛ experience. Am J Psychiatry 151: 169–176. 
 
Muralidharan K, Ali M, Silveira LE, et al. (2013) Efficacy of second generation antipsychotics in 
treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials. J 
Affect Disord 150: 408–414. 
 
Naranjo CA, Herrmann N, Mittmann N, et al. (1995) Recent advances in geriatric 
psychopharmacology. Drugs Aging 7: 184–202. 
 
Narayan V and Haddad PM (2011) Antidepressant discontinuation manic states: A critical review of 
the literature and suggested diagnostic criteria. J Psychopharmacol 25: 306–313. 
 
NICE (2014) Bipolar Disorder: Assessment and Management (NICE2014). Available at: 
https://www.nice.org.uk/guidance/cg185 
 
Nicholas J, Larsen ME, Proudfoot J, et al. (2015) Mobile apps for bipolar disorder: A systematic 
review of features and content quality. J Med Internet Res 17: e198. 
 
Nierenberg AA, Ostacher MJ, Calabrese JR, et al. (2006) Treatment resistant bipolar depression: A 
STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, 
inositol, or risperidone. Am J Psychiatry 163: 210–216. 
 
Nolen WA and Weisler RH (2013) The association of the effect of lithium in the maintenance 
treatment of bipolar disorder with lithium plasma levels: A post hoc analysis of a double-blind study 
comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). 
Bipolar Disord 15: 100–109. 
 
Nutt DJ and Sharpe M (2008) Uncritical positive regard? Issues in the efficacy and safety of 
psychotherapy. J Psychopharmacol 22: 3–6. 
 
Nutt DJ, King LA, Phillips LD, et al. (2010) Drug harms in the UK: A multicriteria decision analysis. 
Lancet 376: 1558–1565. 
 
O͛BƌieŶ A ;ϮϬϭϱͿ CoŵpaƌiŶg the ƌisk of tardive dyskinesia in older adults with first-generation and 
second-generation antipsychotics: A systematic review and meta-analysis. Int J Geriatr Psychiatry 
(epub ahead of print). 
 
Oates M (2003) Suicide: The leading cause of maternal death. Br J Psychiatry 183: 279–281. 
 
Ogawa Y, Tajika A, Takeshima N, et al. (2014) Mood stabilizers and antipsychotics for acute mania: A 
systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. 
CNS Drugs 28: 989–1003. 
 
Okuma T and Kishimoto A (1998) A history of investigation on the mood stabilizing effect of 
carbamazepine in Japan. Psychiatry Clin Neurosci 52: 3–12. 
 
Omtzigt JG, Los FJ, Grobbee DE, et al. (1992) The risk of spina bifida aperta after first-trimester 
exposure to valproate in a prenatal cohort. Neurology 42: 119–125. 
 
Oquendo MA, Lizardi D, Greenwald S, et al. (2004) Rates of lifetime suicide attempt and rates of 
lifetime major depression in different ethnic groups in the United States. Acta Psychiatr Scand 110: 
446–451. 
  
Oquendo MA, Waternaux C, Brodsky B, et al. (2000) Suicidal behaviour in bipolar mood disorder: 
Clinical characteristics of attempters and nonattempters. J Affect Disord 59: 107–117. 
 
Osborn DPJ, Levy G, Nazareth I, et al. (2007) Relative risk of cardiovascular and cancer mortality in 
people with severe mental illness from the UŶited KiŶgdoŵ͛s GeŶeƌal PƌaĐtiĐe ‘eseaƌĐh Dataďase. 
Arch Gen Psychiatry 64: 242–249. 
 
Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. (2013) The International Society for Bipolar Disorders 
(ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170: 1249–1262. 
 
Pacchiarotti I, Murru A, Kotzalidis GD, et al. (2015) Hyperprolactinemia and medications for bipolar 
disorder: Systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 25: 
1045–1059. 
 
Pande AC, Crockatt JG, Janney CA, et al. (2000) Gabapentin in bipolar disorder: A placebo-controlled 
trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2: 249–255. 
 Parikh SV, Zaretsky A, Beaulieu S, et al. (2012) A randomized controlled trial of psychoeducation or 
cognitive-behavioral therapy in bipolar disorder: A Canadian Network for Mood and Anxiety 
treatments (CANMAT) study [CME]. J Clin Psychiatry 73: 803–810. 
 
Parker G, Tully L, Olley A, et al. (2006) SSRIs as mood stabilizers for Bipolar II Disorder? A proof of 
concept study. J Affect Disord 92: 205–214. 
 
Patel NC, DelBello MP, Bryan HS, et al. (2006) Open-label lithium for the treatment of adolescents 
with bipolar depression. J Am Acad Child Adolesc Psychiatry 45: 289–297. 
 
Paton C, Adroer R and Barnes TRE (2013) Monitoring lithium therapy: The impact of a quality 
improvement programme in the UK. Bipolar Disord 15: 865–875. 
 
Paton C, Crawford MJ, Bhatti SF, et al. (2015) The use of psychotropic medication in patients with 
emotionally unstable personality disorder under the care of UK mental health services. J Clin 
Psychiatry 76: e512–518. 
 
Pavlova B, Perlis RH, Alda M, et al. (2015) Lifetime prevalence of anxiety disorders in people with 
bipolar disorder: A systematic review and meta-analysis. Lancet Psychiatry 2: 710–717. 
 
Peet M (1994) Induction of mania with selective serotonin re-uptake inhibitors and tricyclic 
antidepressants. Br J Psychiatry 164: 549–550. 
  
Perlick D, Clarkin JF, Sirey J, et al. (1999) Burden experienced by caregivers of persons with bipolar 
affective disorder. Br J Psychiatry 175: 56–62. 
 
Perry A, Tarrier N, Morriss R, et al. (1999) Randomised controlled trial of efficacy of teaching patients 
with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 318: 149–
153. 
 
Perugi G, Angst J, Azorin JM, et al. (2015) Mixed features in patients with a major depressive 
episode: The BRIDGE-II-MIX study. J Clin Psychiatry 76: E351–E358. 
 
Petrides G, Tobias KG, Kellner CH, et al. (2011) Continuation and maintenance electroconvulsive 
therapy for mood disorders: Review of the literature. Neuropsychobiology 64: 129–140. 
 
Phillips L, Fasolo M, Zafiropoulos N, et al. (2011) Is quantitative benefit– risk modelling of drugs 
desirable or possible? Drug Discov Today Technol 8: e3–e10. 
 
Pompili M, Gonda X, Serafini G, et al. (2013) Epidemiology of suicide in bipolar disorders: A 
systematic review of the literature. Bipolar Disord 15: 457–490. 
 
Popovic D, Reinares M, Goikolea JM, et al. (2012) Polarity index of pharmacological agents used for 
maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 22: 339–346. 
 
Popovic D, Torrent C, Goikolea JM, et al. (2014) Clinical implications of predominant polarity and the 
polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand 129: 366–374. 
 
Posner K, Oquendo MA, Gould M, et al. (2007) Columbia Classification Algorithm of Suicide 
Assessment (C-CASA): Classification of suiĐidal eǀeŶts iŶ the FDA͛s pediatƌiĐ suiĐidal ƌisk analysis of 
antidepressants. Am J Psychiatry 164: 1035–1043. 
  
Post RM, Altshuler LL, Leverich GS, et al. (2006) Mood switch in bipolar depression: Comparison of 
adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189: 124–131. 
  
Post RM, Denicoff KD, Frye MA, et al. (1998) A history of the use of anticonvulsants as mood 
stabilizers in the last two decades of the 20th century. Neuropsychobiology 38: 152–166. 
  
Post RM, Ketter TA, Pazzaglia PJ, et al. (1996) Rational polypharmacy in the bipolar affective 
disorders. Epilepsy Res Suppl 11: 153–180. 
  
Potash JB and DePaulo J-RJ (2000) Searching high and low: A review of the genetics of bipolar 
disorder. Bipolar Disord 2: 8–26. 
 
Powell J, Geddes J, Deeks J, et al. (2000) Suicide in psychiatric hospital in-patients - Risk factors and 
their predictive power. Br J Psychiatry 176: 266–272. 
  
Prescribing Observatory for Mental Health (2013) Topic 7d. Monitoring of patients prescribed 
lithium: Supplementary report. Prescribing Observatory for Mental Health. 
  
Preston GA, Marchant BK, Reimherr FW, et al. (2004) Borderline personality disorder in patients with 
bipolar disorder and response to lamotrigine. J Affect Disord 79: 297–303. 
  
Prien RF, Kupfer DJ, Mansky PA, et al. (1984) Drug therapy in the prevention of recurrences in 
unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing 
lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen 
Psychiatry 41: 1096–1104. 
  
Quiroz JA, Yatham LN, Palumbo JM, et al. (2010) Risperidone long-acting injectable monotherapy in 
the maintenance treatment of bipolar I disorder. Biol Psychiatry 68: 156–162. 
  
Read J, van Os J, Morrison AP, et al. (2005) Childhood trauma, psychosis and schizophrenia: A 
literature review with theoretical and clinical implications. Acta Psychiatr Scand 112: 330–350. 
 
Redlich R, Dohm K, Grotegerd D, et al. (2015) Reward processing in unipolar and bipolar depression: 
A functional MRI study. Neuropsychopharmacology 40: 2623–2631. 
  
Reinares A, Vieta E, Colom F, et al. (2006) What really matters to bipolar patieŶts͛ Đaƌegiǀeƌs: 
Sources of family burden. J Affect Disord 94: 157–163. 
  
Reinares M, Colom F, Sanchez-Moreno J, et al. (2008) Impact of caregiver group psychoeducation on 
the course and outcome of bipolar patients in remission: A randomized controlled trial. Bipolar 
Disord 10: 511–519. 
  
Rice F, Jones I and Thapar A (2007) The impact of gestational stress and prenatal growth on 
emotional problems in offspring: A review. Acta Psychiatr Scand 115: 171–183. 
  
Robertson E, Jones I, Haque S, et al. (2005) Risk of puerperal and nonpuerperal recurrence of illness 
following bipolar affective puerperal (post-partum) psychosis. Br J Psychiatry 186: 258–259. 
Rogers R and Goodwin G (2005) Lithium may reduce gambling severity 
in pathological gamblers with bipolar disorder. Evid Based Mental 
Health 8: 80. 
  
Rosa AR, Singh N, Whitaker E, et al. (2014) Altered plasma glutathione levels in bipolar disorder 
indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived 
neurotrophic factor (BDNF) levels. Psychol Med 44: 2409–2418. 
 
Rosa FW (1991) Spina bifida in infants of women treated with carbamazepine during pregnancy. N 
Engl J Med 324: 674–677. 
  
Rummel-Kluge C, Komossa K, Schwarz S, et al. (2012) Second-generation antipsychotic drugs and 
extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisons. 
Schizophrenia Bull 38: 167–177. 
  
Rush AJ, Trivedi MH, Ibrahim HM, et al. (2003) The 16-Item Quick Inventory of Depressive 
Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric 
evaluation in patients with chronic major depression. Biol Psychiatry 54: 573–583. 
  
Sachs GS, Nierenberg AA, Calabrese JR, et al. (2007) Effectiveness of adjunctive antidepressant 
treatment for bipolar depression. N Engl J Med 356: 1711–1722. 
  
Sachs GS, Printz DJ, Kahn DA, et al. (2000) The expert consensus guideline series: Medication 
treatment of bipolar disorder 2000. Postgrad Med Spec No: 1–104. 
  
Sajatovic M (2002) Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry 17: 865–
873. 
  
Salloum IM and Thase ME (2000) Impact of substance abuse on the course and treatment of bipolar 
disorder. Bipolar Disord 2: 269–280.  
 
Samren EB, van Duijn CM, Christiaens GC, et al. (1999) Antiepileptic drug regimens and major 
congenital abnormalities in the offspring. Ann Neurol 46: 739–746. 
  
Santos Pina L, Bouckaert F, Obbels J, et al. (2016) Maintenance electroconvulsive therapy in severe 
bipolar disorder: A retrospective chart review. J ECT 32: 23–28. 
  
Sato T, Bottlender R, Kleindienst N, et al. (2002) Syndromes and phenomenological subtypes 
underlying acute mania: A factor analytic study of 576 manic patients. Am J Psychiatry 159: 968–974. 
  
Saunders KEA, Bilderbeck AC, Price J, et al. (2015) Distinguishing bipolar disorder from borderline 
personality disorder: A study of current clinical practice. Eur Psychiatry 30: 965–974. 
  
Savitz JB, van der Merwe L, Stein DJ, et al. (2008) Neuropsychological task performance in bipolar 
spectrum illness: Genetics, alcohol abuse, medication and childhood trauma. Bipolar Disord 10: 
479–494. 
  
Schaffer A, Isometsa ET, Azorin JM, et al. (2015) A review of factors associated with greater 
likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the 
International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. 
Aust N Z J Psychiatry 49: 1006–1020. 
  
Schalkwijk S, Undurraga J, Tondo L, et al. (2014) Declining efficacy in controlled trials of 
antidepressants: Effects of placebo dropout. Int J Neuropsychopharmacol 17: 1343–1352. 
  
Schoeyen HK, Kessler U, Andreassen OA, et al. (2015) Treatment-resistant bipolar depression: A 
randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological 
treatment. Am J Psychiatry 172: 41–51. 
  
Scott J (1996) Cognitive therapy of affective disorders: A review. J Affect Disord 37: 1–11. Scott J and 
Pope M (2002) Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 63: 
384–390. 
  
Scott J, Colom F and Vieta E (2007) A meta-analysis of relapse rates with adjunctive psychological 
therapies compared to usual psychiatric treatment for bipolar disorders. Int J 
Neuropsychopharmacol 10: 123–129. 
  
Scott J, Garland A and Moorhead S (2001) A pilot study of cognitive therapy in bipolar disorders. 
Psychol Med 31: 459–467. 
  
Scott J, Paykel E, Morriss R, et al. (2006) Cognitive-behavioural therapy for severe and recurrent 
bipolar disorders - Randomised controlled trial. Br J Psychiatry 188: 313–320. 
  
Scott J, Stanton B, Garland A, et al. (2000) Cognitive vulnerability in patients with bipolar disorder. 
Psychol Med 30: 467–472. 
  
Severus E, Taylor MJ, Sauer C, et al. (2014) Lithium for prevention of mood episodes in bipolar 
disorders: Systematic review and metaanalysis. Int J Bipolar Disord 2: 15. 
  
Shah A, Carreno FR and Frazer A (2014) Therapeutic modalities for treatment resistant depression: 
Focus on vagal nerve stimulation and ketamine. Clin Psychopharmacol Neurosci 12: 83–93. 
  
Shekelle PG, Woolf SH, Eccles M, et al. (1999) Clinical guidelines: Developing guidelines. BMJ 318: 
593–596. Sidor MM and Macqueen GM (2011) Antidepressants for the acute treatment 
of bipolar depression: A systematic review and meta-analysis. J Clin Psychiatry 72: 156–167. 
 
Simon GE, Ludman EJ, Bauer MS, et al. (2006) Long-term effectiveness and cost of a systematic care 
program for bipolar disorder. Arch Gen Psychiatry 63: 500–508. 
  
Simon NM, Otto MW, Wisniewski SR, et al. (2004) Anxiety disorder comorbidity in bipolar disorder 
patients: Data from the first 500 participants in the systematic treatment enhancement program for 
bipolar disorder (STEP-BD). Am J Psychiatry 161: 2222–2229. 
  
Singh MK, Ketter TA and Chang KD (2010) Atypical antipsychotics for acute manic and mixed 
episodes in children and adolescents with bipolar disorder: efficacy and tolerability. Drugs 70: 433–
442. 
  
Smith LA, Cornelius VR, Azorin JM, et al. (2010) Valproate for the treatment of acute bipolar 
depression: Systematic review and metaanalysis. J Affect Disord 122: 1–9. 
  
“ŵith LF aŶd Whitfield MJ ;ϭϵϵϱͿ WoŵeŶ͛s knowledge of taking oral contraceptive pills correctly 
and of emergency contraception: Effect of providing information leaflets in general practice. Br J Gen 
Pract 45: 409–414. 
  
“oŶg J, “j̈laŶdeƌ A, BeƌgeŶ “, et al. ;ϮϬϭϱͿ “uicidal behavior during lithium and valproate medication 
for bipolar disorder: A register based study. Posters. Bipolar Disorders 17: 94. DOI: 
10.1111/bdi.12309 
 
Sproule BA, Hardy BG and Shulman KI (2000) Differential pharmacokinetics of lithium in elderly 
patients. Drugs Aging 16: 165–177. Staring ABP, Van der Gaag M, Koopmans GT, et al. (2010) 
Treatment adherence therapy in people with psychotic disorders: Randomised controlled trial. Br J 
Psychiatry 197: 448–455. 
  
Straker D, Correll CU, Kramer-Ginsberg E, et al. (2005) Cost-effective screening for the metabolic 
syndrome in patients treated with secondgeneration antipsychotic medications. Am J Psychiatry 162: 
1217–1221. 
  
Strakowski SM, DelBello MP, Fleck DE, et al. (2000) The impact of substance abuse on the course of 
bipolar disorder. Biol Psychiatry 48: 477–485. 
  
Strakowski SM, MeElroy SL, Keck P-WJ, et al. (1994) The co-occurrence of mania with medical and 
other psychiatric disorders. Int J Psychiatry Med 24: 305–328. 
  
Stratford HJ, Cooper MJ, Di Simplicio M, et al. (2015) Psychological therapy for anxiety in bipolar 
spectrum disorders: A systematic review. Clin Psychol Rev 35: 19–34. 
  
Suppes T, Baldessarini RJ, Faedda GL, et al. (1991) Risk of recurrence following discontinuation of 
lithium treatment in bipolar disorder. Arch Gen Psychiatry 48: 1082–1088. 
 
Suppes T, Frank E, DePaulo JR, et al. (2014) Letter to the editor in response to 2012 article by Frances 
and Jones. Bipolar Disord 16: 214–215. 
  
Suppes T, Vieta E, Gustafsson U, et al. (2013) Maintenance treatment with quetiapine when 
combined with either lithium or divalproex in bipolar I disorder: Analysis of two large randomized, 
placebocontrolled trials. Depress Anxiety 30: 1089–1098. 
  
Suppes T, Vieta E, Liu S, et al. (2009) Maintenance treatment for patients with bipolar I disorder: 
Results from a North American study of quetiapine in combination with lithium or divalproex (trial 
127). Am J Psychiatry 166: 476–488. 
  
Suppes T, Webb A, Paul B, et al. (1999) Clinical outcome in a randomized 1-year trial of clozapine 
versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J 
Psychiatry 156: 1164–1169. 
  
Swartz HA and Frank E (2001) Psychotherapy for bipolar depression: A phase-specific treatment 
strategy? Bipolar Disord 3: 11–22. 
  
Taylor DM, Cornelius V, Smith L, et al. (2014) Comparative efficacy and acceptability of drug 
treatments for bipolar depression: A multiple-treatments meta-analysis. Acta Psychiatr Scand 130: 
452–469. 
 
ten Have M, Vollebergh W, Bijl R, et al. (2002) Bipolar disorder in the general population in The 
Netherlands (prevalence, consequences and care utilisation): Results from The Netherlands Mental 
Health Survey and Incidence Study (NEMESIS). J Affect Disord 68: 203–213. 
  
Terp IM and Mortensen PB (1998) Post-partum psychoses. Clinical diagnoses and relative risk of 
admission after parturition. Br J Psychiatry 172: 521–526. 
  
Thase ME, Jonas A, Khan A, et al. (2008a) Aripiprazole monotherapy in non-psychotic bipolar I 
depression. J Clin Psychopharmacol 28: 13–20. 
  
Thase ME, Macfadden W, Weisler RH, et al. (2006) Efficacy of quetiapine monotherapy in bipolar I 
and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin 
Psychopharmacol 26: 600–609. 
  
Thase ME, Trivedi MH, Nelson JC, et al. (2008b) Examining the efficacy of adjunctive aripiprazole in 
major depressive disorder: A pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 10: 
440–447. 
  
The UK ECT Review Group (2003) Electroconvulsive therapy – systematic review and meta-analysis 
of efficacy and safety in depressive disorders. Lancet 361: 799–808. 
  
Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. (1996) Effect of prophylactic treatment 
on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. 
Pharmacopsychiatry 29: 103–107. 
  
Tidemalm D, Langstrom N, Lichtenstein P, et al. (2008) Risk of suicide after suicide attempt according 
to coexisting psychiatric disorder: Swedish cohort study with long-term follow-up. BMJ 337: a2205. 
  
Tijssen MJA, van Os J, Wittchen HU, et al. (2010) Evidence that bipolar disorder is the poor outcome 
fraction of a common developmental phenotype: An 8-year cohort study in young people. Psychol 
Med 40: 289–299. 
  
Toffol E, Hatonen T, Tanskanen A, et al. (2015) Lithium is associated with decrease in all-cause and 
suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. 
J Affect Disord 183: 159–165. 
  
Tohen M, Calabrese JR, Sachs GS, et al. (2006) Randomized, placebocontrolled trial of olanzapine as 
maintenance therapy in patients with bipolar I disorder responding to acute treatment with 
olanzapine. Am J Psychiatry 163: 247–256. 
  
Tohen M, Chengappa KNR, Suppes T, et al. (2004) Relapse prevention in bipolar I disorder: 18-month 
comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 184: 337–
345. 
  
Tohen M, Greil W, Calabrese JR, et al. (2005) Olanzapine versus lithium in the maintenance 
treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J 
Psychiatry 162: 1281–1290. 
  
Tohen M, Katagiri H, Fujikoshi S, et al. (2013) Efficacy of olanzapine monotherapy in acute bipolar 
depression: A pooled analysis of controlled studies. J Affect Disord 149: 196–201. 
Tohen M, Khalsa HM, Salvatore P, et al. (2012) Two-year outcomes in first-episode psychotic 
depression the McLean-Harvard First-Episode Project. J Affect Disord 136: 1–8. 
  
Tohen M, Vieta E, Calabrese J, et al. (2003) Efficacy of olanzapine and olanzapine-fluoxetine 
combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60: 1079–1088. 
  
Tondo L, Hennen J and Baldessarini RJ (2001) Lower suicide risk with long-term lithium treatment in 
major affective illness: A meta-analysis. Acta Psychiatr Scand 104: 163–172. 
  
Tondo L, Isacsson G and Baldessarini RJ (2003) Suicidal behaviour in bipolar disorder – Risk and 
prevention. CNS Drugs 17: 491–511. 
  
Tondo L, Vazquez G and Baldessarini RJ (2010) Mania associated with antidepressant treatment: 
Comprehensive meta-analytic review. Acta Psychiatr Scand 121: 404–414. 
  
Torrent C, Amann B, Sanchez-Moreno J, et al. (2008) Weight gain in bipolar disorder: 
Pharmacological treatment as a contributing factor. Acta Psychiatr Scand 118: 4–18. 
  
Torrent C, Bonnin CdM, Martinez-Aran A, et al. (2013) Efficacy of functional remediation in bipolar 
disorder: A multicenter randomized controlled study. Am J Psychiatry 170: 852–859. 
 
Tyrer SP and Brittlebank AD (1993) Misdiagnosis of bipolar affective disorder as personality disorder. 
Can J Psychiatry 38: 587–589. 
 
Undurraga J and Baldessarini RJ (2012) Randomized, placebo-controlled trials of antidepressants for 
acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology 37: 851–864. 
 
Urry E and Landolt H-P (2015) Adenosine, caffeine, and performance: From cognitive neuroscience 
of sleep to sleep pharmacogenetics. Curr Top Behav Neurosci 25: 331–366. 
  
Vajda FJE, O͛BƌieŶ TJ, LaŶdeƌ CM, et al. (2014) The teratogenicity of the newer antiepileptic drugs – 
an update. Acta Neurol Scand 130: 234–238. 
  
Valenti M, Benabarre A, Garcia-Amador M, et al. (2008) Electroconvulsive therapy in the treatment 
of mixed states in bipolar disorder. Eur Psychiatry 23: 53–56. 
  
Vallarino M, Henry C, Etain B, et al. (2015) An evidence map of psychosocial interventions for the 
earliest stages of bipolar disorder. Lancet Psychiatry 2: 548–563. 
  
Valtonen H, Suominen K, Mantere O, et al. (2005) Suicidal ideation and attempts in bipolar I and II 
disorders. J Clin Psychiatry 66: 1456–1462. 
  
van der Loos MLM, Mulder P, Hartong EGTM, et al. (2011) Long-term outcome of bipolar depressed 
patients receiving lamotrigine as addon to lithium with the possibility of the addition of paroxetine in 
nonresponders: A randomized, placebo-controlled trial with a novel design. Bipolar Disord 13: 111–
117. 
  
van der Loos MLM, Mulder PGH, Hartong EGTM, et al. (2009) Efficacy and safety of lamotrigine as 
add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled 
trial. J Clin Psychiatry 70: 223–231. 
  
Van Meter AR, Moreira AL and Youngstrom EA (2011) Meta-analysis of epidemiologic studies of 
pediatric bipolar disorder. J Clin Psychiatry 72: 1250–1256. 
  
Vancampfort D, Vansteelandt K, Correll CU, et al. (2013) Metabolic syndrome and metabolic 
abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators. Am J 
Psychiatry 170: 265–274. 
  
Vazquez GH, Tondo L, Undurraga J, et al. (2013) Overview of antidepressant treatment of bipolar 
depression. Int J Neuropsychopharmacol 16: 1673–1685. 
  
Vieta E, Angst J, Reed C, et al. (2009) Predictors of switching from mania to depression in a large 
observational study across Europe (EMBLEM). J Affect Disord 118: 118–123. 
  
Vieta E, Calabrese JR, Goikolea JM, et al. (2007) Quetiapine monotherapy in the treatment of 
patients with bipolar I or II depression and a rapid-cycling disease course: A randomized, double 
blind, placebocontrolled study. Bipolar Disord 9: 413–425. 
  
Vieta E, Montgomery S, Sulaiman AH, et al. (2012) A randomized, double- blind, placebo-controlled 
trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with 
bipolar I disorder. Eur Neuropsychopharmacol 22: 825–835. 
  
Vieta E, Suppes T, Eggens I, et al. (2008) Efficacy and safety of quetiapine in combination with lithium 
or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect 
Disord 109: 251–263. 
  
Vieta E, Torrent C and Martinez-Aran A (2014) Functional Remediation for Bipolar disorder. 
Cambridge: Cambridge University Press. Vieta E and Valenti M (2013) Mixed states in DSM-5: 
Implications for clinical care, education, and research. J Affect Disord 148: 28–36. 
  
Viguera AC, Nonacs R, Cohen LS, et al. (2000) Risk of recurrence of bipolar disorder in pregnant and 
nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 157: 179–184. 
  
Viktorin A, Lichtenstein P, Thase ME, et al. (2014) The risk of switch to mania in patients with bipolar 
disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. 
Am J Psychiatry 171: 1067–1073. 
  
Wals M, Hillegers MH, Reichart CG, et al. (2001) Prevalence of psychopathology in children of a 
bipolar parent. J Am Acad Child Adolesc Psychiatry 40: 1094–1102. 
  
Webb RT, Lichtenstein P, Larsson H, et al. (2014) Suicide, hospital-presenting suicide attempts, and 
criminality in bipolar disorder: Examination of risk for multiple adverse outcomes. J Clin Psychiatry 
75: E809–E816. 
  
Wehr TA, Sack DA and Rosenthal NE (1987) Sleep reduction as a final common pathway in the 
genesis of mania. Am J Psychiatry 144: 201–204. 
  
Weisler RH (2014) Continuation of quetiapine versus switching to placebo or lithium for 
maintenance treatment of bipolar I disorder (Trial 144: A randomized controlled study) (erratum). J 
Clin Psychiatry 75: 290. 
  
Weisler RH, Calabrese JR, Thase ME, et al. (2008) Efficacy of quetiapine monotherapy for the 
treatment of depressive episodes in bipolar I disorder: A post hoc analysis of combined results from 
2 doubleblind, randomized, placebo-controlled studies. J Clin Psychiatry 69: 769–782. 
  
Weisler RH, Nolen WA, Neijber A, et al. (2011) Continuation of quetiapine versus switching to 
placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized 
controlled study). J Clin Psychiatry 72: 1452–1464. 
  
Wesseloo R, Kamperman AM, Munk-Olsen T, et al. (2016) Risk of postpartum relapse in bipolar 
disorder and postpartum psychosis: A systematic review and meta-analysis. Am J Psychiatry 173: 
117–127. 
  
Westman J, Wahlbeck K, Laursen TM, et al. (2015) Mortality and life expectancy of people with 
alcohol use disorder in Denmark, Finland and Sweden. Acta Psychiatr Scand 131: 297–306. 
  
Wheeldon TJ, Robertson C, Eagles JM, et al. (1999) The views and outcomes of consenting and non-
consenting patients receiving ECT. Psychol Med 29: 221–223.  
 
Wilson MP, Pepper D, Currier GW, et al. (2012) The psychopharmacology of agitation: Consensus 
statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology 
Workgroup. West J Emerg Med 13: 26–34. 
  
Winokur G, Coryell W, Keller M, et al. (1993) A prospective follow-up of patients with bipolar and 
primary unipolar affective disorder. Arch Gen Psychiatry 50: 457–465. 
  
Yatham LN, Beaulieu S, Schaffer A, et al. (2015a) Optimal duration of risperidone or olanzapine 
adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT 
randomized double-blind trial. Mol Psychiatry. 
  
Yatham LN, Vieta E, Goodwin GM, et al. (2015b) Agomelatine or placebo as adjunctive therapy to a 
mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. The British 
Journal of Psychiatry 208: 78–86. 
  
Yazici O, Kora K, Polat A, et al. (2004) Controlled lithium discontinuation in bipolar patients with 
good response to long-term lithium prophylaxis. J Affect Disord 80: 269–271. 
  
Yildiz A, Nikodem M, Vieta E, et al. (2015) A network meta-analysis on comparative efficacy and all-
cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 45: 299–317. 
  
Yildiz A, Vieta E, Leucht S, et al. (2011) Efficacy of antimanic treatments: Meta-analysis of 
randomized, controlled trials. Neuropsychopharmacology 36: 375–389. 
  
Yip SW, Doherty J, Wakeley J, et al. (2012) Reduced subjective response to acute ethanol 
administration among young men with a broad bipolar phenotype. Neuropsychopharmacology 37: 
1808–1815. 
  
Young AH, McElroy SL, Bauer M, et al. (2010) A double-blind, placebocontrolled study of quetiapine 
and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin 
Psychiatry 71: 150–162. 
  
Young BK, Camicioli R and Ganzini L (1997) Neuropsychiatric adverse effects of antiparkinsonian 
drugs. Characteristics, evaluation and treatment. Drugs Aging 10: 367–383. 
 
Youngstrom E, Genzlinger J, Egerton G, et al. (2015) Multivariate Meta-analysis of the discriminative 
validity of caregiver, youth, and teacher rating scales for pediatric bipolar disorder: Mother knows 
best about mania. Arch Sci Psychol 3: 112–137. 
  
Youngstrom E and Van Meter A (2015) The state of assessment for pediatric bipolar disorder: It is 
time to throw away the old textbook. Bipolar Disord 17: 23–23. 
  
Zanarini MC (2009) Psychotherapy of borderline personality disorder. Acta Psychiatr Scand 120: 
373–377. 
 
Zarate CA, Payne JL, Singh J, et al. (2004) Pramipexole for bipolar II depression: A placebo-controlled 
proof of concept study. Biol Psychiatry 56: 54–60. 
  
Zarate CA and Tohen M (2004) Double-blind comparison of the continued use of antipsychotic 
treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 161: 169–171. 
  
Zhornitsky S, Potvin S, Moteshafi H, et al. (2011) Dose-response and comparative efficacy and 
tolerability of quetiapine across psychiatric disorders: A systematic review of the placebo-controlled 
monotherapy and add-on trials. Int Clin Psychopharmacol 26: 183–192. 
 
Annex: Additional information about medicines 
For newer medicines, clinicians may wish to consult Summaries of Product Characteristics (SmPCs). 
However, there is some question about their accuracy and utility, certainly for adverse drug 
reactions (Ferner et al., 2005). Many Trusts will have a medicines information service. 
Unexpected adverse reactions in bipolar patients should be reported to the relevant licensing 
authority. There is much accumulated experience to guide the use of lithium. Nevertheless, it is 
potentially toxic and there is an important potential for litigation if accepted procedures are not 
followed. Experience with the anticonvulsants is growing in bipolar patients and is extensive from 
the epilepsy field. 
 
Lithium 
 
Initial workup 
•GeŶeƌal ŵediĐal histoƌǇ, phǇsiĐal eǆaŵiŶatioŶ aŶd ǁeight. 
•Blood creatinine concentrations, e-GFR, thyroid function (Kripalani et al., 2009). 
 
Dosing 
•Lithiuŵ is aǀailaďle iŶ a confusing variety of formulations: immediate or modified release, tablet or 
liquid. The pharmacokinetics are not very different but the doses may be. It is probably best to 
prescribe as a proprietary brand to avoid confusion. 
•Lithium is usually best given as a single dose at night, to facilitate adherence. Twice a day dosing 
may be associated with a higher risk of renal side effects. 
•If possible start at a dose that will allow some calibration for renal function: e.g. 400 mg (as lithium 
carbonate) if normal renal function. 
•Titrate the dosage further upward if necessary (generally to serum concentrations of 0.6 to 0.8 
mmol/L) according to response and adverse reactions. 
•The ĐoŵŵoŶest dose foƌ ǇouŶgeƌ patieŶts is ϴϬϬ ŵg/daǇ, ǁhiĐh ĐaŶ ďe tapeƌed at the ĐliŶiĐiaŶ͛s 
discretion. 
•Check lithium concentration after dosage increases (steady-state concentrations are likely to be 
reached about 5 days after a dosage adjustment). 
•The ͞optiŵal͟ ŵaiŶteŶaŶĐe dose is the highest toleƌated ǁithout sigŶifiĐaŶt adǀeƌse ƌeaĐtioŶs. It 
will vary from patient to patient. 
 
•Oldeƌ patieŶts, aŶd otheƌs ǁith ƌeduĐed ƌeŶal fuŶĐtioŶ, ǁill ƌeƋuiƌe loǁeƌ doses. 
•In acute mania, higher serum concentrations (1.0 to 1.5 mmol/L) are claimed to be more 
efficacious, but this approach should be reserved for unusual circumstances where alternative 
treatments are contra-indicated or have failed. A lower dose should be restored long term. 
 
Long-term monitoring of laboratory values 
 
•MeasuƌeŵeŶt of lithiuŵ ĐoŶĐeŶtƌatioŶs is pƌiŵaƌilǇ to aǀoid doses leadiŶg to toxicity (over 0.8 
mmol/L), rather than as a strict guide to efficacy (concentrations over 0.6 mmol/L appear best). 
•As long as lithium heparin is not used as an anticoagulant, plasma can be used to measure the 
lithium concentration; plasma and serum lithium concentrations are identical. 
•Blood for estimation of lithium concentration should be drawn 12 hours after the last dose. 
•Serum lithium concentrations should be checked when-eǀeƌ the patieŶt͛s ĐliŶiĐal status ĐhaŶges, 
for example during intercurrent illnesses, such as infections, when it is thought that renal function 
may be changing, and when other drugs that may interact with lithium are introduced. The most 
important drug interactions are with diuretics, ACE inhibitors and non-steroidal anti-inflammatory 
drugs. 
•If it has not been necessary to check the lithium concentration otherwise, it may be checked every 
3–6 months in stable patients, if only to reassure the clinician that the treatment is still adequate. 
Monitoring at this frequency appears to be recommended because it is feared that less frequent 
monitoring will lead to no monitoring at all. In fact, less frequent (annual) but assured monitoring of 
every patient would probably be more rational and cost effective. Rapid decline in renal function 
would be unlikely to be detected unless monitoring was more frequent than 3 monthly, and is 
anyway very rare. 
•Renal and thyroid function should be checked every 12 months in patients with stable renal and 
thyroid function (and no change of lithium dose) or whenever the clinical status changes. 
 
Adverse reactions and effects 
 
•Adǀeƌse ƌeaĐtioŶs iŶĐlude tƌeŵoƌ, polǇuƌia, polǇdipsia, ǁeight gaiŶ, ĐogŶitiǀe pƌoďleŵs, sedatioŶ oƌ 
lethargy, impaired coordination, gastrointestinal distress, hair loss, benign leukocytosis, acne, and 
oedema. 
•The common adverse reactions can usually be reduced or eliminated by lowering the lithium dose 
or changing the dosage schedule. 
•During long-term lithium treatment (>10 years), 10–20%of patients develop morphological kidney 
changes. These changes are not generally associated with renal failure, although there are case 
reports of renal insufficiency attributed to lithium. 
•Fluid restriction is contra-indicated. Troublesome polyuria can be reduced by amiloride (check 
other electrolytes). 
•Lithium can cause hypothyroidism; if the serum TSH rises consider adding levothyroxine or seek a 
specialist opinion.  
•GiǀeŶ the ĐoŶsisteŶt finding of frequent hyperparathy roidism, calcium concentrations should be 
checked before and during treatment. 
•For persistent tremor consider adding propranolol (asthma is a contra-indication). 
•Most patients experience toxic effects with concentrations above 1.5 mmol/L; concentrations 
above 2.0 mmol/L are associated with life-threatening toxicity and require urgent treatment: 
haemodialysis may be needed to minimize toxicity. 
•Lithium toxicity should also be suspected even when concentrations are in the usual target range in 
compromised patients with symptoms that are consistent with toxicity. 
 
Lithium discontinuation 
 
Abrupt discontinuation of lithium provokes manic relapse in bipolar I patients (50% in the next 12 
weeks). Accordingly, lithium should always be tapered over at least 4 weeks or longer except in 
medical emergency or overdose. 
 
Valproate 
 
Initial workup 
 
General medical history, with special attention to hepatic, haematological, and bleeding 
abnormalities, physical examination, and weight. 
 
 
 
• Liver function tests. 
•Pregnancy tests in women of child-bearing age. 
•Earlier estimated risks for development of polycystic ovarian syndrome appear to have been 
misleading for valproate (Duncan, 2001). 
 
Dosing 
 
•Valpƌoate foƌŵulatioŶs aƌe ĐloselǇ siŵilaƌ: 
•Doses will be given for valproate semisodium because almost all the controlled data were obtained 
with this formulation. For hospitalized patients with mania, valproate semisodium can be 
administered at an initial dosage of 20 to 30 mg/kg per day in inpatients. A serum valproate 
concentration between 50 and 125 µg/mL has been associated with an acute response. 
•For outpatients, elderly patients, or patients with hypo-mania or euthymia, start at 500 mg 
valproate semisodium at night. Titrate the dose upward by 250 to 500 mg/day every few days, 
depending on adverse reactions. The SmPC suggests divided doses, but in practice a single dose can 
often be given at night. The maximum adult daily dosage is 60 mg/kg/day, but all patients taking 
daily doses higher than 45 mg/kg should be carefully monitored. However, a total dose of 1250 
mg/day is the highest usually well tolerated by outpatients. 
 
•Valpƌoate foƌŵulatioŶs aƌe ĐloselǇ siŵilaƌ: 
•Doses will be given for valproate semisodium because almost all the controlled data were obtained 
with this formulation. For hospitalized patients with mania, valproate semisodium can be 
administered at an initial dosage of 20 to 30 mg/kg per day in inpatients. A serum valproate 
concentration between 50 and 125 µg/mL has been associated with an acute response. 
•For outpatients, elderly patients, or patients with hypo-mania or euthymia, start at 500 mg 
valproate semisodium at night. Titrate the dose upward by 250 to 500 mg/day every few days, 
depending on adverse reactions. The SmPC suggests divided doses, but in practice a single dose can 
often be given at night. The maximum adult daily dosage is 60 mg/kg/day, but all patients taking 
daily doses higher than 45 mg/kg should be carefully monitored. However, a total dose of 1250 
mg/day is the highest usually well tolerated by outpatients. 
 
Drug–drug interactions 
 
•MaŶǇ dƌug iŶteƌaĐtions have been reported for valproate due to protein binding displacement, 
other kinds of pharmacokinetic interactions, some pharmacodynamics effects and even a 
combination of these effects. Seek expert advice if in doubt. 
•Valproate inhibits the metabolism of lamotrigine, which must be initiated at half the usual dose 
when added to valproate. Accordingly, lamotrigine dosage should be reduced when valproate is 
added to it. 
•Valproate can significantly lower plasma levels of olanzapine when co-prescribed. 
 
Carbamazepine Initial workup 
•GeŶeƌal ŵediĐal histoƌǇ ǁith speĐial atteŶtioŶ to ďlood dǇsĐƌasias oƌ liǀeƌ disease. 
•Complete blood count (CBC) with differential and platelet count, liver function tests, and 
creatinine. 
•Serum electrolytes in the elderly, who may be at higher risk of hyponatraemia. 
 
Precautions 
 
Similar to valproate, carbamazepine is associated with multiple drug–drug interactions. Induction of 
enzymes can reduce the effectiveness of co-prescribed medications including antipsychotics, 
antidepressants, and oral contraceptives. 
 
Dosing 
•CaƌďaŵazepiŶe is usuallǇ staƌted at a dose of ϰϬϬ ŵg at Ŷight foƌ outpatieŶts ǁith aĐute ŵaŶia. 
•In hospitalized patients with acute mania, the dosage may be increased in increments of 200 
mg/day up to 800–1000 mg/day or higher if tolerated. 
•Maintenance dose ranges from 200 to 1600 mg/day in routine clinical practice and should be as 
high as possible without producing adverse reactions. 
 
Long-term monitoring of laboratory values 
•CBC, platelet ĐouŶt, aŶd liver function tests may be performed during the first 2 months of 
treatment. 
•Monitoring is less important than clinical vigilance for potentially serious adverse reactions (see 
below). 
 
Adverse reactions and effects 
•The ŵost ĐoŵŵoŶ dose ƌelated adǀeƌse reactions include fatigue, nausea, and neurological 
symptoms such as diplopia, blurred vision, and ataxia. 
•Less frequent adverse reactions include rashes, mild leukopenia, mild rises in liver enzymes, mild 
thrombocytopenia, hyponatraemia, and (less commonly) hypo-osmolality. 
•Rare, idiosyncratic, but serious and potentially fatal adverse effects include agranulocytosis, 
aplastic anaemia, thrombocytopenia, hepatic failure, Stevens–Johnson syndrome, toxic 
epidermolysis, and pancreatitis. 
•Awareness of the possible significance of fever, sore throat, rash, mouth ulcers, and bruising or 
bleeding is essential in view of the rare but severe adverse reactions. Patients should be encouraged 
to seek urgent medical attention if they occur. 
•Other rare adverse reactions include systemic hypersensitivity reactions; alopecia; cardiac 
conduction disturbances; psychiatric symptoms, including sporadic cases of psychosis; and, very 
rarely, renal effects, including renal failure, oliguria, hematuria, and proteinuria. 
 
The carbamazepine analogue oxcarbazepine may be a useful alternative to carbamazepine based on 
its superior adverse reactions profile. 
 
Lamotrigine 
Dosing 
 
•Doses of laŵotƌigiŶe should ďe iŶĐƌeased sloǁlǇ, aŶd staƌteƌ paĐks aƌe aǀailaďle foƌ this puƌpose, 
giving 25 mg/day for the first 2 weeks, then 50 mg/day for weeks 3 and 4. After that, 50 mg/day can 
be added at weekly intervals as clinically indicated up to doses of 400 mg/day. 
•In patients who are receiving valproate, or other inhibitors of hepatic metabolism, the dose or the 
dosage schedule should be halved (i.e. 12.5 mg/day or 25 mg every other day for 2 weeks, then 25 
mg/day during weeks 3 and 4). 
•Concurrent treatment with carbamazepine, or other inducers of hepatic metabolism, will lead to 
increased metabolism of lamotrigine and will require that dosing be doubled. 
 
Adverse reactions and effects 
•The ŵost seƌious eaƌlǇ ƌisk is a rash associated with influenza-like symptoms and hypersensitivity. It 
is not established that eaƌlǇ ƌashes ͞pƌogƌess͟ to Stevens–Johnson syndrome and toxic epidermal 
necrolysis, even when the early rash is erythema multiforme. Nevertheless, there have been reports 
of Stevens–Johnson syndrome and toxic epidermal necrolysis and drug withdrawal is there-fore 
recommended. In early clinical trials with patients with epilepsy, rapid titration of lamotrigine 
dosage was associated with an incidence of approximately 0.3% in adults and approximately 1% in 
children. A slow dosage titration schedule (as above) reduces the risk of serious rashes in adults to 
0.01% (comparable to other anticonvulsants). Patients should be informed of the risk of rashes and 
of the need to contact the psychiatrist or primary care physician immediately if any rash occurs. 
•At rash onset, since it is difficult to distinguish between a serious and a more benign rash, 
lamotrigine should always be discontinued. If the rash is trivial and disappears, lamotrigine can be 
reintroduced even more slowly. 
•If rashes are accompanied by fever or sore throat, are diffuse and widespread, or show prominent 
facial or mucosal involvement, all possible provoking agents should be stopped and re-introduction 
should be extremely cautious if attempted at all. 
•Rashes may be more likely if lamotrigine and valproate are administered concomitantly, primarily 
because the half-life of lamotrigine is effectively doubled or tripled because of inhibition of its 
hepatic metabolism by valproate. 
